



(11) EP 2 292 631 A1

(12) EUROPEAN PATENT APPLICATION

(43) Date of publication:  
09.03.2011 Bulletin 2011/10

(51) Int Cl.:  
C07H 21/00 (2006.01) A61K 48/00 (2006.01)  
C12Q 1/68 (2006.01)

(21) Application number: 10164397.1

(22) Date of filing: 23.04.2003

(84) Designated Contracting States:  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IT LI LU MC NL PT RO SE SI SK TR

(72) Inventor: Itescu, Silviu  
New York, NY 10017 (US)

(30) Priority: 23.04.2002 US 128738

(74) Representative: Lawrence, John  
Barker Brettell LLP  
100 Hagley Road  
Edgbaston  
Birmingham  
B16 8QQ (GB)

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
03724217.9 / 1 501 852

(71) Applicant: The Trustees of Columbia University in  
the City of  
New York  
New York,  
New York 10027 (US)

Remarks:


This application was filed on 28-05-2010 as a  
divisional application to the application mentioned  
under INID code 62.

(54) Regeneration of endogenous myocardial tissue by induction of neovascularization

(57) This invention provides a method of treating a  
disorder of a subject's heart involving loss of cardiomy-  
ocytes which comprises administering to the subject an  
amount of an agent effective to cause cardiomyocyte pro-  
liferation within the subject's heart so as to thereby treat

the disorder. This invention further provides the instant  
method wherein the agent is human endothelial progen-  
itor cells, G-CSF, GM-CSF, SDF-1, and IL-8. This inven-  
tion also provides methods of determining the suscepti-  
bility of a cardiomyocyte in a subject to apoptosis.

FIGURE 1B



EP 2 292 631 A1

**Description**

[0001] This application claims priority of U.S. Serial No. 10/128,738, filed April 23, 2002, the contents of which are hereby incorporated by reference.

[0002] Throughout this application, various publications are referenced in parentheses by arabic numbers. Full citations for these references may be found at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.

**Background**

[0003] Healing of a myocardial infarct is complicated by the need for viable myocytes at the peri-infarct rim to undergo compensatory hypertrophy in order to increase pump function in response to the loss of infarcted tissue (1,2). This initiates a process termed cardiac remodelling which is characterized by apoptotic loss of hypertrophied myocytes, expansion of the initial infarct area, progressive collagen replacement, and heart failure (3-6). We have recently put forward the hypothesis that hypertrophied cardiac myocytes undergo apoptosis because the endogenous capillary network cannot provide the compensatory increase in perfusion required for cell survival (7).

[0004] Vascular network formation is the end result of a complex process that begins in the pre-natal period with induction of vasculogenesis by hemangioblasts - cells derived from the human ventral aorta which give rise to both endothelial and hematopoietic elements (8-11). Cells which can differentiate into endothelial elements also exist in adult bone marrow (12-14) and can induce vasculogenesis in ischemic tissues (15-17). In the adult, new blood vessel formation can occur either through angiogenesis from pre-existing mature endothelium or vasculogenesis mediated by bone marrow-derived endothelial precursors. Recently, we identified a specific population of endothelial progenitor cells (angioblasts) derived from human adult bone marrow which has phenotypic and functional characteristics of embryonic angioblasts (7). We showed that intravenous administration of these cells resulted in selective homing to ischemic myocardium, induction of infarct bed vasculogenesis, prevention of peri-infarct myocyte apoptosis, and significant improvement in myocardial function (7).

[0005] We recently discovered that CXC chemokines containing the ELR motif regulate migration of human bone marrow-derived endothelial progenitor cells to sites of tissue ischemia. Moreover, since selective bone marrow homing and engraftment of hematopoietic progenitors depends on CXCR4 binding to SDF-1 expressed constitutively in the bone marrow (28-30), we demonstrated that interruption of CXCR4/SDF-1 interactions could redirect trafficking of human bone marrow-derived endothelial progenitor cells to sites of tissue ischemia, thereby augmenting therapeutic vasculogenesis. Our results indicated that CXC chemokines, including IL-8, Gro- $\alpha$ , and SDF-1, play a central role in regulating human adult bone marrow-dependent vasculogenesis.

[0006] Recent observations have suggested that a second compensatory response of viable cardiomyocytes is to proliferate and regenerate following injury (18,19). We have previously shown that pro-angiogenic factors, such as endothelial progenitor cells at a minimum concentration can induce vasculogenesis. Here we disclose the surprising result that careful dosing of endothelial progenitor cells/other pro-angiogenic agents can induce cardiomyocyte proliferation also, and this proliferation can be enhanced by manipulating CXCR4/stromal derived factor-1 interactions. Moreover, we show that the mechanisms for this enhanced proliferation is via modulation of mRNA expression of a number of stress-inducible genes involved in cardiomyocyte apoptosis and cell-cycling.

**Summary**

[0007] This invention provides a method of treating a disorder of a subject's heart involving loss of cardiomyocytes which comprises administering to the subject an amount of an agent effective to cause cardiomyocyte proliferation within the subject's heart so as to thereby treat the disorder.

[0008] This invention further provides the instant method wherein the agent is human endothelial progenitor cells.

[0009] This invention further provides the instant method comprising administering an effective amount of a second agent that increases the cardiomyocyte proliferation caused by the human endothelial progenitor cells.

[0010] This invention also provides a method of determining the susceptibility of a cardiomyocyte in a subject to apoptosis comprising:

- (a) quantitating the expression of peroxiredoxin in the cardiomyocyte;
- (b) quantitating the expression of Vitamin D3 Up-Regulated Protein-1 in the cardiomyocyte; and
- (c) determining the ratio of peroxiredoxin expression: Vitamin D3 Up-Regulated Protein-1. expression, wherein a low ratio indicates a high susceptibility of the cardiomyocyte to apoptosis and a high ratio indicates a low susceptibility of the cardiomyocyte to apoptosis in the subject.

[0011] According to another aspect of the invention, there is provided a method of treating a disorder of a subject's heart involving loss of cardiomyocytes which comprises administering to the subject an amount of an agent effective to cause cardiomyocyte proliferation within the subject's heart so as to thereby treat the disorder.

[0012] The agent may be human endothelial progenitor cells.

[0013] The method may further comprise administering an effective amount of a second agent that increases the cardiomyocyte proliferation caused by the human endothelial progenitor cells.

[0014] The agent may be an antisense oligonucleotide which specifically inhibits translation of Vitamin D3 Up-Regulated Protein-1 (VDUP-1) mRNA. The agent may be a catalytic nucleic acid which specifically inhibits translation of Vitamin D3 Up-Regulated Protein-1 mRNA. The catalytic nucleic acid may comprise deoxyribonucleotides. The catalytic nucleic acid may comprise ribonucleotides.

[0015] The second agent may be a pro-angiogenic agent. The pro-angiogenic agent may be vascular endothelial growth factor, fibroblast growth factor or angiopeptin. The second agent may induce expression of a pro-angiogenic factor. The second agent may be Hypoxia Inducible Factor-1. The second agent may promote trafficking of the endothelial progenitor cells to the subject's heart. The second agent that promotes trafficking may be an antibody directed against an epitope of CXCR4. The second agent that promotes trafficking may be a CC chemokine. The CC chemokine may be RANTES, EOTAXIN, monocyte chemoattractant protein-1 (MCP-1), MCP-2, MCP-3, or MCP.

[0016] The second agent may be a CXC chemokine. The CXC chemokine may be Interleukin-8, Gro-Alpha, or Stromal-Derived Factor-1. The Stromal-Derived Factor-1 may be Stromal-Derived Factor-1 alpha or Stromal-Derived Factor-1 beta. The second agent may promote mobilization of angio blasts into the bloodstream of the subject. The agent may be G-CSF, GM-CSF, SDF-1, or VEGF. The second agent may be cardiomyocyte progenitor cells. The second agent may be skeletal muscle progenitor cells.

[0017] The effective amount of human endothelial progenitor cells may be between  $2.5 \times 10^5$  and  $7.5 \times 10^5$  endothelial progenitor cells per kg of the subject's body mass. The effective amount may be  $5 \times 10^5$  endothelial progenitor cells per kg of the subject's body mass. The endothelial progenitor cells may be allogeneic with respect to the subject. The subject may be an adult. The subject may be an embryo or a fetus.

[0018] The administering may comprise injecting directly into the subject's peripheral circulation, heart muscle, left ventricle, right ventricle, coronary artery, cerebro-spinal fluid, neural tissue, ischemic tissue, or post-ischemic tissue. The human endothelial progenitor cells may express CD117, CD34 or AC133. The endothelial progenitor cells may express a high level of intracellular GATA-2 activity.

[0019] The agent may induce expression of a mRNA encoding a peroxiredoxin. The agent may be 2 (3)-t-butyl-4-hydroxyanisole.

[0020] The agent may induce expression of a mRNA encoding NF-E2-related factor 2 (Nrf2). The agent may induce dissociation of a Nrf2 protein from a Keap-1. The agent may inhibit association of a Nrf2 protein with a Kelp-1. The agent may inhibit association of a thiol reductase thioredoxin with a VDUP-1 protein. The agent may inhibit c-Ab1 tyrosine kinase activation. The agent may be STI-571. The agent may be a CXC chemokine. The chemokine may be Stromal-Derived Factor-1, 11-8 or Gro-Alpha. The agent may be Stromal-Derived Factor-1 and is administered intramyocardially. The agent may be Stromal-Derived Factor-1 and is administered intracoronary. The agent may be Stromal-Derived Factor-1 and is administered via a stent, a scaffold, or as a slow-release formulation.

[0021] The method may further comprise administering a second agent. The second agent may be GM-CSF, G-CSF, IL-8 or a Gro family chemokine. The second agent may be an inhibitor of CXCR4 or an inhibitor of SDF-1. The agent may be an inhibitor of plasminogen activator inhibitor-1. The agent may be an antibody directed against an epitope of CXCR4. The agent may be G-CSF, GM-CSF, an inhibitor of VDUP1 expression, or a Gro family chemokine. The subject may have a cardiovascular disease. The subject may have congestive heart failure. The subject may have suffered a myocardial infarct. The subject may have suffered myocardial ischemia. The subject may have angina. The subject may have a cardiomyopathy. The subject may be a mammal. The mammal may be a human being.

[0022] According to another aspect of the invention, there is provided a method of determining the susceptibility of a cardiomyocyte in a subject to apoptosis comprising: (a) quantitating the amount of mRNA encoding peroxiredoxin in the cardiomyocyte; (b) quantitating the amount of mRNA encoding Vitamin D3 Up-Regulated Protein-1 in the cardiomyocyte; and (c) determining the ratio of the amount of mRNA encoding peroxiredoxin: amount of mRNA encoding Vitamin D3 Up-Regulated Protein-1, wherein a low ratio indicates a high susceptibility of the cardiomyocyte to apoptosis and a high ratio indicates a low susceptibility of the cardiomyocyte to apoptosis in the subject.

[0023] According to another aspect of the invention, there is provided a method of determining the susceptibility of a cardiomyocyte in a subject to apoptosis comprising: (a) quantitating the expression of a peroxiredoxin protein in the cardiomyocyte; (b) quantitating the expression of Vitamin D3 Up-Regulated Protein-1 in the cardiomyocyte; and (c) determining the ratio of the peroxiredoxin protein expression: Vitamin D3 Up-Regulated Protein-1 expression, wherein a low ratio indicates a high susceptibility of the cardiomyocyte to apoptosis and a high ratio indicates a low susceptibility of the cardiomyocyte to apoptosis in the subject.

[0024] According to another aspect of the invention, there is provided a cardiac progenitor cell.

[0026] According to another aspect of the invention, there is provided a method of inducing cell cycling in a cardiac progenitor cell in a heart tissue of a subject comprising administering to the subject an amount of an agent effective to induce neovascularization of the heart tissue in the subject so as to thereby induce cardiac cell cycling within the heart tissue of the subject.

[0026] According to another aspect of the invention, there is provided a method of improving cardiac function in a subject comprising administering to the subject an amount of an agent effective to induce neovascularization of a heart tissue in the subject so as to thereby improve cardiac function in the subject.

[0027] According to another aspect of the invention, there is provided a method of improving cardiac function in a subject comprising administering to the subject an amount of an agent effective to induce proliferation of cardiomyocytes in the heart tissue in the subject so as to thereby improve cardiac function in the subject.

[0028] The subject may have suffered myocardial ischemia or myocardial infarct.

[0029] The agent may be G-CSF, GM-CSF, IL-8, a Gro family chemokine, an inhibitor of CXCR4, or an inhibitor of SDF-1. The inhibitor of CXCR4 may be a small molecule or a monoclonal antibody. The inhibitor of CXCR4 may be a small molecule and may be AMD 3100. The inhibitor of CXCR4 may be AMD 070. The inhibitor of CXCR4 may be a catalytic nucleic acid, an oligonucleotide, a monoclonal antibody, RNAI, or a small molecule. The inhibitor of SDF-1 may be a small molecule or a monoclonal antibody. The Gro family chemokine may be Gro alpha.

[0030] According to another aspect of the invention, there is provided a method of inducing apoptosis in a cell comprising inhibiting expression of a peroxiredoxin in the cell.

[0031] The cell may express peroxiredoxin. The cell may be supplied by a vasculature, and the vasculature induces expression of the peroxiredoxin. The peroxiredoxin may be peroxiredoxin I, peroxiredoxin II, peroxiredoxin III, peroxiredoxin IV, or peroxiredoxin V. The inhibition of expression of peroxiredoxin may be effected by contacting the cell with a catalytic nucleic acid which binds mRNA encoding peroxiredoxin, thereby inhibiting the expression thereof.

[0032] The cell may be a tumor cell.

[0033] According to another aspect of the invention, there is provided a method of treating a disorder of tissue cells of a subject involving loss of tissue cells which comprises administering to the subject an amount of an agent effective to cause tissue cell proliferation within the tissue of the subject so as to thereby treat the disorder of tissue cells of a subject.

[0034] The agent may be G-CSF, SDF-1, GM-CSF, IL-8, or VEGF. The agent may be an inhibitor of CXCR4/SDF-1 interaction. The inhibitor may be a catalytic nucleic acid, a monoclonal antibody, an antisense oligonucleotide, a small molecule, or RNAI. The agent may be an inducer of peroxiredoxin expression. The tissue may be cardiac tissue, brain tissue, peripheral vascular tissue, hepatic tissue, renal tissue, gastrointestinal tissue, lung tissue, smooth muscle tissue, or striated muscle tissue.

[0035] The agent may be G-CSF, and the G-CSF is a covalent conjugate of is a covalent conjugate of recombinant methionyl human G-CSF and monomethoxypolyethylene glycol.

[0036] According to another aspect of the invention, there is provided a method of treating a disorder of a tissue of a subject involving apoptosis of cells in the tissue which comprises administering to the subject an amount of an agent effective to inhibit apoptosis of cells in the tissue within the subject so as to thereby treat the disorder.

[0037] The agent may be an inhibitor of VDUP-1 expression. The inhibitor of VDUP-1 expression may be catalytic nucleic acid, a monoclonal antibody, an antisense oligonucleotide, a small molecule, or an RNAI. The tissue may be cardiac tissue, cerebrovascular tissue, or cerebral tissue.

[0038] According to another aspect of the invention, there is provided method of inhibiting proliferation of fibroblasts or inflammatory cells in a tissue and thereby inhibiting collagen formation comprising contacting the tissue with an amount of an inhibitor of VDUP-1 expression effective to inhibit proliferation of fibroblasts or inflammatory cells in the tissue.

[0039] The inhibitor of VDUP-1 expression may be a catalytic nucleic acid, a monoclonal antibody, an antisense oligonucleotide, a small molecule, or an RNAI.

#### BRIEF DESCRIPTION OF THE FIGURES

[0040] Figures 1A-1D: IL-8/Gro-Alpha CXC Chemokines Regulate Migration Of Human Endothelial progenitor cells (angioblasts) To Myocardial Tissue In Vivo And Subsequent Development Of Vasculogenesis.

(A) DiI-labelled human endothelial progenitor cells (angioblasts)(>98% CD34+ purity) injected intravenously into nude rats infiltrate rat myocardium after coronary artery ligation and infarction but not after sham operation at 48 hours.

(B) Migration of human endothelial progenitor cells (angioblasts) to ischemic rat myocardium is inhibited by mAbs against either rat IL-8 or the IL-8/Gro-alpha chemokine family receptors CXCR1 and CXCR2 (all  $p < 0.01$ ), but not against VEGF or its receptor Flk-1 (results are expressed as mean + sem of three separate experiments).

(C) Masson's trichrome stain of rat myocardial infarct bed at two weeks after LAD ligation demonstrating diffuse increase in matrix deposition and few capillaries in representative animal injected with saline (x400), diffuse increase in capillaries (arrowheads) and reduction in matrix deposition in representative animal injected with human bone



marrow-derived endothelial progenitor cells (x400), and reduction in capillary numbers in representative animal injected with human endothelial progenitor cells (angioblasts) together with mAb against human eXCR1/2 (x400). (D) Intracardiac injection of IL-8 or SDF-1 at 1 µg/ml significantly increases *in vivo* chemotaxis of DII-labelled human endothelial progenitor cells (angioblast) (98% CD34+ purity) into non-ischemic rat heart in comparison with injection of saline or stem cell factor (SCF),  $p < 0.01$  (results are expressed as mean + sem of three separate experiments). Below is shown representative fluorescence microscopy of intravenously-injected DII-labelled human endothelial progenitor cells infiltrating non-ischemic rat heart after intracardiac injection with saline, IL-8 or SDF-1.

**[0041] Figures 2A-2C: Blocking CXCR4/SDF-1 Interactions Redirects Intravenously Injected Human Endothelial progenitor cells From Bone Marrow To Ischemic Myocardium.**

(A) the proportion of human CD34+CD117<sup>bright</sup> endothelial progenitor cells (angioblasts) in rat bone marrow 2-14 days after intravenous injection is significantly increased following ischemia induced by LAD ligation (results are expressed as mean + sem of bone marrow studies in three animals at each time point).

(B) and (C) depict the effects of mAbs against CXCR4, SDF-1 or CD34 on trafficking of human CD34+ endothelial progenitor cells (angioblasts) to rat bone marrow and myocardium following LAD ligation. Co-administration of anti-CXCR4 or anti-SDF-1 significantly reduced trafficking of intravenously injected human CD34+ cells to rat bone marrow at 48 hours and increased trafficking to ischemic myocardium, whereas anti-CD34 mAb had no effect (results are expressed as mean + sem of bone marrow and cardiac studies performed in three LAD-ligated animals at 48 hours after injection).

**[0042] Figures 3A-3F. Redirected Trafficking Of Human Endothelial progenitor cells (angioblasts) To The Site Of Infarction Induces Vasculogenesis And Protects Cardiomyocytes Against Apoptosis.**

(A) Myocardial infarct bed two weeks post-LAD ligation from representative animals in each group stained with Masson's trichrome (upper panel) or immunoperoxidase after binding of anti-CD31 mAb (lower panel). The infarct zones of rats receiving either  $10^3$  or  $10^5$  endothelial progenitor cells (angioblasts) show myocardial scars composed of paucicellular, dense fibrous tissue stained blue by trichrome (x400). In contrast, the infarct zones of rats injected with  $10^5$  endothelial progenitor cells plus anti-CXCR4 mAb show significant increase in cellularity of granulation tissue, minimal matrix deposition and fibrosis, and numerous medium-sized capillaries of human origin. The infarct zones of rats injected with  $2 \times 10^5$  endothelial progenitor cells show a similar reduction in fibrous tissue and increase in medium-sized capillaries, and an additional increase in large-sized vessels of human origin.

(B) and (C) show the relationship between the number of human CD117<sup>bright</sup> endothelial progenitor cells injected intravenously ( $10^3$ ,  $10^5$ ,  $10^5$  plus anti-CXCR4 mAb, and  $2 \times 10^5$ ) and development of rat infarct bed vasculogenesis at two weeks, defined as the mean number of capillaries/high power field (hpf) with medium- or large-sized lumen diameter (respectively, 0.02 mm mean diameter with 3-6 contiguous endothelial lining cells and 0.05 mm mean diameter with >6 contiguous endothelial lining cells). Results are expressed as the mean + sem of at least 15 hpf in three separate experiments.

(B) the groups receiving either  $2 \times 10^5$  endothelial progenitor cells (angioblasts) or  $10^5$  endothelial progenitor cells plus anti-CXCR4 mAb demonstrated 17-fold higher numbers of medium-sized capillaries compared with the other two groups ( $p < 0.01$ ).

(C) the group receiving  $2 \times 10^5$  endothelial progenitor cells (angioblasts) additionally demonstrated 3.3-fold higher numbers of large-lumen capillaries compared with the groups receiving  $10^3$  or  $10^5$  endothelial progenitor cells ( $p < 0.01$ ), and 2-fold higher numbers of large-lumen capillaries compared with the group receiving  $10^5$  endothelial progenitor cells plus anti-CXCR4 mAb ( $p < 0.01$ ).

(D) shows that co-administration of anti-CXCR4 mAb together with the highest concentration of endothelial progenitor cells (angioblast),  $2 \times 10^5$ , resulted in a further 23% increase in growth of large-lumen capillaries. More strikingly, there was a further 2-fold increase in capillary numbers when  $2 \times 10^5$  endothelial progenitor cells were injected intravenously after direct intracardiac delivery of 1.0 µg/ml SDF-1 into infarcted hearts ( $p < 0.01$ ) (results are expressed as mean + sem of three separate experiments).

(E) shows that at 2 weeks the numbers of apoptotic myocytes at the peri-infarct rim, defined by concomitant staining with anti-desmin mAb and DNA end-labeling using TUNEL technique, are significantly reduced in rats receiving either  $2.0 \times 10^5$  endothelial progenitor cells or  $10^5$  endothelial progenitor cells together with anti-CXCR4 mAb in comparison to rats receiving  $10^3$  or  $10^5$  endothelial progenitor cells ( $p < 0.01$ ) (results are expressed as mean + sem of three separate experiments).

(F) shows that co-administration of anti-CXCR4 mAb or intracardiac injection of SDF-1 resulted in further reductions in cardiomyocyte apoptosis of 65% and 76%, respectively, at two weeks (both  $p < 0.001$ ) (results are expressed as mean + sem of three separate experiments).

[0043] **Figures 4A-4H.** Infarct Bed Vasculogenesis Improves Long-Term Myocardial Function Through Mechanisms Involving Both Cardiomyocyte Protection and Proliferation/Regeneration.

(A) and (B) show the relationship between the number of human CD117<sup>bright</sup> endothelial progenitor cells (angioblasts) injected intravenously ( $10^3$ ,  $10^5$ ,  $10^5$  plus anti-CXCR4 mAb, and  $2 \times 10^5$ ) and improvement in myocardial function at 15 weeks, defined as mean improvement in left ventricular ejection fraction (LVEF) (A) and mean reduction in left ventricular area at end-systole (LVAs) (B). No significant improvement in these parameters was observed in the groups receiving  $10^3$  or  $10^5$  endothelial progenitor cells in comparison to rats receiving saline alone. In contrast, rats receiving  $10^5$  endothelial progenitor cells plus anti-CXCR4 mAb demonstrated significant recovery in LVEF and reduction in LVAs (both  $p < 0.001$ ). The group receiving  $2 \times 10^5$  endothelial progenitor cells demonstrated still 50% greater recovery in LVEF and reduction in LVAs (both  $p < 0.001$ ).

(C) Section from infarct of representative animal receiving  $2 \times 10^5$  endothelial progenitor cells (angioblasts) showing a high frequency of cardiomyocytes staining positively for both cardiac-specific troponin I and rat-specific Ki-67 (arrows). Note the proximity of Ki-67-positive cardiomyocytes to capillaries (arrowheads).

(D) Sections from infarct of representative animal receiving  $2 \times 10^5$  endothelial progenitor cells showing "finger" of cardiomyocytes of rat origin, as determined by expression of rat MHC class I molecules, extending from the peri-infarct region into the infarct zone. These cellular islands contain a high frequency of myocytes staining positively for both cardiac-specific troponin I and rat-specific Ki-67 (arrows). Sections from infarcts of representative animals receiving saline do not show same frequency of dual staining myocytes. Bar graph shows that the group of animals receiving  $2 \times 10^5$  human endothelial progenitor cells has a significantly higher index of cell cycling cardiomyocytes at the peri-infarct region than saline controls or sham operated animals (both  $p < 0.01$ ). No difference between the groups is seen at sites distal to the infarct.

(E) shows that the index of cell-cycling cardiomyocytes at the peri-infarct rim was increased by a further 1.9-fold when  $2 \times 10^5$  human endothelial progenitor cells were intravenously co-administered together with SDF-1 injected directly into the ischemic myocardium alone ( $p < 0.01$ ), or an 8-fold cumulative increase in cell-cycling cardiomyocytes at two weeks compared with LAD-ligated controls receiving saline (results are expressed as mean + sem of three separate experiments).

(F) shows that intravenous co-administration of anti-CXCR4 mAb, or intracardiac co-administration of SDF-1, but not IL-8, results in 2.8 to 4-fold greater LVEF improvement, determined by echocardiography, compared with intravenous injection of  $2 \times 10^5$  endothelial progenitor cells alone ( $p < 0.01$ ) (results are expressed as mean + sem of three separate experiments).

(G) shows that at 15 weeks the mean proportion of scar/normal left ventricular myocardium in rats receiving either or  $10^5$  endothelial progenitor cells together with anti-CXCR4 mAb was significantly reduced in comparison to rats receiving either  $10^3$  or  $10^5$  endothelial progenitor cells (angioblasts) alone, or saline ( $p < 0.01$ ). The group receiving  $2.0 \times 10^5$  endothelial progenitor cells demonstrated still 38% greater reduction in the ratio of scar/muscle tissue (results are expressed as mean + sem of three separate experiments).

(H) Sections of rat hearts stained with Masson's trichrome at 15 weeks after LAD ligation and injection of  $2.0 \times 10^6$  G-CSF mobilized human cells containing  $10^3$  (left) or  $2.0 \times 10^5$  (right) CD117<sup>bright</sup> endothelial progenitor cells. Hearts of rats receiving  $10^3$  endothelial progenitor cells had greater loss of anterior wall mass, collagen deposition (lighter gray), and septal hypertrophy compared with hearts of rats receiving  $2.0 \times 10^5$  endothelial progenitor cells.

[0044] **Figure 5:** This figure shows mRNA expression of three genes in the ischemic rat hearts at various time points. You will see that at 48 hours and 2 weeks after LAD ligation and ischemia, HBP23 (the rat homologue of human PAG/NKEF-A,B,C, all of which are part of the family of peroxiredoxins (Prx)) is decreased, and vitamin D3 upregulated protein VDUP-1 is increased. The early (48 hour) reduction in PRX and increase in VDUP-1 results in a compensatory increase in thiol reductase thioredoxin (TRX). Note that endothelial progenitor cell therapy reverses this pattern of mRNA expression.

**Figure 6:** DNA sequence (SEQ ID NO:1) corresponding to mRNA encoding VDUP-1.

**Figure 7:** This figure shows catalytic DNA 5'-AT-3' cleavage sites on VDUP-1 DNA (SEQ ID NO:3) corresponding to the coding region of VDUP-1 mRNA. Cleavage site pairs are uppercase.

**Figure 8:** This figure shows catalytic DNA 5'-GC-3' cleavage sites on VDUP-1 DNA (SEQ ID NO:3) corresponding to the VDUP-1 RNA. Cleavage site pairs are uppercase.

**Figure 9:** This figure shows catalytic DNA 5'-GT-3' cleavage sites on VDUP-1 DNA (SEQ ID NO:3) corresponding to the VDUP-1 mRNA. Cleavage site pairs are uppercase.

Figure 10: This figure shows catalytic DNA 5'-AC-3' cleavage sites on VDUP-1 DNA (SEQ ID NO:3) corresponding to the VDUP-1 mRNA. Cleavage site pairs are uppercase.

Figure 11: This figure shows sites which can be cleaved by a hammerhead ribozyme in VDUP-1 DNA (SEQ ID NO: 3) corresponding to the VDUP-1 RNA coding region. Uppercase "T" represents cleavage site.

Figure 12: This figure shows that at VDUP-1 enzyme concentrations ranging from 0.05 $\mu$ M to 5 $\mu$ M the sequence-specific VDUP1 DNA enzyme cleaved a synthetic rat VDUP1 oligonucleotide in a concentration- and time-dependent manner.

Figure 13 (a): Shows intramyocardial injection of the rat sequence-specific VDUP1 DNA enzyme at 48 hours after LAD ligation resulted in a 75% mean inhibition of proliferating cardiac fibroblasts in the infarct zone two weeks later in comparison to injection of scrambled DNA enzyme control ( $p < 0.01$ ). (b) Shows injection of VDUP1 DNA enzyme resulted in 20% mean reduction in apoptotic cardiomyocytes at the peri-infarct region relative to injection with the scrambled DNA enzyme control ( $p < 0.05$ ).

Figure 14(a) Shows inhibition of fibroblast proliferation and cardiomyocyte apoptosis resulted in significant reduction of mature scar deposition in the infarct zone, from a mean of 35% for animals receiving control scrambled DNA enzyme to a mean of 20% for those receiving VDUP1 DNA enzyme ( $p < 0.01$ ). (b) Shows animals receiving VDUP1 DNA enzyme demonstrated a 50% mean recovery in cardiac function, as determined by ejection fraction, whereas no improvement was seen in animals receiving scrambled control DNA enzyme ( $p < 0.01$ )

Figure 15 (a): Shows that G-CSF, when used systematically at the same dosages after myocardial infarction, is a more potent inducer of cardiac neovascularization than GM-CSF. (b) Shows G-CSF is a more potent inhibitor of cardiomyocyte apoptosis than GM-CSF.

Figure 16 (a): Shows G-CSF is a more potent inducer of cardiomyocyte regeneration than GM-CSF, and (b) shows that G-CSF enables significantly greater recovery of cardiac function after acute myocardial infarction.

Figure 17 (a): Shows intravenous administration of anti-CXCR4 monoclonal antibody after acute myocardial infarction induces significantly greater numbers of blood vessels at the peri-infarct region. (b) Shows the greater recovery of cardiac/myocardial function than with control antibodies.

Figure 18: Shows myocardial expression of SDF-1 mRNA increased by two weeks, but not within the first 48 hours after myocardial infarction, and is inhibited by subcutaneously injecting GM-CSF.

Figure 19 (a): Shows intramyocardial injection of SDF-1 induces neovascularization at the peri-infarct region and (b) protects cardiomyocytes at the peri-infarct region against apoptosis.

Figure 20(a): Shows intramyocardial administration of SDF-1 alone, and synergistically with GM-CSF induces cardiomyocyte regeneration at the peri-infarct region, and (b) improves cardiac function.

Figure 21(a): Shows Human angio blasts, or endothelial progenitor cells, induce neovascularization as early as 5 days post-infarct. (b) Shows Human angio blasts, or endothelial progenitor cells protect peri-infarct cardiomyocytes against apoptosis as early as 5 days post infarct.

Figure 22(a): Shows animals receiving human bone marrow-derived CD34+ cells demonstrated numerous clusters of small, cycling cells at the peri-infarct region that were of rat origin, as defined by a monoclonal antibody specific for rat Ki67, (b) Shows tissues obtained from animals sacrificed at two weeks after human CD34+ administration no longer demonstrated clusters of small, cycling cardiomyocyte progenitors, but instead a high frequency of large, mature rat cardiomyocytes at the peri-infarct region with detectable DNA activity, as determined by dual staining with mAbs reactive against cardiomyocyte-specific troponin and mAbs reactive against rat Ki67. (c) Shows cycling by the same staining.

Figure 23 Shows by RT-PCR, HBP23 mRNA levels in rat hearts decreased at two weeks post-LAD ligation by a mean of 34% compared with normal rat hearts.

Figure 24 (a): Shows a DNA enzyme against HBP23 cleaved the 23-base oligonucleotide synthesized from the

sequence of rat HBP23 mRNA, in a dose- and time-dependent manner. (b) Shows densitometric analysis of RT-PCR products following reverse transcription of cellular mRNA, demonstrating the HBP23 DNA enzyme inhibited steady-state mRNA levels in cultured rat cells by over 80% relative to the scrambled DNA.

Figure 25(a) Shows HBP23 DNA enzyme had no effect on induction of neovascularization by human bone marrow angioblasts, no increased myocardial capillary density in comparison to saline controls is seen. (b) Shows injection of the HBP23 DNA enzyme, but not the scrambled control, abrogated the anti-apoptotic effects of neovascularization. (c) Shows injection of the HBP23 DNA enzyme, but not the scrambled control, abrogated the improvement in cardiac function.

#### Detailed Description

[0045] As used herein, "VEGF" is defined as vascular endothelial growth factor. "VEGF-R" is defined as vascular endothelial growth factor receptor. "FGF" is defined as fibroblast growth factor. "IGF" is defined as Insulin-like growth factor. "SCF" is defined as stem cell factor. "G-CSF" is defined as granulocyte colony stimulating factor. "M-CSF" is defined as macrophage colony stimulating factor. "GM-CSF" is defined as granulocyte-macrophage colony stimulating factor. "MCP" is defined as monocyte chemoattractant protein.

[0046] As used herein "angioblasts" is synonymous with the term "endothelial progenitor cells".

[0047] As used herein, "CXC" chemokine refers to the structure of the chemokine. Each "C" represents a cysteine and "X" represents any amino acid. "CXCR4" refers to CXC receptor 4.

[0048] As used herein, "CC" chemokine refers to the structure of the chemokine. Each "C" represents a cysteine.

[0049] A "cardiac progenitor cell" refers to a cell that is resident in the heart, or that comes into the heart from elsewhere after acute ischemia, is smaller than mature cardiomyocytes, expresses alpha sarcomeric actin but is negative for tropoin, is normally quiescent but can be induced to go into cell cycle as defined by positive Ki67 staining. "Cardiac progenitor cell" may be used synonymously with "cardiomyocyte progenitor cell".

[0050] "Catalytic" shall mean the functioning of an agent as a catalyst, i.e. an agent that increases the rate of a chemical reaction without itself undergoing a permanent structural change.

[0051] "Nucleic acid" shall include without limitation any nucleic acid, including, without limitation, DNA, RNA, oligonucleotides, or polynucleotides, and analogs or derivatives thereof. The nucleotides that form the nucleic acid may be nucleotide analogs or derivatives thereof. The nucleic acid may incorporate non nucleotides.

[0052] "Nucleotides" shall include without limitation nucleotides and analogs or derivatives thereof. For example, nucleotides may comprise the bases A, C, G, T and U, as well as derivatives thereof. Derivatives of these bases are well known in the art, and are exemplified in PCR Systems, Reagents and Consumables (Perkin Elmer Catalogue 1996-1997, Roche Molecular Systems, Inc., Branchburg, New Jersey, USA).

[0053] "Proliferation" and "regeneration" are used synonymously when referring to cardiomyocytes in this application. "Proliferation" in respect to cardiomyocytes, shall mean a fold increase in proportion of cardiomyocytes entering the cell cycle relative to untreated rat heart.

[0054] "Trafficking" means the blood-borne migration of cells, in particular angioblast/endothelial progenitor cells.

[0055] This invention provides a method of treating a disorder of a subject's heart involving loss of cardiomyocytes which comprises administering to the subject an amount of an agent effective to cause cardiomyocyte proliferation within the subject's heart so as to thereby treat the disorder.

[0056] In one embodiment the agent is human endothelial progenitor cells. In one embodiment the endothelial progenitor cells are bone marrow-derived. In another they are derived from cord blood, or embryonic or fetal sources. Effective amounts of endothelial progenitor cells sufficient to cause cardiomyocyte proliferation can be done based on animal data using routine computational methods. In one embodiment the effective amount is about  $1.5 \times 10^5$  endothelial progenitor cells per kg body mass to about  $3 \times 10^5$  per kg body mass. In another embodiment the effective amount is about  $3 \times 10^5$  per kg body mass to about  $4.5 \times 10^5$  endothelial progenitor cells per kg body mass. In another embodiment the effective amount is about  $4.5 \times 10^5$  per kg body mass to about  $5.5 \times 10^5$  endothelial progenitor cells per kg body mass. In another embodiment the effective amount is about  $5.5 \times 10^5$  per kg body mass to about  $7 \times 10^5$  endothelial progenitor cells per kg body mass. In another embodiment the effective amount is about  $7 \times 10^5$  per kg body mass to about  $1 \times 10^6$  endothelial progenitor cells per kg body mass. In another embodiment the effective amount is about  $1 \times 10^6$  per kg body mass to about  $1.5 \times 10^6$  endothelial progenitor cells per kg body mass. In one embodiment the effective amount of human endothelial progenitor cells is between about  $1.5 \times 10^6$  and  $4.5 \times 10^6$  endothelial progenitor cells per kg of the subject's body mass and in a preferred embodiment the effective amount is about  $5 \times 10^5$  endothelial progenitor cells per kg of the subject's body mass.

[0057] In one embodiment the endothelial progenitor cells are allogeneic with respect to the subject. In differing embodiments the subject is an adult or a fetus. In another embodiment the endothelial progenitor cells are derived from cloned autologous embryonic stem cells.

[0058] In one embodiment the agent induces expression of a mRNA encoding a peroxiredoxin. The expression of peroxiredoxin mRNA may be increased, for example, by administration of 2(3)-t-butyl-4-hydroxyanisole (BHA) (see 106) which has been shown to increase expression of Peroxiredoxin-1 when administered by diet. Alternatively, local control of  $O_2$  can have the same effect (see 107). Peroxiredoxin mRNA expression, such as that of thiol peroxidases, may also be induced by heme, cadmium or cobalt (see 108). Peroxiredoxins include, but are not limited to, PAG, HBP23, MSP23, NKEF.

[0059] In another embodiment the agent induces expression of a mRNA encoding NF-E2-related factor 2 (Nrf2). Cytoplasmic NF-E2-related factor 2 (Nrf2) expression can be indirectly increased by raising free Nrf2 levels. Since Nrf2 is tightly bound to keep1 in the cytoplasm then reducing expression of keep1 mRNA is a suitable target e.g. by keep1 antisense oligonucleotides or catalytic nucleic acids (see 109 for keep1). Also, blocking the interaction between Nrf2 and Keep1 by inhibiting the interaction of the Neh2 domain of Nrf2 and the DGR domain of keep1, e.g. by using the entire Neh2 domain of nrf2, amino acids 1-73, or only the hydrophilic region, amino acids 33-73 (see 109) will increase free cytoplasmic Nrf-2. In another embodiment the agent induces dissociation of a Nrf2 protein from a Keep-1. In another embodiment the agent inhibits association of a Nrf2 protein with a Keep-1. In another embodiment the agent inhibits association of a thiol reductase thioredoxin with a VDUP-1 protein. In another embodiment the agent inhibits c-Ab1 tyrosine kinase activation. In a further embodiment the agent is STI-571.

[0060] In one embodiment the agent is a CXCR chemokine. In further embodiments the agent is Stromal-Derived Actor-1, IL-8 or Gro-Alpha. In one embodiment the amount of CXCR chemokine administered is between 0.2 and 5  $\mu$ g/ml at a max volume of 10ml for a 70kg human subject. In a preferred embodiment the amount is about 1  $\mu$ g/ml. In one embodiment the agent is an inhibitor of plasminogen activator inhibitor-1. In another embodiment the agent is an antibody directed against an epitope of CXCR4. In one embodiment the amount of antibody directed against an epitope of CXCR4 is between 25 and 75  $\mu$ g/ml, at a max volume of 10ml for a 70kg human subject. A simple calculation is performed for subjects of different mass. In a preferred embodiment the amount is about 50  $\mu$ g/ml.

In differing embodiments the agent is Stromal-Derived Factor-1 alpha or Stromal-Derived Factor-1 beta. In differing embodiments the chemokine can be administered intramyocardially, intracoronary, and/or via a stent, a scaffold, or as a slow-release formulation.

[0061] In differing embodiments the agent is G-CSF, CM-CSF, or a Gro family chemokine. In a further embodiment the agent is Gro alpha.

[0062] In a further embodiment the instant method further comprises administering an effective amount of a second agent that increases the cardiomyocyte proliferation caused by the human endothelial progenitor cells. Effective amounts of the second agent are amounts sufficient to enhance or accelerate cardiomyocyte proliferation in the presence of administered endothelial progenitor cells. In further embodiments the endothelial progenitor cells express CD117, CD34, AC133 or a high level of intracellular GATA-2 activity. In one embodiment the administering comprises injecting directly into the subject's peripheral circulation, heart muscle, left ventricle, right ventricle, coronary artery, cerebro-spinal fluid, neural tissue, ischemic tissue, or past-ischemic tissue.

[0063] In one embodiment the second agent is an antisense oligonucleotide which specifically inhibits translation of Vitamin D3 Up-Regulated Protein-1 (VDUP-1) mRNA.

[0064] Therapeutically useful targeted inhibition of VDUP-1 protein (SEQ ID NO:2) expression can be achieved through the use of antisense oligonucleotides. Antisense oligonucleotides are small fragments of DNA and derivatives thereof complementary to a defined sequence on a specified mRNA. A VDUP-1 antisense oligonucleotide specifically binds to targets on the VDUP-1 mRNA (SEQ ID NO:1) molecule and in doing so inhibits the translation thereof into VDUP-1 protein (SEQ ID NO:2).

[0065] Antisense oligonucleotide molecules synthesized with a phosphorothioate backbone have proven particularly resistant to exonuclease damage compared to standard deoxyribonucleic acids, and so they are used in preference. A phosphorothioate antisense oligonucleotide for VDUP-1 mRNA can be synthesized on an Applied Biosystems (Foster City, CA) model 380B DNA synthesizer by standard methods. E.g. Sulfurization can be performed using tetraethylthiuram disulfide/acetonitrile. Following cleavage from controlled pore glass support, oligodeoxynucleotides can be base de-protected in ammonium hydroxide at 60°C for 8 h and purified by reversed-phase HPLC [0.1M triethylammonium bicarbonate /acetonitrile; Prop-1 support]. Oligomers can be deprotected in 3% acetic acid and precipitated with 2% lithium perchlorate/acetone, dissolved in sterile water and reprecipitated as the sodium salt from 1 M NaCl/ethanol. Concentrations of the full length species can be determined by UV spectroscopy.

[0066] Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

[0067] Hybridization of antisense oligonucleotides with VDUP-1 mRNA interferes with one or more of the normal functions of VDUP-1 mRNA. The functions of mRNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in by the RNA.

[0068] Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothio-

ates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and borano-phosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Also, oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof) are included. Various salts, mixed salts and free acid forms are also included.

[0069] Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,678; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,598; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

[0070] In accordance with this invention, persons of ordinary skill in the art will understand that messenger RNA includes not only the information to encode a protein using the three letter genetic code, but also associated ribonucleotides which form a region known to such persons as the 5'-untranslated region, the 3'-untranslated region, the 5' cap region and intron/exon junction ribonucleotides. Thus, antisense oligonucleotides or the catalytic nucleic acids described below may be formulated in accordance with this invention which are targeted wholly or in part to these associated ribonucleotides as well as to the informational ribonucleotides. The antisense oligonucleotides may therefore be specifically hybridizable with a transcription initiation site region, a translation initiation codon region, a 5' cap region, an intron/exon junction, coding sequences, a translation termination codon region or sequences in the 5'- or 3'-untranslated region. Similarly, the catalytic nucleic acids may specifically cleave a transcription initiation site region, a translation initiation codon region, a 5' cap region, an intron/exon junction, coding sequences, a translation termination codon region or sequences in the 5'- or 3'-untranslated region. As is known in the art, the translation initiation codon is typically 5'-AVG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule). A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'UUG or 5'-CUG, and 5'-AUA, 5'-11GG and 5'-CUG have been shown to function in vivo. Thus, the term "translation initiation codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine in eukaryotes. It is also known in the art that eukaryotic genes may have two or more alternative translation initiation codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "translation initiation codon" refers to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding VDUP-1, regardless of the sequence(s) of such codons. It is also known in the art that a translation termination codon of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The term "translation initiation codon region" refers to a portion of such an RNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. This region is one preferred target region. Similarly, the term "translation termination codon region" refers to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon. This region is also one preferred target region. The open reading frame or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other preferred target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. mRNA splice sites may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions may also be preferred targets.

[0071] Once the target site or sites have been identified, antisense oligonucleotides can be chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired disruption of the function of the molecule. "Hybridization", in the context of this invention, means hydrogen bonding, also known as Watson-Crick base pairing, between complementary bases, usually on opposite nucleic acid strands or two regions of a nucleic acid strand. Guanine and cytosine are examples of complementary bases which are known to form three hydrogen bonds between them. Adenine and thymine are examples of complementary bases which form two hydrogen bonds between them. "Specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity such that stable and specific binding occurs between the DNA or RNA target and the catalytic

nucleic acids. Similarly, catalytic nucleic acids are synthesized once cleavage target sites on the VDUP-1 mRNA molecule.

[0072] It is preferred to administer antisense oligonucleotides or catalytic nucleic acids or analogs thereof or other agents to mammals suffering from cardiovascular disease, in either native form or suspended in a carrier medium in amounts and upon treatment schedules which are effective to therapeutically treat the mammals to reduce the detrimental effects of cardiovascular disease. One or more different catalytic nucleic acids or antisense oligonucleotides or analogs thereof targeting different sections of the nucleic acid sequence of VDUP-1 mRNA may be administered together in a single dose or in different doses and at different amounts and times depending upon the desired therapy. The catalytic nucleic acids or antisense oligonucleotides can be administered to mammals in a manner capable of getting the oligonucleotides initially into the blood stream and subsequently into cells, or alternatively in a manner so as to directly introduce the catalytic nucleic acids or antisense oligonucleotides into the cells or groups of cells, for example cardiomyocytes, by such means by electroporation or by direct injection into the heart. Antisense oligonucleotides whose presence in cells can inhibit transcription or protein synthesis can be administered by intravenous injection, intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, orally or rectally. Human pharmacokinetics of certain antisense oligonucleotides have been studied. See (105) Incorporated by reference in its entirety. It is within the scale of a person's skill in the art to determine optimum dosages and treatment schedules for such treatment regimens.

[0073] Any of the agents employed in this invention can be administered intracoronary or intramyocardially, for example by injection. The agents can be delivered in various means as otherwise discussed, including by stents, such as drug-eluting stents, and in time-release formats such as slow-release. Where the agents are proteins, including but not limited to SDF-1, G-CSF, GM-CSF, and VEGF, the agents can be administered directly or indirectly, or may be administered via induction of gene expression, through gene therapy, adenoviral delivery and other such methods familiar to those skilled in the art.

[0074] Doses of the oligonucleotides or analogs thereof of the present invention in a pharmaceutical dosage unit will be an efficacious, nontoxic quantity administered to a human patient in need of cardiomyocyte regeneration (or inhibition of VDUP-1 expression) from 1-8 or more times daily or every other day. Dosage is dependent on severity and responsiveness of the effects of abnormal cardiovascular disease to be treated, with course of treatment lasting from several days to months or until a cure is effected or a reduction of the effects is achieved. Oral dosage units for human administration generally use lower doses. The actual dosage administered may take into account the size and weight of the patient, whether the nature of the treatment is prophylactic or therapeutic in nature, the age, weight, health and sex of the patient, the route of administration, and other factors.

[0075] In another embodiment the second agent is a pro-angiogenic agent. In further embodiments the pro-angiogenic agent is vascular endothelial growth factor, fibroblast growth factor or angiopoietin. In another embodiment the second agent induces expression of a pro-angiogenic factor. In a further embodiment the second agent is Hypoxia Inducible Factor-1.

[0076] In another embodiment: the second agent is a catalytic nucleic acid which specifically inhibits translation of Vitamin D3 Up-Regulated Protein-1 RNA. In a further embodiment the catalytic nucleic acid comprises deoxyribonucleotides. In another embodiment the catalytic nucleic acid comprises ribonucleotides.

[0077] Catalytic nucleic acid molecules can cleave Vitamin D3 Up-Regulated Protein-1 (VDUP-1) mRNA (corresponding DNA shown in SEQ ID NO:1, Figure 5) at each and any of the consensus sequences therein. Since catalytic ribo- and deoxyribo- nucleic acid consensus sequences are known, and the VDUP-1. Protein mRNA sequence is known, one of ordinary skill could readily construct a catalytic ribo- or deoxyribo nucleic acid molecule directed to any of the VDUP-1 protein mRNA consensus sequences based on the instant specification. In preferred embodiments of this invention the catalytic deoxyribonucleic acids include the 10-23 structure. Examples of catalytic ribonucleic acids include hairpin and hammerhead ribozyme. In preferred embodiments of this invention, the catalytic ribonucleic acid molecule is formed in a hammerhead (50) or hairpin motif (51,52,53), but may also be formed in the motif of a hepatitis delta virus (54), group I intron (60), RNaseP RNA (in association with an RNA guide sequence) (55,56) or Neurospora VS RNA (57,58,59).

[0078] To target the VDUP-1 mRNA (SEQ ID NO:1), catalytic nucleic acids can be designed based on the consensus cleavage sites 5'-purine:pyrimidine-3' in the VDUP-1 mRNA sequence (104) (see figures 8-10) for cleavage sites on DNA corresponding to the RNA encoding VDUP-1 (SEQ ID NO:2). Those potential cleavage sites located on an open loop of the mRNA according to RNA folding software e.g. RNADraw 2.1 are particularly preferred as targets (61). The DNA based catalytic nucleic acids can utilize the structure where two sequence-specific arms are attached to a catalytic core based on the VDUP-1 mRNA sequence. Further examples of catalytic DNA structure are detailed in (62) and (63). Commercially available mouse brain polyA-RNA (Ambion) can serve as a template in the *in vitro* cleavage reaction to test the efficiency of the catalytic deoxyribonucleic acids. Catalytic RNA, as described above, is designed similarly. Hammerhead ribozymes can cleave any 5'-NUH-3' triplets of a mRNA, where U is conserved and N is any nucleotide and H can be C,U,A, but not G. For example, the sites which can be cleaved by a hammerhead ribozyme in human VDUP-1 mRNA coding region are shown in figure 10.

[0079] Cleaving of VDUP-1 mRNA with catalytic nucleic acids interferes with one or more of the normal functions of VDUP-1 mRNA. The functions of mRNA to be interfered with include all vital functions such as, for example, translocation



of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in by the RNA.

**[0080]** The nucleotides may comprise other bases such as inosine, deoxyinosine, hypoxanthine may be used. In addition, isoteric purine 2'-deoxy-furanoside analogs, 2'-deoxynebularine or 2'-deoxyxanthosine, or other purine or pyrimidine analogs may also be used. By carefully selecting the bases and base analogs, one may fine tune the hybridization properties of the oligonucleotide. For example, inosine may be used to reduce hybridization specificity, while diaminopurines may be used to increase hybridization specificity.

**[0081]** Adenine and guanine may be modified at positions N3, N7, N9, C2, C4, C5, C6, or C8 and still maintain their hydrogen bonding abilities. Cytosine, thymine and uracil may be modified at positions N1, C2, C4, C5, or C6 and still maintain their hydrogen bonding abilities. Some base analogs have different hydrogen bonding attributes than the naturally occurring bases. For example, 2-amino-2'-dA forms three (3), instead of the usual two (2), hydrogen bonds to thymine (T). Examples of base analogs that have been shown to increase duplex stability include, but are not limited to, 5-fluoro-2'-dU, 5-bromo-2'-dU, 5-methyl-2'-dC, 5-propynyl-2'-dC, 5-propynyl-2'-dU, 2-amino-2'-dA, 7-deazaguanosine, 7-deazadenosine, and N2-Imidazolylpropyl-2'-dG.

**[0082]** Nucleotide analogs may be created by modifying and/or replacing a sugar moiety. The sugar moieties of the nucleotides may also be modified by the addition of one or more substituents. For example, one or more of the sugar moieties may contain one or more of the following substituents: amino, alkylamino, aralkyl, heteroalkyl, heterocycloalkyl, aminoalkylamino, O, H, an alkyl, polyalkylamino, substituted silyl, F, Cl, Br, CN, CF<sub>3</sub>, OCF<sub>3</sub>, OCN, O-alkyl, S-alkyl, SOMe, SO<sub>2</sub>Me, ONO<sub>2</sub>, NH-alkyl, OCH<sub>2</sub>CH=CH<sub>2</sub>, OCH<sub>2</sub>CCH<sub>3</sub>, OCCHO, allyl, O-allyl, NO<sub>2</sub>, N<sub>3</sub>, and NH<sub>2</sub>. For example, the 2' position of the sugar may be modified to contain one of the following groups: H, OH, OCN, O-alkyl, F, CN, CF<sub>3</sub>, allyl, O-allyl, OCF<sub>3</sub>, S-alkyl, SOMe, SO<sub>2</sub>Me, ONO<sub>2</sub>, NO<sub>2</sub>, N<sub>3</sub>, NH<sub>2</sub>, NH-alkyl, or OCH=CH<sub>2</sub>, OCCH<sub>3</sub>, wherein the alkyl may be straight, branched, saturated, or unsaturated. In addition, the nucleotide may have one or more of its sugars modified and/or replaced so as to be a ribose or hexose (i.e. glucose, galactose) or have one or more anomeric sugars. The nucleotide may also have one or more L-sugars.

**[0083]** Representative United States patents that teach the preparation of such modified bases/nucleosides/nucleotides include, but are not limited to, U.S. Pat. Nos. 6,248,878, and 6,251,666 which are herein incorporated by reference.

**[0084]** The sugar may be modified to contain one or more linkers for attachment to other chemicals such as fluorescent labels. In an embodiment, the sugar is linked to one or more aminoalkyloxy linkers. In another embodiment, the sugar contains one or more alkylamino linkers. Aminoalkyloxy and alkylamino linkers may be attached to biotin, cholic acid, fluorescein, or other chemical moieties through their amino group.

**[0085]** Nucleotide analogs or derivatives may have pendant groups attached. Pendant groups serve a variety of purposes which include, but are not limited to, increasing cellular uptake of the oligonucleotide, enhancing degradation of the target nucleic acid, and increasing hybridization affinity. Pendant groups can be linked to any portion of the oligonucleotide but are commonly linked to the end(s) of the oligonucleotide chain. Examples of pendant groups include, but are not limited to: acridine derivatives (i.e. 2-methoxy-6-chloro-9- aminoacridine); cross-linkers such as psoralen derivatives, azidophenacyl, proflavin, and azidoproflavin; artificial endonucleases; metal complexes such as EDTA-Fe (II), o-phenanthroline-Cu(II), and porphyrin-Fe(II); alkylating moieties; nucleases such as amino-1-hexanolstaphylococcal nuclease and alkaline phosphatase; terminal transferases; abzymes; cholesteryl moieties; lipophilic carriers; peptide conjugates; long chain alcohols; phosphate esters; amino; mercapto groups; radioactive markers; nonradioactive markers such as dyes; and polylysine or other polyamines. In one example, the nucleic acid comprises an oligonucleotide conjugated to a carbohydrate, sulfated carbohydrate, or glycan. Conjugates may be regarded as a way as to introduce a specificity into otherwise unspecific DNA binding molecules by covalently linking them to a selectively hybridizing oligonucleotide.

**[0086]** The catalytic nucleic acid binding domains (i.e. the non-catalytic domains) or antisense oligonucleotide may comprise modified bonds. For example internucleoside bonds of the oligonucleotide may comprise phosphorothioate linkages. The nucleic acid may comprise nucleotides having moiety may be modified by replacing one or both of the two bridging oxygen atoms of the linkage with analogues such as -NH-, -CH<sub>2</sub>-, or -S-. Other oxygen analogues known in the art may also be used. The phosphorothioate bonds may be stereo regular or stereo random.

**[0087]** The oligonucleotide moiety may have one or more of its sugars modified or replaced so as to be ribose, glucose, sucrose, or galactose, or any other sugar. Alternatively, the phosphorothioate oligonucleotide may have one or more of its sugars substituted or modified in its 2' position, i.e. 2'-allyl or 2'-O-allyl. An example of a 2'-O-allyl sugar is a 2'-O-methyliribonucleotide. Further, the phosphorothioate oligonucleotide may have one or more of its sugars substituted or modified to form an  $\alpha$ -anomeric sugar.

**[0088]** A catalytic nucleic acid may include non-nucleotide substitution. The non-nucleotide substitution includes either abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid or polyhydrocarbon compounds. The term "abasic" or "abasic nucleotide" as used herein encompasses sugar moieties lacking a base or having other chemical groups in place of base at the 1' position.

**[0089]** Determining the effective amount of the instant nucleic acid molecules can be done based on animal data using



routine computational methods. In one embodiment, the effective amount contains between about 10 ng and about 100 µg of the instant nucleic acid molecules per kg body mass. In another embodiment, the effective amount contains between about 100 ng and about 10 µg of the nucleic acid molecules per kg body mass. In a further embodiment, the effective amount contains between about 1 µg and about 5 µg, and in a further embodiment about 2 µg, of the nucleic acid molecules per kg body mass.

[0090] In another embodiment the second agent is cardiomyocyte progenitor cells. In another embodiment the second agent is skeletal muscle progenitor cells. Either of these cell types can be derived from embryonic, fetal or adult subjects.

[0091] In one embodiment the second agent promotes trafficking of the endothelial progenitor cells to the subject's heart. In a further embodiment the second agent that promotes trafficking is an antibody directed against an epitope of CXCR4.

[0092] In another further embodiment the second agent that promotes trafficking is a CC chemokine. In further embodiments the CC chemokine is RANTES, EOTAXIN, monocyte chemoattractant protein-1 (MCP-1), MCP-2, MCP-8, or MCP.

[0093] In another further embodiment the second agent that promotes trafficking is a CXC chemokine. In further embodiments the CXC chemokine is Interleukin-8, Gro-Alpha, or Stromal-Derived Factor-1.

[0094] In one embodiment the second agent promotes mobilization of angioblasts into the subject's bloodstream. In different embodiments the agent is G-CSF, GM-CSF, SDF-1, or VEGF.

[0095] This invention also provides a method of determining the susceptibility of a cardiomyocyte in a subject to apoptosis comprising:

(a) quantitating the amount of a mRNA encoding peroxiredoxin in the cardiomyocyte;

(b) quantitating the amount of a mRNA encoding Vitamin D3 Up-Regulated Protein-1 in the cardiomyocyte; and

(c) determining the ratio of the amount of mRNA encoding peroxiredoxin: amount of mRNA encoding Vitamin D3 Up-Regulated Protein-1, wherein a low ratio indicates a high susceptibility of the cardiomyocyte to apoptosis and a high ratio indicates a low susceptibility of the cardiomyocyte to apoptosis in the subject.

[0096] This invention also provides a method of determining the susceptibility of a cardiomyocyte in a subject to apoptosis comprising:

(a) quantitating the expression of a peroxiredoxin protein in the cardiomyocyte;

(b) quantitating the expression of Vitamin D3 Up-Regulated Protein-1 in the cardiomyocytes; and

(c) determining the ratio of the peroxiredoxin protein expression: Vitamin D3 Up-Regulated Protein-1 expression, wherein a low ratio indicates a high susceptibility of the cardiomyocyte to apoptosis and a high ratio indicates a low susceptibility of the cardiomyocyte to apoptosis in the subject.

[0097] A ratio that is at least two standard deviations above that found in control patients with normal hearts is considered a high ratio. Quantitation of expression of protein in cardiomyocytes is performed using routine methods known to those of skill in the art, for example, northern and western blots.

[0098] This invention further provides a cardiac progenitor cell. In an embodiment the cardiac progenitor cell is resident in the heart, or that comes into the heart from elsewhere after acute ischemia, is smaller than mature cardiomyocytes, expresses alpha sarcomeric actin but is negative for troponin, is normally quiescent but can be induced to go into cell cycle as defined by positive Ki67 staining.

[0099] This invention further provides a method of inducing cell cycling in a cardiac progenitor cell in a heart tissue of a subject comprising administering to the subject an amount of an agent effective to induce neovascularization of the heart tissue in the subject so as to thereby induce cardiac cell cycling within the heart tissue of the subject.

[0100] This invention further provides a method of improving cardiac function in a subject comprising administering to the subject an amount of an agent effective to induce neovascularization of a heart tissue in the subject so as to thereby improve cardiac function in the subject.

[0101] This invention further provides a method of improving cardiac function in a subject comprising administering to the subject an amount of an agent effective to induce proliferation of cardiomyocytes in the heart tissue in the subject so as to thereby improve cardiac function in the subject.

[0102] Cardiac function, or myocardial function, can be determined by any combination of improvement in ejection fraction, perfusion, reduction in anginal symptoms, improvement in quality of life, increased walking ability, longevity of life, reduction in heart medication, and/or prevention of heart failure, as this terms are normally understood in the art.

An improvement in cardiac function in a subject is measured by determining any of these factors in a subject before and after treatment by any of the instant methods.

[0103] In one embodiment of the instant methods, the subject has suffered myocardial ischemia or myocardial infarct. In different embodiments the agent is G-CSF, GM-CSF, IL-8, a Gro family chemokine, an inhibitor of CXCR4, or an inhibitor of SDF-1. In further embodiments the inhibitor of CXCR4 is a small molecule or a monoclonal antibody, the inhibitor of CXCR4 is a small molecule and is AMD 3100, the inhibitor of SDF-1 is a small molecule or a monoclonal antibody, and the Gro family chemokine is Gro alpha. In another embodiment the inhibitor is AMD 070. In differing embodiments the the inhibitor of CXCR4 is a catalytic nucleic acid, an oligonucleotide, RNAi, (RNA interference) or a small molecule.

[0104] This invention further provides a method of inducing apoptosis in a cell comprising inhibiting expression of a peroxiredoxin in the cell. In one embodiment the cell is a tumor cell. In different embodiments the peroxiredoxin is peroxiredoxin I, II, III, IV, or V. In one embodiment the inhibition of expression of peroxiredoxin is effected by contacting the cell with a catalytic nucleic acid which binds mRNA encoding peroxiredoxin, thereby inhibiting the expression thereof. In different embodiments the inhibition of expression of peroxiredoxin is effected by contacting the cell with an antisense oligonucleotide, a monoclonal antibody, RNA interference or a small molecule.

[0105] This invention further provides a method of treating a disorder of a tissue cells of a subject involving loss of tissue cells which comprises administering to the subject an amount of an agent effective to cause tissue cell proliferation within the tissue of the subject so as to thereby treat the disorder. In differing embodiments the tissue is cardiac tissue, brain tissue, peripheral vascular tissue, hepatic tissue, renal tissue, gastrointestinal tissue, lung tissue, smooth muscle tissue, or striated muscle tissue. In differing embodiments the agent is G-CSF, SDF-1, GM-CSF, IL-8, VEGF. In one embodiment the agent is an inhibitor of CXCR4/SDF-1 interaction. In further embodiments the inhibitor is a catalytic nucleic acid, a monoclonal antibody, a antisense oligonucleotide, a small molecule, or RNAi. In one embodiment the agent is an inducer of peroxiredoxin expression. In further embodiments the peroxiredoxin is peroxiredoxin I, II, III, IV, or V.

[0106] In any of the instant methods wherein the agent is G-CSF, the G-CSF may be a covalent conjugate of recombinant methionyl human G-CSF (Filgrastim) and monomethoxypolyethylene glycol, such as Neulasta. Filgrastim is a water-soluble 175 amino acid protein with a molecular weight of approximately 19 kilodaltons (kd). Filgrastim is obtained from the bacterial fermentation of a strain of *Escherichia coli* transformed with a genetically engineered plasmid containing the human G-CSF gene. To produce pegfilgrastim, a 20 kd monomethoxypolyethylene glycol molecule is covalently bound to the N-terminal methionyl residue of Filgrastim. The average molecular weight of pegfilgrastim is approximately 39 kd. Neulasta is supplied in 0.8 mL prefilled syringes for subcutaneous (SC) injection. Each syringe contains 6 mg pegfilgrastim (based on protein weight), in a sterile, clear, colorless, preservative-free solution (pH 4.0) containing acetate (0.35 mg), sorbitol (30 mg), polysorbate 2.0 (0.02 mg), and sodium (0.02 mg) in water for injection, USP.

[0107] This invention provides a method of treating a disorder of a tissue of a subject involving apoptosis of cells in the tissue which comprises administering to the subject an amount of an agent effective to inhibit apoptosis of cells in the tissue within the subject so as to thereby treat the disorder. In one embodiment the agent is an inhibitor of VDUP-1 expression. In further embodiments the inhibitor of VDUP-1 expression is catalytic nucleic acid, a monoclonal antibody, an antisense oligonucleotide, a small molecule, or an RNAi. In differing embodiments the tissue is cardiac tissue, cerebrovascular tissue, or cerebral tissue.

[0108] This invention also provides a method of inhibiting proliferation of fibroblasts or inflammatory cells in a tissue and thereby inhibiting collagen formation comprising contacting the tissue with an inhibitor of VDUP-1 expression. In one embodiment the inhibitor of VDUP-1 expression is a catalytic nucleic acid, a monoclonal antibody, an antisense oligonucleotide, a small molecule, or an RNAi.

[0109] In one embodiment the subject of any of the above methods is a mammal and in a preferred further embodiment the mammal is a human being. In one embodiment the subject has a cardiovascular disease. In further embodiments the subject has congestive heart failure, has suffered a myocardial infarct, has suffered myocardial ischemia, has angina, or has a cardiomyopathy.

[0110] This invention will be better understood by reference to the Experimental Details which follow, but those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention as described more fully in the claims which follow thereafter.

## EXPERIMENTAL RESULTS (I)

### CXC Chemokines Regulate Endothelial Progenitor Cell Migration To The Heart.

[0111] We investigated the in vivo role of CXC receptor-ligand interactions in mediating chemotaxis of human Endothelial progenitor cell to ischemic tissue and subsequent induction of vasculogenesis, using myocardial infarction in the LAD-ligated nude rat model. As shown in Figure 1a, DiI-labelled human CD34+ cells obtained by G-CSF mobilization (>98% CD34 purity, containing 6-12% CD117<sup>bright</sup> endothelial progenitor cells) were selectively detected in infarcted

myocardium after intravenous injection, but not in myocardium from sham-operated rats. Co-administration of blocking mAbs against rat Cinc (the rat homologue of human IL-8 and Gro- $\alpha$ ), or against the human surface receptors for these pro-angiogenic chemokines, CXCR1 or CXCR2, reduced myocardial trafficking of human bone marrow-derived CD34+ cells at 48 hours by 40-60% relative to control antibodies ( $p < 0.01$ ). Figure 1b. By two weeks, rats receiving human CD34+ cells demonstrated significantly increased infarct bed microvasculature in comparison to rats receiving saline, Figure 1c, and this was reduced by 50% when anti-CXCR1/2 mAbs were co-administered. Since we have previously shown that the vasculogenic properties of CD34+ cells are abolished after depletion of the minor CD117<sup>bright</sup> angioblast fraction (7), these results indicate that by regulating angioblast migration to ischemic tissues CXC chemokines influence the development of vasculogenesis at these sites. In contrast, although direct intracardiac injection of IL-8 or SDF-1 at 1.0  $\mu$ g/ml into non-infarcted hearts resulted in 2.3 and 2.5-fold increases in myocardial infiltration by human CD34+ cells at 48 hours (both  $p < 0.01$ ). Figure 1d, no vasculogenesis was observed at two weeks under these conditions. Together, these results indicate that following chemokine-induced migration to the infarct zone, differentiation of endothelial progenitor cell to mature endothelial cells and induction of vasculogenesis require additional factors, as yet undefined, which are produced under ischemic conditions.

#### Inhibiting CXCR4/SDF-1 Interactions Redirects Endothelial Progenitor Cells to The Heart.

[0112] Although LAD coronary artery ligation resulted in trafficking of intravenously injected human endothelial progenitor cells to the site of ischemic myocardium, it was also accompanied by increased distribution of human cells to rat bone marrow. As shown in Figure 2a, at 2-14 days after intravenous injection of  $2 \times 10^6$  human CD34+ cells bone marrow from LAD-ligated rats contained 5-8 fold higher levels of human CD117<sup>bright</sup> endothelial progenitor cells compared with bone marrow from normal rats,  $p < 0.001$ . This was presumably due to the proliferative effects of factors in ischemic serum since we have previously shown that culture for 2 days with ischemic serum increases proliferation of CD34+CD117<sup>bright</sup> human endothelial progenitor cells by 4-5 fold (7). Because the migration of actively cycling CD34+ cells to bone marrow is promoted by SDF-1 produced constitutively by marrow stromal cells (31), we investigated whether the distribution of human CD34+CD117<sup>bright</sup> endothelial progenitor cells to ischemic rat bone marrow involved SDF-1/CXCR4 interactions. As shown in Figure 2b, co-administration of mAbs against either human CXCR4 or rat SDF-1 significantly inhibited migration of intravenously administered human endothelial progenitor cells to ischemic rat bone marrow compared with anti-CD34 control antibody (both  $p < 0.001$ ). Moreover, co-administration of mAbs against either human CXCR4 or rat SDF-1 increased trafficking of CD34+ human endothelial progenitor cells to ischemic rat myocardium by means of 24% and 17%, respectively (both  $p < 0.001$ ). Figure 2c.

#### Capillary Lumen Size Is Dependent On Absolute Angioblast Numbers.

[0113] We next examined the relationship between angioblast number, myocardial neovascularization, and protection against myocyte apoptosis. Two days following LAD ligation animals were intravenously injected with G-CSF mobilized CD34+ human cells reconstituted with varying proportions of CD117<sup>bright</sup> endothelial progenitor cells ( $10^3$ ,  $10^4$ ,  $10^5$  plus anti-CXCR4 mAb,  $2 \times 10^5$ , and  $2 \times 10^5$  plus anti-CXCR4 mAb). Similar numbers of DII-labelled human cells were detected in the infarct zone 48 hours after injecting each cellular population, data not shown. Induction of neovascularization at two weeks was measured by performing quantitative analysis of medium- and large-sized capillaries, defined, respectively, as having 3-6 or  $> 6$  contiguous endothelial lining cells. Medium-sized capillaries had mean lumen diameter of  $0.020 \text{ mm} \pm 0.002$ , while large-sized capillaries had mean lumen diameter of  $0.053 \text{ mm} \pm 0.004$  ( $p < 0.001$ ). Notably, large-lumen capillaries overlapped in size with arterioles which could be distinguished by a thin layer containing 2-3 smooth muscle cells of rat origin, as determined by positive staining with desmin and rat MHC class I mAbs. As shown in Figures 3a-c, both the group receiving  $2 \times 10^5$  endothelial progenitor cells and the one receiving  $10^5$  endothelial progenitor cells plus anti-CXCR4 mAb demonstrated 1.7-fold higher numbers of medium-sized capillaries compared with the other two groups ( $p < 0.01$ ). The group receiving  $2 \times 10^5$  endothelial progenitor cells additionally demonstrated 3.3-fold higher numbers of large-lumen capillaries compared with the groups receiving  $10^3$  or  $10^5$  endothelial progenitor cells ( $p < 0.01$ ), and 2-fold higher numbers of large-lumen capillaries compared with the group receiving  $10^5$  endothelial progenitor cells plus anti-CXCR4 mAb ( $p < 0.01$ ). As shown in Figure 3d, co-administration of anti-CXCR4 mAb together with the highest concentration of endothelial progenitor cells,  $2 \times 10^5$ , resulted in a further 23% increase in growth of large-lumen capillaries. More strikingly, there was a further 2-fold increase in capillary numbers when  $2 \times 10^5$  endothelial progenitor cells were injected intravenously after direct intracardiac delivery of 1.0  $\mu$ g/ml SDF-1 into infarcted hearts ( $p < 0.01$ ). Since no similar increase in peri-infarct capillary numbers was seen after intracardiac delivery of IL-8, we interpret these results to indicate that the endogenous IL-8 concentrations in ischemic rat hearts were sufficient to saturate angioblast CXCR1/2 receptors in vivo, whereas intracardiac injection of SDF-1 resulted in a shift in the balance of SDF-1 expression between bone marrow and heart, and consequently resulted in redirected angioblast trafficking to the ischemic heart.

[0114] As shown in Figure 3e, the number of apoptotic cardiomyocytes at the infarct rim was significantly reduced in

both rats receiving  $10^5$  Endothelial progenitor cells plus anti-CXCR4 mAb and those receiving  $2 \times 10^5$  endothelial progenitor cells compared with the groups receiving either  $10^3$  or  $10^5$  endothelial progenitor cells alone (both  $p < 0.001$ ). Moreover, co-administration of anti-CXCR4 mAb or intracardiac injection of SDF-1 resulted in further reductions in cardiomyocyte apoptosis of 65% and 76%, respectively, Figure 3f (both  $p < 0.001$ ). Together, these data indicate that post-infarct cardioprotection against myocyte apoptosis is dependent on myocardial neovascularization induced by a critical number of intravenously injected endothelial progenitor cells. This threshold can apparently be lowered by strategies that prevent endothelial progenitor cell redistribution to the bone marrow, such as interrupting CXCR4/SDF-1 interactions, or enhanced SDF-1 expression in the ischemic myocardium.

#### Capillary Lumen Size As Determinant Of Improvement In Cardiac Function.

[0115] We next examined the effect of increasing the number of human endothelial progenitor cells trafficking to ischemic myocardium on long-term myocardial function, defined as the degree of improvement in left ventricular ejection fraction (LVEF) and reduction in left ventricular end-systolic area (LVAs) at 15 weeks after intravenous injection, Figures 4a and b. No improvement in these parameters was observed in the groups receiving  $10^3$  or  $10^5$  endothelial progenitor cells in comparison to rats receiving saline alone. In contrast, rats receiving  $10^5$  endothelial progenitor cells plus anti-CXCR4 mAb demonstrated significant improvement in these parameters, 22 + 2% mean recovery in LVEF and 24 + 4% mean reduction in LVAs (both  $p < 0.001$ ). Even more strikingly, the group receiving  $2 \times 10^5$  endothelial progenitor cells had a mean recovery in LVEF of 34 + 4% and a mean reduction in LVAs of 37 + 6% (both  $p < 0.001$ ), or 50% further improvement in both parameters. These results were very surprising to us since both groups of animals had demonstrated the same degree of neovascularization involving medium-sized capillaries at two weeks together with similar levels of protection against early apoptosis of cardiomyocytes. This suggested that the additional functional long-term improvement in rats receiving  $2 \times 10^5$  human endothelial progenitor cells was related to the early development of large-sized capillaries and was mediated through a different mechanism than protection against myocyte apoptosis.

#### Large Capillaries Induce Sustained Regeneration Of Endogenous Myocytes.

[0116] Although myocyte hypertrophy and increase in nuclear ploidy have generally been considered the primary mammalian cardiac responses to ischemia, damage, and overload (1,2) recent observations have suggested that human cardiomyocytes have the capacity to proliferate and regenerate in response to injury (18,19). Therefore, we investigated whether the additive improvement in cardiac function observed after injection of  $2 \times 10^5$  human endothelial progenitor cells involved induction of cardiomyocyte proliferation and/or regeneration. At two weeks after LAD ligation rats receiving  $2 \times 10^5$  human endothelial progenitor cells demonstrated numerous "fingers" of cardiomyocytes of rat origin, as determined by expression of rat MHC class molecules, extending from the peri-infarct region into the infarct zone. Similar extensions were seen less frequently in animals receiving  $10^3$  and  $10^5$  endothelial progenitor cells, and very rarely in those receiving saline. As shown in Figure 4c, the islands of cardiomyocytes at the peri-infarct rim in animals receiving  $2 \times 10^5$  human endothelial progenitor cells contained a high frequency of rat myocytes with DNA activity, as determined by dual staining with mAbs reactive against cardiomyocyte-specific troponin I and rat Ki-67. In contrast, in animals receiving saline there was a high frequency of cells with fibroblast morphology and reactivity with rat Ki-67, but not troponin I, within the infarct zone. The number of cardiomyocytes progressing through cell cycle at the peri-infarct region of rats receiving  $2 \times 10^5$  human endothelial progenitor cells was 40-fold higher than that at sites distal to the infarct, where myocyte DNA activity was no different than in sham-operated rats. As shown in Figure 4d, animals receiving  $2 \times 10^5$  human endothelial progenitor cells had a 20-fold higher number of cell-cycling cardiomyocytes at the peri-infarct rim than that found in non-infarcted hearts ( $1.19 \pm 0.2\%$  vs  $0.06 \pm 0.03\%$ ,  $p < 0.01$ ) and 3.5-fold higher than in the same region in LAD-ligated controls receiving saline ( $1.19 \pm 0.2\%$  vs  $0.344 \pm 0.1\%$ ,  $p < 0.01$ ). When  $2 \times 10^5$  human endothelial progenitor cells were intravenously injected after direct intracardiac delivery of 1.0  $\mu\text{g/ml}$  SDF-1 into infarcted hearts, the number of cell-cycling cardiomyocytes at the peri-infarct rim was increased by a further 1.9-fold compared with intravenous injection of  $2 \times 10^5$  human endothelial progenitor cells alone (Figure 4e,  $p < 0.01$ ). Thus, intracardiac injection of SDF-1 in combination with intravenous injection of  $2 \times 10^5$  human endothelial progenitor cells resulted in approximately an 8-fold cumulative increase in cell-cycling cardiomyocytes at two weeks compared with LAD-ligated controls receiving saline, and translated into over 4-fold greater LVEF improvement, determined by echocardiography, compared with intravenous injection of  $2 \times 10^5$  endothelial progenitor cells alone (Figure 4f,  $p < 0.01$ ). Co-administration of anti-CXCR4 mAb augmented LVEF improvement by 2.8-fold ( $p < 0.01$ ) while intracardiac injection of IL-8 conferred no additive benefit.

[0117] Quantitation of the ratio of fibrous tissue to myocytes at 15 weeks demonstrated significantly reduced proportions of scar/normal left ventricular myocardium in both the group receiving  $2 \times 10^5$  endothelial progenitor cells and the one receiving  $10^5$  endothelial progenitor cells plus anti-CXCR4 mAb, respectively 13% and 21% compared with 37-46% for each of the other groups ( $p < 0.01$ ), Figure 4g. Since both groups had nearly identical levels of protection against early cardiomyocyte apoptosis, we infer that the additional 38% reduction in scar/myocyte ratio seen in the group injected

with  $2 \times 10^5$  endothelial progenitor cells actually reflects proliferation/regeneration of endogenous rat cardiomyocytes induced by nutrient supply from large-vessel neovascularization. This presumably accounts for the increase in functional improvement seen in this group. We conclude that the ratio of scar size to left ventricular muscle mass reflects, in part, positive effects imparted by the ability of the residual myocardium to proliferate and regenerate, in addition to negative effects of the initial infarct size and positive effects of anti-apoptotic, cardioprotective mechanisms. The overall effects of medium- and large-size neovasculation combining to both protect against myocyte apoptosis and induce myocyte proliferation/regeneration are shown dramatically in Figure 4h where, in contrast to saline controls, injection with  $2 \times 10^5$  endothelial progenitor cells resulted in almost complete salvage of the anterior myocardium, normal septal size and minimal collagen deposition.

#### Effecting Regeneration

##### PAI-1-inhibiting catalytic nucleic acid augments human angioblast-dependent cardiomyocyte regeneration.

[0118] We investigated whether possible neovascularization induced by a catalytic nucleic acid (designated E2) capable of inhibiting expression of PAI-1 was associated with cardiomyocyte regeneration. Injection of E2 alone did not induce cardiomyocytes regeneration despite the increase in neovascularization. Combining E2 injection with intravenously delivered human endothelial progenitor cells strikingly increased the degree of cardiomyocyte regeneration, to levels 7.5-fold higher than in saline controls ( $p < 0.01$ ). A scrambled DNA control enzyme (E0) had no such effect. Moreover, whereas E2 alone did not improve myocardial function, as determined by recovery in left ventricular ejection fraction at two weeks combining E2 with human endothelial progenitor cells resulted in almost doubling of the positive effect of endothelial progenitor cells alone on cardiac functional recovery. These results emphasize the importance of cardiomyocyte regeneration as the primary mechanism by which cardiac function is improved after infarction. Since combining E2 with human endothelial progenitor cells resulted in 62% greater numbers of large capillaries at the peri-infarct rim than use of either approach alone, these results indicate that angioblast-induced cardiomyocyte regeneration and improvement in cardiac function can be optimized by use of synergistic approaches, such as strategies that inhibit PAI-1 expression, which augment neovascularization either directly or through angioblast-dependent processes.

[0119] We further discovered that intravenous injection of human CD34+CD117bright angioblasts resulted in a four-fold increase in proliferation/regeneration of rat cardiomyocyte at the peri-infarct region relative to saline controls, as determined by dual staining for troponin and Ki67 ( $p < 0.01$ ). Combining E2 injection with intravenously delivered human angioblasts strikingly increased the degree of cardiomyocyte regeneration, to levels 7.5-fold higher than in saline controls ( $p < 0.01$ ). The scrambled DNA enzyme E0 had no such effect.

##### Gene effects on myocyte proliferation

[0120] We hypothesized that myocardial neovascularization induces the signals required to elicit myocyte proliferation, and therapeutic intervention mimicking this could have striking implications for repair and regeneration of hearts damaged by episodes of ischemia or other insults.

[0121] To begin approaching this complex problem, we have employed the technique of cDNA Subtractive Hybridization. This technique enables comparison of the pattern of gene expression between two different sets of conditions. Our initial approach was to compare which genes are differentially expressed between hearts from normal rats and rats who have undergone left anterior descending (LAD) coronary artery ligation 48 hours earlier. We hypothesized that whatever the altered pattern of gene over- or underexpression after 48 hours of ischemia, neovascularization would result in a reversal in the pattern towards that seen in the non-ischemic rat heart.

[0122] Using cDNA subtractive hybridization we observed a striking reciprocal change in expression of a group of genes whose function is linked through their regulation of cellular apoptosis and cell cycle progression following oxidative stress and other inducers of DNA damage. Whereas expression of certain antioxidant genes such as superoxide dismutase was upregulated in ischemic tissue, the antioxidant stress responsive genes induced by hemein, notably heme binding protein 23 (HBP23) and glutathione-S-transferase, were down-regulated. Moreover, a recently-identified protein, Vitamin D3 Up-Regulated Protein (VDUP1), whose mRNA expression is induced by hydrogen peroxide ( $H_2O_2$ ) following oxidative stress and whose function counterbalances that of HBP23, was upregulated in ischemic hearts. These findings are particularly striking when considered in the context of previous observations that the presence of deficits in antioxidants and increased oxidative stress accompanying myocardial infarction appear to be directly implicated in the pathogenesis of post-infarct heart failure (74,75).

[0123] As shown in Figure 5, using RT-PCR, the reciprocal changes in mRNA expression of HBP23 and VDUP1 in ischemic vs normal rat hearts were confirmed. Moreover, mRNA expression of these two genes returned to normal in rat tissue two weeks after intravenous injection of human adult bone marrow-derived progenitors and infarct zone neovascularization. In contrast, in LAD-ligated rat hearts receiving saline, no change in mRNA expression of these genes

was observed at two weeks in comparison to the pattern observed at 48 hours. To comprehend the relationship between the effects of neovascularization on these altered expression patterns of HBP23 and VDUP1 following ischemia, and the observed protection against cardiomyocyte apoptosis together with induction of cardiomyocyte proliferation/regeneration, it is important to understand in detail the molecular effects of the products encoded by these genes on cellular apoptosis and cell cycle progression.

[0124] When cells proliferate, the mitotic cycle progression is tightly regulated by an intricate network of positive and negative signals. Progress from one phase of the cell cycle to the next is controlled by the transduction of mitogenic signals to cyclically expressed proteins known as cyclins and subsequent activation or inactivation of several members of a conserved family of serine/threonine protein kinases known as the cyclin-dependent kinases (cdks) (67). Growth arrest observed with such diverse processes as DNA damage, terminal differentiation, and replicative senescence is due to negative regulation of cell cycle progression by two functionally distinct families of Cdk inhibitors, the Ink4 and Cip/Kip families (54). The cell cycle inhibitory activity of p21Cip1/WAF1 is intimately correlated with its nuclear localization and participation in quaternary complexes of cell cycle regulators by binding to G1 cyclin-CDK through its N-terminal domain and to proliferating cell nuclear antigen (PCNA) through its C-terminal domain (68-71). The latter interaction blocks the ability of PCNA to activate DNA polymerase, the principal replicative DNA polymerase (72). For a growth-arrested cell to subsequently enter an apoptotic pathway requires signals provided by specific apoptotic stimuli in concert with cell-cycle regulators. For example, caspase-mediated cleavage of p21, together with upregulation of cyclin A-associated cdk2 activity, have been shown to be critical steps for induction of cellular apoptosis by either deprivation of growth factors (73) or hypoxia of cardiomyocytes (74).

[0125] The apoptosis signal-regulating kinase 1 (ASK1) is a pivotal component in the mechanism of cytokine- and stress-induced apoptosis (75,76). Under basal conditions, resistance to ASK1-mediated apoptosis appears to be the result of complex formation between ASK1, cytoplasmic p21Cip1/WAF1 (77), and the thiol reductase thioredoxin (TRX) (78). Intact cytoplasmic expression of p21Cip1/WAF1 appears to be important for both prevention of apoptosis in response to ASK1 (75) and in maintaining a state of terminal differentiation (77). Moreover, the reduced form of TRX, but not the oxidized form, binds to the N-terminal portion of ASK1 and is a physiologic inhibitor of ASK1-mediated cellular apoptosis (78). The recently-identified protein VDUP1 has been shown to compete with ASK1 for binding of the reduced form of TRX (78,79), resulting in augmentation of ASK1-mediated apoptosis (80). This indicates that ASK1-mediated cellular apoptosis is increased by processes that result in a net dissociation of TRX from ASK1, such as either generation of TRX-VDUP1 complexes or generation of oxidized TRX by changes in cellular redox status accompanying oxidative stress.

[0126] TRX and glutathione constitute the major cellular reducing systems that maintain the thiol-disulfide status of the cytosol (81). The redox-active/dithiol active site of TRX is highly conserved across all species, Trp-Cys-Gly-Pro-Cys-Lys. The two cysteine residues at the active site, Cys-32 and Cys-35, undergo reversible oxidation-reduction reactions catalyzed by a NADPH-dependent enzyme TRX reductase. These reactions involve electron transfer via disulfide bridges formed with members of a family of antioxidant enzymes known as peroxiredoxins (Prxs), which show peroxidase activity (82,83). Prxs are distinct from other peroxidases in that they have no cofactors, such as metals or prosthetic groups. Prxs generally have two conserved cysteines at the N- and C-terminal regions (84), and their antioxidant effects are coupled with the physiological electron donor activity of the TRX system (82,85, 86). Prxs with 95-97% sequence homology have been identified in rats (Heme-binding protein 23, HBP23) (87), mice (mouse macrophage stress protein 23, MSP23) (88) and humans (proliferation-associated gene product, PAG (89) and human natural killer cell-enhancing factor A (90)).

[0127] Prxs are members of a repertoire of oxidative stress responsive genes whose expression is regulated by NF-E2-related factor 2 (Nrf2) which binds to an anti-oxidant responsive element (ARE) present in the promoter of each (91). These include glutathione-S-transferase, heme oxygenase-1, and TRX. Under basal conditions, Nrf2 is bound to a specific protein, Keap1, in the cytosol (92). However, under conditions of oxidative stress Nrf2 dissociates from Keap1 and translocates to the nucleus where it induces transcriptional activation of the anti-oxidant genes containing ARE motifs. Although the precise extracellular signalling pathways have not been elucidated, nuclear translocation of Nrf2 and subsequent ARE activation appear to be dependent on pathways activated by phosphatidylinositol 3-kinase (P13 kinase) (93). In addition, hemin is a potent inducer of Nrf2 dissociation from Keap1, resulting in TRX gene transcription through the ARE (94).

[0128] During periods of rapid changes in cellular redox Prxs presumably serve to maintain the cytosolic levels of reduced TRX by accepting electrons from the oxidized form of TRX. This homeostatic mechanism likely enables maintenance of sufficient levels of reduced TRX to ensure adequate binding to ASK1 and prevention of cellular apoptosis. If the endogenous Prx system is overloaded, as might occur during changes in cellular redox when excess oxidized TRX is generated, cellular apoptosis will occur through the unopposed effects of ASK1. To counteract this, transcriptional activation of Prxs must occur following oxidative stress via nuclear translocation of Nrf2. This can be achieved either by Nrf2 dissociation from Keap1 via hemin- and P13 kinase-dependent mechanisms (93,94), or by increasing Nrf2 mRNA and protein expression as occurs following increase in oxygen tension (95,96).

[0129] In addition to directly interacting with TRX, the Prx gene products (PAG, HBP23, MSP23, NKEF, etc) specifically

bind the SH3 domain of c-Abl, a non-receptor tyrosine kinase, inhibiting its activation by various stimuli, including agents that damage DNA (97). c-Abl activation through the SH3 domain induces either arrest of the cell cycle in phase G1 or cellular apoptosis (98). Cell cycle arrest is dependent on the kinase activity of c-Abl (98) and is mediated by the ability of c-Abl to downregulate the activity of the cyclin-dependent kinase Cdk2 and induce the expression of p21 (99). The apoptotic effects of c-Abl are dependent on the ability of nuclear c-Abl to phosphorylate p73, a member of the p53 family of tumor-suppressor proteins which can induce apoptosis (100,101). Recently, it has been shown that cytoplasmic, rather than nuclear, forms of c-Abl are activated by H<sub>2</sub>O<sub>2</sub> and that this results in mitochondrial localization of c-Abl, c-Abl dependent cytochrome c release, and cellular apoptosis following oxidative stress (102,103). By associating with c-Abl in vivo, the PAG gene product (and presumably the other Prxs) can inhibit tyrosine phosphorylation induced by c-Abl overexpression and rescue cells from both the cytostatic and pro-apoptotic effects of the activated c-Abl gene product (97).

[0130] Our finding that Nrf2-dependent oxidative stress responsive genes are downregulated following myocardial ischemia likely reflects direct effects of hemin and oxygen deprivation. The end result of Prx downregulation in the ischemic heart would be augmentation in ASK1-dependent cellular apoptosis as well as Abl-dependent apoptosis and cell cycle arrest. The observed parallel increase in VDUP1 expression would further augment ASK1-dependent cellular apoptosis. Thus, the ratio in expression of PAG or other Prx mRNA or protein to VDUP1 mRNA or protein can form the basis of a diagnostic assay to predict the degree of risk for cardiomyocyte apoptosis and cell cycle arrest after ischemia, as well as enable monitoring of the response to specific therapy after myocardial ischemia that protects cardiomyocytes against apoptotic death and enhances myocardial proliferation/regeneration.

[0131] Reversing the reduced expression of the Prxs following myocardial ischemia would increase Prxs in the heart in order to protect the ischemic myocardium against apoptosis through both c-Abl inhibition and reduction of oxidised TRX, and to enable cardiomyocyte proliferation/regeneration by inhibiting the effects of c-Abl on cell cycle progression from G1 to S phase.

[0132] Increasing Nrf2 mRNA or causing dissociation of Nrf2 protein from Keap1, or preferably cause both to occur simultaneously, in the setting of myocardial ischemia in order to increase transcription and activity of members of a repertoire of oxidative stress responsive genes whose expression is regulated by binding of Nrf2 to an anti-oxidant responsive element (ARE) in their promoters, including the Prxs, TRX and glutathione-S-transferase would result in both protection of cardiomyocytes against apoptosis as well as induce cardiomyocyte cell cycle progression following oxidative stress.

[0133] Reducing the expression of VDUP1 following myocardial ischemia would protect the ischemic myocardium against apoptosis by reducing binding of TRX to VDUP1, and consequently increasing TRX-ASK1 interactions.

[0134] Neovascularization of the myocardium, by either bone marrow-derived endothelial progenitors or any other process, is an example of one method which causes induction of Prx expression and reduction in VDUP1 expression after myocardial ischemia, and results in both protection against redox-mediated apoptosis and induction of myocardial proliferation/regeneration.

[0135] Small molecules which specifically inhibit binding of Nrf2 to Keap1 would be expected to have similar protective effects against cardiomyocyte apoptosis and to induce myocardial proliferation/regeneration after ischemia. Similarly, small molecules that specifically inhibit binding of TRX to VDUP1, would be expected to have similar protective effects against cardiomyocyte apoptosis after ischemia.

[0136] Use of small molecules to specifically inhibit c-Abl tyrosine kinase activation after myocardial ischemia would be expected to have similar protective effects against cardiomyocyte apoptosis and to induce myocardial proliferation/regeneration after ischemia. A specific example of a small molecule to inhibit c-Abl tyrosine kinase activation is STI-571. Use of this or related molecules after myocardial infarction would protect against cardiomyocyte apoptosis and induce myocardial proliferation/regeneration.

#### DNA Enzyme Specific For VDUP-1 Cleaves Synthetic Rat VDUP-1 Oligonucleotide

[0137] By subtractive hybridization, we found that mRNA expression of the protein VDUP1 is significantly increased in the heart after acute ischemia. VDUP1 has been shown to bind the cytosolic protein thioredoxin, TRX, which functions to maintain the thiol-disulfide status of the cytosol. By binding to reduced forms of TRX, VDUP1 prevents the ability of reduced TRX to undergo reversible oxidation-reduction reactions catalyzed by a NADPH-dependent enzyme, TRX reductase. This results in cellular apoptosis due to excessive cytosolic and mitochondrial production of oxygen radicals.

[0138] VDUP1 competes for TRX binding with another cytosolic protein that is normally bound to reduced TRX, the apoptosis signal-regulating kinase 1 (ASK1). ASK-1 is a pivotal component in the mechanism of cytokine- and stress-induced apoptosis. Its activation results in excessive phosphorylation and activation of p38 MAP kinase, a principal mediator of cellular apoptosis. The reduced form of TRX, but not the oxidised form, binds to the N-terminal portion of ASK1 and is a physiologic inhibitor of ASK1-mediated cellular apoptosis. Binding of VDUP1 to TRX results in a net dissociation of ASK1 from TRX, potentially resulting in augmentation of ASK1-mediated apoptosis via p38 MAP kinase-



dependent pathways.

[0139] With respect to cardiac overexpression of VDUP1, the anticipated effects would be those due to excessive p38 MAP kinase activation and oxidative redox damage, including cardiomyocyte apoptosis, fibroblast proliferation, collagen secretion and scar formation. Similar effects would be expected to be the consequence of VDUP1 overexpression in other tissues undergoing acute or chronic ischemic injury, for example the brain following cerebrovascular ischemia/stroke.

[0140] We have developed a DNA enzyme targeting the VDUP1 mRNA. The DNA enzyme, once delivered to the ischemic myocardium (or other ischemic tissues such as the brain) can inhibit local VDUP1 mRNA and protein expression, thus reducing p38 MAP kinase activation and oxidative damage.

[0141] As shown in figure 12, at enzyme concentrations ranging from 0.05uM to 5uM the sequence-specific VDUP1 DNA enzyme cleaved a synthetic rat VDUP1 oligonucleotide in a concentration- and time-dependent manner.

[0142] VDUP-1 DNAzyme Reduces Fibroblast Proliferation And Protects Against Cardiomyocyte Apoptosis. As shown in figure 13(a), intramyocardial injection of the rat sequence-specific VDUP1 DNA enzyme at 48 hours after LAD ligation resulted in a 75% mean inhibition of proliferating cardiac fibroblasts in the infarct zone two weeks later in comparison to injection of scrambled DNA enzyme control ( $p < 0.01$ ). In addition, as seen in figure 13(b), injection of VDUP1 DNA enzyme resulted in 20% mean reduction in apoptotic cardiomyocytes at the peri-infarct region relative to injection with the scrambled DNA enzyme control ( $p < 0.05$ ).

[0143] VDUP-1 DNAzyme Reduces Myocardial Scar And Improves Cardiac Function After Acute Infarction. Inhibition of fibroblast proliferation and cardiomyocyte apoptosis resulted in significant reduction of mature scar deposition in the infarct zone, from a mean of 35% for animals receiving control scrambled DNA enzyme to a mean of 20% for those receiving VDUP1 DNA enzyme, figure 14(a) ( $p < 0.01$ ). Most dramatic was the effect on cardiac function. As shown in figure 14(b), animals receiving VDUP1 DNA enzyme demonstrated a 50% mean recovery in cardiac function, as determined by ejection fraction, whereas no improvement was seen in animals receiving scrambled control DNA enzyme ( $p < 0.01$ ).

[0144] Clearly, VDUP1 DNA enzyme prevents cardiomyocyte apoptosis, cardiac fibroblast proliferation and scar formation, resulting in significant improvement in cardiac function after acute ischemia. These effects are presumably due to prevention of p38 MAP kinase activation and protection against redox damage. Similar results might be obtained by administering the VDUP1 DNA enzyme to other tissue sites of reduced blood flow such as the brain after cerebrovascular ischemia.

#### G-CSF

[0145] G-CSF is a more potent inducer of neovascularization after myocardial infarction than GM-CSF. As shown in figure 15(a), rats injected subcutaneously with human G-CSF at 10 ug/kg for four days starting at two days after myocardial infarction induced by left anterior descending (LAD) coronary artery ligation demonstrated approximately 7.5-fold greater numbers of large-diameter blood vessels at the peri-infarct region two weeks later relative to saline-treated controls ( $p < 0.01$ ). Rat GM-CSF administered at the same dosage regimen was less effective, though still inducing 4-fold greater numbers of large-lumen vessels than in control animals.

[0146] Additionally, G-CSF is a more potent inhibitor of cardiomyocyte apoptosis after myocardial infarction than GM-CSF. G-CSF injection was a more potent agent for protecting against cardiomyocyte apoptosis than GM-CSF used at the same dosage regimen, figure 15(b). G-CSF administration resulted in 36 + 16% reduction in the numbers of apoptotic cardiomyocytes at the peri-infarct region by two weeks relative to saline-treated controls ( $p < 0.01$ ), whereas GM-CSF only reduced apoptotic cardiomyocyte numbers by 12 + 9%.

[0147] G-CSF is a more potent inducer of cardiomyocyte regeneration and functional cardiac recovery after myocardial infarction than GM-CSF. Next we examined the effects of bone marrow mobilization on cardiomyocyte cell cycling/regeneration and on functional cardiac recovery. As shown in figure 16(a), rats injected subcutaneously with human G-CSF at 10 ug/kg for four days starting at two days after myocardial infarction demonstrated 3.2-fold greater numbers of cycling cardiomyocytes two weeks later at the peri-infarct region relative to saline-treated controls ( $p < 0.05$ ). Rat GM-CSF administered at the same dosage regimen was less effective, resulting in 2.6-fold greater numbers of cycling cardiomyocytes. As shown in figure 16(b), this correlated with functional cardiac recovery. Whereas saline-treated animals had a 17% mean loss in cardiac function from day 2 to day 14 after infarction as measured by ejection fraction, GM-CSF treated animals had a loss of only 10% in cardiac function, and G-CSF treated animals actually had a 10% mean improvement in cardiac function ( $P < 0.01$ ). We interpret these functional data to reflect the superior effects of G-CSF bone marrow mobilization on myocardial neovascularization, protection against cardiomyocyte apoptosis and induction of cardiomyocyte cell cycling.



Anti-CXCR4 Antibodies

**[0148]** Intravenous administration of anti-CXCR4 antibody increases myocardial neovascularization and improves cardiac function after acute infarction. The major mechanism by which G-CSF causes mobilization of bone marrow elements is through interruption of interactions between the chemokine receptor CXCR4 on bone marrow resident stem cells and its ligand SDF-1. G-CSF induces both cleavage of the N-terminus of CXCR4 and accumulation of serine proteases which directly cleave and inactivate SDF-1. To examine whether similar mechanisms were responsible for the effects of G-CSF administration on myocardial neovascularization and improvement in cardiac function, we investigated the effect of interrupting CXCR4-SDF1 interactions by intravenously administering a monoclonal anti-CXCR4 antibody 48 hours after LAD ligation. As shown in figure 17(a) at two weeks after antibody administration animals receiving anti-CXCR4 mAb demonstrated a two-fold increase in neovascularization at the peri-infarct region compared with control animals receiving either saline or anti-CXCR2 mAb. Moreover, as seen in figure 17(b) anti-CXCR4 treated animals demonstrated a mean recovery in ejection fraction of 10% at two weeks whereas those receiving anti-CXCR2 mAb had a mean loss in cardiac function of 8% ( $p < 0.05$ ). These data support the concept that the observed effects of G-CSF administration result from interrupting CXCR4 interactions in the bone marrow, enabling endothelial progenitor cells to be mobilized to the peripheral circulation, and to home to ischemic myocardium where the resultant neovascularization results in improvement in cardiac function.

SDF-1

**[0149]** SDF-1 mRNA expression is not induced early in acutely ischemic myocardium, and its late induction is inhibited by GM-CSF. Next, we sought to identify a strategy by which the effects of GM-CSF could be augmented to approach those seen with G-CSF treatment alone, such as increasing chemotactic signals in the acutely ischemic myocardium. Since chemotaxis of CD34+ bone marrow stem cells is regulated by interactions between CXCR4 receptors on the CD34+ cells and the CXK chemokine SDF-1, we investigated whether SDF-1 mRNA expression was induced in the acutely ischemic myocardium. As shown in figure 18, no difference in myocardial SDF-1 mRNA was observed at 48 hours after LAD ligation in experimental animals relative to non-ischemic controls. By two weeks after infarction, myocardial SDF-1 mRNA expression had increased by 3.3-fold compared with saline-treated controls ( $p < 0.01$ ). We interpreted this delayed production of SDF-1 as most likely reflecting elaboration by infiltrating cells such as macrophages. In contrast, systemic GM-CSF administration was accompanied by approximately 4.5-fold inhibition in SDF-1 mRNA expression at two weeks, to levels actually lower than in non-ischemic controls. Since SDF-1 is a potent chemotactic factor for endothelial progenitor cells, these data suggested that systemic GM-CSF administration may result in suboptimal myocardial homing of endothelial progenitors due to decreased myocardial expression of chemotactic ligands such as SDF-1.

**[0150]** Intramyocardial injection of SDF-1 after acute myocardial infarction results in neovascularization and protection against cardiomyocyte apoptosis. To determine whether altered SDF-1 expression in the acutely ischemic heart affects endothelial progenitor cell chemotaxis and cardiomyocyte function, we examined the effects of direct intramyocardial injection of SDF-1 protein at 48 hours after LAD ligation. As shown in figures 19 (a) and (b), intramyocardial injection of 4ug/kg human recombinant SDF-1 in a total volume of 0.2 ml at 5 peri-infarct sites two days post-LAD ligation resulted by two weeks in a 5-fold increase in neovascularization and a 44 ± 9% reduction in apoptotic cardiomyocytes at the peri-infarct region relative to control animals receiving intramyocardial saline injections (both  $p < 0.05$ ). The effects of intramyocardial SDF-1 injection on neovascularization and on extent of protection against cardiomyocyte apoptosis were in strikingly close parallel to the results obtained with systemic administration of G-CSF. Although addition of subcutaneously administered GM-CSF resulted in a synergistic increase in myocardial neovascularization, no further benefit in protection against cardiomyocyte apoptosis was observed. These results suggest that there is a finite amount of protection against cardiomyocyte apoptosis that can be induced by neovascularization, and that this cannot be improved upon by further by induction of additional new blood vessels.

**[0151]** Intramyocardial injection of SDF-1 induces cardiomyocyte regeneration. As shown in figure 20(a), intramyocardial injection of 4ug/kg human recombinant SDF-1 in a total volume of 0.2 ml at 5 peri-infarct sites two days post-LAD ligation resulted in a 4.5-fold increase in the number of cycling cardiomyocytes at the peri-infarct region relative to saline-injected controls ( $p < 0.01$ ). Addition of systemic GM-CSF administration resulted in synergistic effects on cardiomyocyte regeneration. Notably, the numbers of cycling cardiomyocytes at the peri-infarct region in animals receiving combined therapy with SDF-1 and GM-CSF significantly exceeded those seen in animals receiving G-CSF alone (7-fold versus 3.2-fold above saline treated controls,  $p < 0.01$ ). Since mean numbers of large-lumen vessels at the peri-infarct region were similar in animals receiving combined therapy with SDF-1 and GM-CSF and in those receiving G-CSF alone (8.0 vs 7.5/high power field), these data suggest that SDF-1 enhanced cardiomyocyte cycling/regeneration by an alternative mechanism in addition to induction of neovascularization.

**[0152]** Intramyocardial injection of SDF-1 improves cardiac function and is synergistic with bone marrow mobilization.

Intramyocardial injection of SDF-1 resulted in a similar degree of functional myocardial recovery as was seen with systemic G-CSF administration (10% mean improvement in ejection fraction between days 2 and 14 post-LAD ligation compared with 10% mean improvement for G-CSF treated animals and 17% mean loss for saline-treated controls,  $p < 0.01$  for both treatment arms). Most strikingly, combining SDF-1 injection with bone marrow mobilization by GM-CSF resulted in significant augmentation in functional recovery (21% mean improvement in ejection fraction,  $p < 0.01$ ), figure 20(b). These data indicate that intramyocardial administration of SDF-1 causes improvement in cardiac function after acute ischemia through two separate mechanisms, a direct mechanism which involves induction of cardiomyocyte cycling and regeneration and an indirect mechanism operating through enhanced chemotaxis of mobilized bone marrow-derived endothelial progenitors and cardiac neovascularization. Optimal results are likely to be seen when combining intramyocardial SDF-1 treatment with the most potent mobilizers of bone marrow endothelial progenitors, including G-CSF and other agents that inhibit CXCR4 interactions with SDF-1 in the bone marrow.

#### METHODS AND MATERIALS

**[0153] Purification and characterization of cytokine-mobilized human CD34+ cells:** Single-donor leukopheresis products were obtained from humans treated with recombinant G-CSF 10 mg/kg (Amgen, CA) sc daily for four days. Donors were healthy individuals undergoing standard institutional procedures of bone marrow mobilization, harvesting and isolation for allogeneic stem cell transplants. Mononuclear cells were separated by Ficol-Hypaque, and highly-purified CD34+ cells (>98% positive) were obtained using magnetic beads coated with anti-CD34 monoclonal antibody (mAb) (Miltenyi Biotec, CA). Purified CD34 cells were stained with fluorescein-conjugated mAbs against CD34 and CD117 (Becton Dickinson, CA), AC133 (Miltenyi Biotec, CA), CD54 (Immunotech, CA), CD62E (BioSource, MA), VEGFR-2, Tie-2, vWF, eNOS, CXCR1, CXCR2, and CXCR4 (all Santa Cruz Biotech, CA), and analyzed by four-parameter fluorescence using FACScan (Becton Dickinson, CA). Cells positively selected for CD34 expression were also stained with phycoerythrin (PE)-conjugated anti-CD117 mAb (Becton Dickinson, CA), and sorted for bright and dim fluorescence using a Facstar Plus (Becton Dickinson) and a PE filter. Intracellular staining for GATA-2 was performed by permeabilizing one million cells from each of the brightly and dimly fluorescing cell populations using a Pharmingen Cytotfix/Cytoperm™ kit, incubating for 30 minutes on ice with 10  $\mu$ l of fluorochrome-conjugated mAbs against both CD117 and CD34 surface antigens (Becton Dickinson, CA). After resuspension in 250  $\mu$ l of Cytotfix/Cytoperm™ solution for 20 minutes at 4 degrees C, cells were incubated with a fluorochrome-labeled mAb against GATA-2 (Santa Cruz Biotech, CA) or IgG control for 30 minutes at 4 degrees C, and analyzed by three-parameter flow cytometry.

**[0154] Chemotaxis of human bone-marrow derived endothelial progenitors:** Highly-purified CD34+CD117<sup>bright</sup> cells (>98% purity) were plated in 48-well chemotaxis chambers fitted with membranes (8 mm pores) (Neuro Probe, MD). After incubation for 2 hours at 37°C, chambers were inverted and cells were cultured for 3 hours in medium containing IL-8, SDF-1 alpha/beta, and SCF at 0.2, 1.0 and 5.0  $\mu$ g/ml. The membranes were fixed with methanol and stained with Leukostat™ (Fischer Scientific, 111). Chemotaxis was calculated by counting migrating cells in 10 high-power fields.

**[0155] Animals, surgical procedures, injection of human cells, and quantitation of cellular migration into tissues:** Rowett (mu/rnu) athymic nude rats (Harian Sprague Dawley, Indianapolis, Indiana) were used in studies approved by the "Columbia University Institute for Animal Care and Use Committee". After anesthesia, a left thoracotomy was performed, the pericardium was opened, and the left anterior descending (LAD) coronary artery was ligated. Sham-operated rats had a similar surgical procedure without having a suture placed around the coronary artery. For studies on cellular migration,  $2.0 \times 10^6$  CD34+ cells obtained from a single donor after G-CSF mobilization were injected into the tail vein 48 hours after LAD ligation either alone or together with 50  $\mu$ g/ml monoclonal antibody (mAb) with known functional inhibitory activity against either human CXCR1, human CXCR2, human CXCR4, rat SDF-1 (all R & D Systems, MN), human CD34 (Pharmingen, CA), or rat IL-8 (ImmunoLaboratories, Japan). Controls received either isotype control antibodies at the same concentration or saline after LAD ligation. Prior to injection,  $2.0 \times 10^6$  human cells were incubated with 2.5  $\mu$ g/ml of the fluorescent carbocyanine DiI dye (Molecular Probes) for 5 minutes at 37°C and 15 minutes at 4°C. After washing in PBS, DiI-labeled human cells were resuspended in saline and injected intravenously  $2.0 \times 10^6$  CD34+ human cells were also injected into the tail vein of sham-operated or LAD-ligated rats receiving three intramyocardial injections of 1.0  $\mu$ g/ml recombinant human IL-8, SDF-1, SCF or saline. Each group consisted of 6-10 rats. Quantitation of myocardial infiltration after injection of human cells was performed by assessment of DiI fluorescence in hearts from rats sacrificed 2 days after injection (expressed as number of DiI-positive cells per high power field, minimum 5 fields examined per sample). Quantitation of rat bone marrow infiltration by human cells was performed in 12 rats at baseline, days 2, 7, and 14 by flow cytometric and RT-PCR analysis of the proportion of HLA class I-positive cells relative to the total rat bone marrow population. For studies on neoangiogenesis and effects on myocardial viability and function,  $2.0 \times 10^6$  DiI-labeled human CD34+ cells obtained from a single donor after G-CSF mobilization were reconstituted with  $10^8$ ,  $10^5$ , or  $2.0 \times 10^5$  immunopurified CD34+CD117<sup>bright</sup> cells, and injected into the rat tail vein 48 hours after LAD ligation. In the presence or absence of a mAb with known inhibitory activity against CXCR4. Each group consisted of 6-10 rats. Histologic and functional studies were performed at 2 and 15 weeks.

**[0156] Measurement of rat CXC chemokine mRNA and protein expression:** Poly(A)<sup>+</sup> mRNA was extracted by standard methods from the hearts of 3 normal and 12 LAD-ligated rats. RT-PCR was used to quantify myocardial expression of rat IL-8 and Gro- $\alpha$  mRNA at baseline and at 6, 12, 24 and 48 hours after LAD ligation after normalizing for total rat RNA as measured by GAPDH expression. After priming with oligo (dT) 15-mer and random hexamers, and reverse transcribed with Moloney murine lymphotropic virus reverse transcriptase (Invitrogen, Carlsbad, CA, USA), cDNA was amplified in the polymerase chain reaction (PCR) using Tag polymerase (Invitrogen, Carlsbad, CA, USA), radiolabeled dideoxy-nucleotide ([ $\alpha$ 32P]-ddATP: 3,000 Ci/mmol, Amersham, Arlington Heights, IL), and primers for rat Cinc (rat homologue of human IL-8/Gro- $\alpha$  and GAPDH (Fisher Genosys, CA). Primer pairs (sense/antisense) for rat Cinc and GAPDH were, gaagatagattgcacccgatg (SEQ ID NO:4)/catagcctcacatttc (SEQ ID NO:5), ggcgccgtcgccaatgagctgcgc (SEQ ID NO:6)/cttggggacacccctcagcatctttgg (SEQ ID NO:7), and ctctaccacggcgaagtcaa (SEQ ID NO:8)/gggatgacctgcccacagc (SEQ ID NO:9), respectively. The labelled samples were loaded into 2% agarose gels, separated by electrophoresis, and exposed for radiography for 6 h at -70°C. Serum levels of rat IL-8/Gro- $\alpha$  were measured at baseline and at 6, 12, 24 and 48 hours after LAD ligation in four rats by a commercial ELISA using polyclonal antibodies against the rat IL-8/Gro homologue Cinc (ImmunoLaboratories, Japan). The amount of protein in each serum sample was calculated according to a standard curve of optical density (OD) values constructed for known levels of rat IL-8/Gro- $\alpha$  protein. Anti-Cinc antibodies were also used according to the manufacturer's instructions at 1:200 dilution in immunohistochemical studies to identify the cellular source of Cinc production in rat myocardium after LAD ligation. Positively-staining cells were visualized as brown through the Avidin/Biotin system described below.

**[0157] Histology and measurement of infarct size:** Following excision at 2 and 15 weeks, left ventricles from each experimental animal were sliced at 10-15 transverse sections from apex to base. Representative sections were fixed in formalin and stained for routine histology (H&E) to determine cellularity of the myocardium, expressed as cell number per high power field (HPF) (600x). A Masson trichrome stain was performed, which labels collagen blue and myocardium red, to evaluate collagen content on a semiquantitative scale (0-3+), with 1+ light blue, 2+ light blue and patches of dark blue, and 3+ dark blue staining. This enabled measurement of the size of the myocardial scar using a digital image analyzer. The lengths of the infarcted surfaces, involving both epicardial and endocardial regions, were measured with a planimeter digital image analyzer and expressed as a percentage of the total ventricular circumference. Final infarct size was calculated as the average of all slices from each heart. All studies were performed by a blinded pathologist. Infarct size was expressed as percent of total left ventricular area. Final infarct size was calculated as the average of all slices from each heart.

**[0158] Quantitation of capillary density:** In order to quantitate capillary density and species origin of the capillaries, additional sections were stained freshly with mAbs directed against rat or human CD31 (Serotec, UK, and Research Diagnostics, NJ, respectively), factor VIII (Dako, CA), and rat or human MHC class I (Accurate Chemicals, CT). Arterioles were differentiated from large capillaries by the presence of a smooth muscle layer, identified by staining sections with a monoclonal antibody against muscle-specific desmin (Dako, Ca). Staining was performed by immunoperoxidase technique using an Avidin/Biotin Blocking Kit, a rat-absorbed biotinylated anti-mouse IgG, and a peroxidase-conjugate (all Vector Laboratories Burlingame, CA). Capillary density was determined at 2 weeks post infarction from sections labeled with anti-CD31 mAb, and confirmed with anti-factor VIII mAb, and compared to the capillary density of the unimpaired myocardium. Values are expressed as the number of CD31-positive capillaries per HPF (400x).

**[0159] Quantitation of cardiomyocyte proliferation:** Cardiomyocyte DNA synthesis and cell cycling was determined by dual staining of rat myocardial tissue sections obtained from LAD-ligated rats at two weeks after injection of either saline or CD34<sup>+</sup> human cells, and from healthy rats as negative controls, for cardiomyocyte-specific troponin I and human- or rat-specific Ki-67. Briefly, paraffin embedded sections were microwaved in a 0.1M EDTA buffer, and stained with either a primary monoclonal antibody against rat Ki-67 at 1:3000 dilution (gift of Giorgio Catoretti, Columbia University) or human Ki-67 at 1:300 dilution (Dako, CA) and incubated overnight at 4 degrees C. Following washes, sections were incubated with a species-specific secondary antibody conjugated with alkaline phosphatase at 1:200 dilution (Vector Laboratories Burlingame, CA) for 30 minutes and positively-staining nuclei were visualized as blue with a BCIP/NBT substrate kit (Dako, CA). Sections were then incubated overnight at 4 degrees C with a monoclonal antibody against cardiomyocyte-specific troponin I (Accurate Chemicals, CT) and positively-staining cells were visualized as brown through the Avidin/Biotin system described above. Cardiomyocytes progressing through cell cycle in the infarct zone, peri-infarct region, and area distal to the infarct were calculated as the proportion of troponin I-positive cells per high power field co-expressing Ki-67.

**[0160] Measurement of myocyte apoptosis by DNA end-labeling of paraffin tissue sections:** For in situ detection of apoptosis at the single cell level we used the TUNEL method of DNA end-labeling mediated by dextrynucleotidyl transferase (TdT) (Boehringer Mannheim, Mannheim, Germany). Rat myocardial tissue sections were obtained from LAD-ligated rats at two weeks after injection of either saline or CD34<sup>+</sup> human cells, and from healthy rats as negative controls. Briefly, tissues were deparaffinized with xylene and rehydrated with graded dilutions of ethanol and two washes in phosphate-buffered saline (PBS). The tissue sections were then digested with Proteinase K (10 $\mu$ g/ml in Tris/HCL) for 30 minutes at 37°C. The slides were then washed 3 times in PBS and incubated with 50 $\mu$ l of the TUNEL reaction mixture (TdT and

fluorescein-labeled dUTP) and incubated in a humid atmosphere for 60 minutes at 37°C. For negative controls TdT was eliminated from the reaction mixture. Following 3 washes in PBS, the sections were then incubated for 30 minutes with an antibody specific for fluorescein-conjugated alkaline phosphatase (AP) (Boehringer Mannheim, Mannheim, Germany). The TUNEL stain was visualized with a substrate system in which nuclei with DNA fragmentation stained blue, (BCIP/NBT substrate system, Dako, Carpinteria, CA). The reaction was terminated following three minutes of exposure with PBS. To determine the proportion of blue-staining apoptotic nuclei within myocytes, tissue was counterstained with a monoclonal antibody specific for desmin. Endogenous peroxidase was blocked by using a 3% hydrogen peroxidase solution in PBS for 15 minutes, followed by washing with 20% goat serum solution. An anti-troponin I antibody (Accurate Chemicals, CT) was incubated overnight (1:200) at 40 degrees C. Following 3 washes sections were then treated with an anti-rabbit IgG, followed by a biotin conjugated secondary antibody for 30 minutes (Sigma, Saint Louis, Missouri). An avidin-biotin complex (Vector Laboratories, Burlingame, CA) was then added for an additional 30 minutes and the myocytes were visualized brown following 5 minutes exposure in DAB solution mixture (Sigma, Saint Louis, Missouri). Tissue sections were examined microscopically at 200x magnification. Within each 200x field 4 regions were examined, containing at least 250 cells per region and cumulatively approximating 1 mm<sup>2</sup> of tissue, at both the peri-infarct site and distally to this site. Stained cells at the edges of the tissue were not counted. Results were expressed as the mean number of apoptotic myocytes per mm<sup>2</sup> at each site examined.

[0161] Analysis of Myocardial Function: Echocardiographic studies were performed using a high frequency liner array transducer (SONOS 5500, Hewlett Packard, Andover, MA). 2D images were obtained at mid-papillary and apical levels. End-diastolic (EDV) and end-systolic (ESV) left ventricular volumes were obtained by bi-plane area-length method, and % left ventricular ejection fraction was calculated as  $[(EDV-ESV)/EDV] \times 100$ .

[0162] cDNA Subtractive Hybridization: Briefly, messenger RNA was isolated from each heart, and 1 µg was used for first-strand cDNA synthesis with random primers. The subtractive hybridization was performed with the PCR-select cDNA subtraction kit (CLONTECH), following the manufacturer's recommendations. After second-strand synthesis, the two cDNA libraries were digested with RsaI. Digestion products of the "tester" library were ligated to a specific adapter (T7 promoter), then hybridized with a 30-fold excess of the "driver" library for subtraction. After hybridization, the remaining products were further amplified by PCR. In the forward subtraction, which determines the genes that are overexpressed in the ischemic sample, the ischemic tissue is the "tester" and the normal tissue is the "driver." In the reverse subtraction, the "tester" and the "driver" are switched to determine the genes that are down-regulated in the ischemic sample.

## REFERENCES

### [0163]

1. Soonpaa MH, Field LJ. Assessment of cardiomyocyte DNA synthesis in normal and injured adult mouse hearts. *Am J Physiol* 272, H220-6 (1997).
2. Kellerman S, Moore JA, Zierhut W, Zimmer HG, Campbell J, Gerdes AM. Nuclear DNA content and nucleation patterns in rat cardiac myocytes from different models of cardiac hypertrophy. *J Mol Cell Cardiol* 24, 497-505 (1992).
3. Colucci, W. S. Molecular and cellular mechanisms of myocardial failure. *Am. J. Cardiol.* 80(11A), 15L-25L (1997).
4. Ravichandran, L. V. and Puvanakrishnan, R. In vivo labeling studies on the biosynthesis and degradation of collagen in experimental myocardial infarction. *Biochem. Intl.* 24, 405-414 (1991).
5. Agocha, A., Lee, H. W., Eghali-Webb, M. Hypoxia regulates basal and induced DNA synthesis and collagen type I production in human cardiac fibroblasts: effects of TGF-beta, thyroid hormone, angiotensin II and basic fibroblast growth factor. *J. Mol. Cell. Cardiol.* 29, 2233-2244 (1997).
6. Pfeffer, J. M., Pfeffer, M. A., Fletcher, P. J., Braunwald, E. Progressive ventricular remodeling in rat with myocardial infarction. *Am. J. Physiol.* 260, H1406-414 (1991).
7. Kocher, AA, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived endothelial progenitor cells prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. *Nat Med* 7, 430-6 (2001).
8. Kennedy, M. et al. A common precursor for primitive erythropoiesis and definitive haematopoiesis. *Nature* 386, 488-493 (1997).

9. Choi, K., Kennedy, M., Kazarov, A., Papadimitriou, Keller, G. A common precursor for hematopoietic and endothelial cells. *Development* 125, 725-732 (1998).
- 5 10. Elefanti, A. G., Robb, L., Birner, R., Begley, C. G. Hematopoietic-specific genes are not induced during *In vitro* differentiation of *scl*-null embryonic stem cells. *Blood* 90, 1435-1447 (1997).
11. Labastie, M. C., Cortes, F., Romeo, P. H., Dulac, C., Peault, B. Molecular identity of hematopoietic precursor cells emerging in the human embryo. *Blood* 92, 3624-3635 (1998).
- 10 12. Rafii S, et al. Isolation and characterization of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion. *Blood* 84, 10-19 (1994).
13. Shi, Q. et al. Evidence for circulating bone marrow-derived endothelial cells. *Blood* 92, 362-367 (1998).
- 15 14. Lin, Y., Weisendorf, D. J., Solovery, A., Hebbel, R. P. Origins of circulating endothelial cells and endothelial outgrowth from blood. *J. Clin. Invest.* 105, 71-77 (2000).
15. Asahara, T. et al. Isolation of putative progenitor cells for endothelial angiogenesis. *Science* 275, 964-967 (1997).
- 20 16. Takahashi, T. et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. *Nat. Med.* 5, 434-438 (1999).
17. Kalke, C. et al. Transplantation of *ex vivo* expanded endothelial progenitor cells for therapeutic neovascularization. *Proc. Natl. Acad. Sci. USA* 97, 3422-3427 (2000).
- 25 18. Kajstura J, Leri A, Finato N, di Loreto N, Beltramo CA, Anversa P. Myocyte proliferation in end-stage cardiac failure in humans. *Proc Natl Acad Sci, USA* 95, 8801-8805 (1998).
19. Beltrami AP, et al. Evidence that human cardiac myocytes divide after myocardial infarction. *N Engl J Med* 344, 1750-7 (2001).
- 30 20. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat. Med.* 1:27 (1995).
21. Strieter, RM, et al. Interleukin-8: a chemotactic factor that induces neovascularization. *Am. J. Pathol.* 141,1279-1284 (1992).
- 35 22. Murdoch C, Monk PN, Finn A. Cxc chemokine receptor expression on human endothelial cells. *Cytokine* 11,704-12 (1999).
- 40 23. Koch, AE, et al. Interleukin-8 (IL-8) as a macrophage-derived mediator of angiogenesis. *Science*, 258:1798-1801 (1992).
24. Strieter, RM, et al The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. *J. Biol. Chem.* 270, 27348-27357 (1995).
- 45 25. Angiolillo, AL, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis *in vivo*. *J Exp Med* 182,155-62 (1995).
26. Feli C, Augustin HG. Endothelial cells differentially express functional CXC-chemokine receptor-4 (CXCR-4/fusin) under the control of autocrine activity and exogenous cytokines. *Biochem Biophys Res Commun* 247, 38-45 (1998).
- 50 27. Tachibana, K, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. *Nature* 393, 591-594 (1998).
- 55 28. Mohle R, Bautz F, Rafii S, Moore MA, Brugger W, Kanz L. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. *Blood* 91, 4523-30 (1998).

29. Imai, K. et al. Selective secretion of chemoattractants for haemopoietic progenitor cells by bone marrow endothelial cells: a possible role in homing of haemopoietic progenitor cells to bone marrow. *Br J Haematol* 106, 905-11 (1999).
- 5 30. Peled, A. et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. *Science* 283, 845-88 (1999).
31. Voermans C, Gerritsen WR, von dem Borne AE, van der Schoot CE. Increased migration of cord blood-derived CD34+ cells, as compared to bone marrow and mobilized peripheral blood CD34+ cells across uncoated or fibronectin-coated filters. *Exp. Hematol.* 27, 1806-14 (2000).
- 10 32. Janowska-Wieczorek, A. et al. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34+ cells and their transmigration through reconstituted basement membrane. *Blood* 93, 3379-3390 (1999).
- 15 33. Heymans, S. et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. *Nat. Med.* 5, 1135-1142 (1999).
34. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M. Expression of Interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. *Am J Pathol* 151, 1105-1113 (1997).
- 20 35. Masure, S., Proost, P., Van Damme, J., Opdenakker, MD. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. *Eur. J. Biochem.* 198,391-398 (1991).
- 25 36. Hart, P. H. et al. Activation of human monocytes by granulocyte-macrophage colony-stimulating factor: increased urokinase-type plasminogen activator activity. *Blood* 77, 841-848 (1991).
37. Stacey, K. J., Fowles, L. F., Colman, M. S., Ostrowski, M. C., Hume, D. A. Regulation of urokinase-type plasminogen activator gene transcription by macrophage colony-stimulating factor. *Mol. Cell. Biol.* 15, 3430-3441 (1995).
- 30 38. Pei, X. H. et al. G-CSF increases secretion of urokinase-type plasminogen activator by human lung cancer cells. *Clin. Exp. Metastasis* 16, 551-558 (1998).
39. Semerad, CL, et al. A role for G-CSF receptor signalling in the regulation of hematopoietic cell function but not lineage commitment or differentiation. *Immunity* 11, 153-161 (1999).
- 35 40. Nagasawa, T, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. *Nature* 382, 635-638 (1996).
- 40 41. Rempel SA, Dudas S, Ge S, Gutierrez JA. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. *Clin Cancer Res* 6, 102-11 (2000).
42. Globerson, A. Hematopoietic stem cells and aging. *Exp. Gerontol.* 34, 137-146 (1999).
- 45 43. de la Rubia, J., Diaz, M.A., Verdeguer, A., et al. Donor age-related differences in PBPC mobilization with rHuG-CSF. *Transfusion* 41, 201-205 (2001).
44. Leferovich JM, et al. Heart regeneration in adult MRL mice. *Proc Natl Acad Sci USA* 98, 9830-9835 (2001).
- 50 45. Vander Heiden MG, Plas DR, Rathmell JC, Fox CJ, Harris MH, Thompson CB. Growth factors can influence cell survival through effects on glucose metabolism. *Mol Cell Biol* 21, 5899-5912 (2001).
46. Rössig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM, and Dimmeler S. Akt-dependent phosphorylation of p21Cip1 regulates PCNA binding and proliferation of endothelial cells. *Mol Cell Biol* 21, 5644-5657 (2001).
- 55 47. Tomita S, et al. Autologous transplantation of bone marrow cells improves damaged heart function. *Circulation* 100, II-247 (1999).

# EP 2 292 631 A1

48. Orlic D, et al. Bone marrow cells regenerate infarcted myocardium. *Nature* 410, 701-705 (2001)
49. Kehat I, et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. *J Clin Invest.* 108, 407-14 (2001).
50. Rossi et al., 1992, *Aids Research and Human Retroviruses* 8, 183.
51. Hampel et al., EP0360257
52. Hampel and Tritz, 1989 *Biochemistry* 28, 4929.
53. Hamper et al., 1990 *Nucleic Acids Res.* 18, 299.
54. Perrotta and Been, 1992 *Biochemistry* 31, 18.
55. Guerrier-Takada et al., 1983 *Cell* 35, 849.
56. Forster and Altman, 1990 *Science* 249, 783.
57. Saville and Collins, 1990 *Cell* 61, 685-696.
58. Saville and Collins, 1991 *Proc. Natl. Acad. Sci. USA* 88, 8826-8830.
59. Guo and Collins, 1995 *EMBO J.* 14, 368.
60. Cech et al., U.S. Pat. No. 4,987,071.
61. Matzura O, Wennborg A (1996) RNAdraw: an integrated program for RNA secondary structure calculation and analysis under 32-bit Microsoft Windows. *Comput Appl Biosci* 12:247-9.
62. Santoro SW, Joyce GF (1997) A general purpose RNA-cleaving DNA enzyme. *Proc Natl Acad Sci USA* 94:4262-6.
63. Santoro SW, Joyce GF (1998) Mechanism and utility of an RNA-cleaving DNA enzyme. *Biochemistry* 37: 13330-42.
64. MacLellan WR and Schneider MD. Genetic dissection of cardiac growth control pathways *Annu. Rev. Physiol.* 2000. 62:289-320.7.
65. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G(1)-phase progression. *Genes Dev.* 1999;13:1501-1512.
66. Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. *Am J Pathol.* 1996, 148:291-300.
67. Hill MF, Singal PK. Right and left myocardial antioxidant responses during heart failure subsequent to myocardial infarction. *Circulation* 1997 96:2414-20.
68. Li, Y. , Jenkins, C.W. , Nichols, M.A. and Xiong, Y. (1994) Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. *Oncogene*, 9, 2261-2268
69. Steinman, R.A. , Hoffman, B. , Iro, A. , Guillof, C. , Liebermann, D.A. and E1-Houseini, M.E. (1994) Induction of p21 (WAF1/CIP1) during differentiation. *Oncogene*, 9, 3389-3396
70. Halevy, O. , Novitch, B.G. , Spicer, D.B. , Skapek, S.X. , Rhee, J. , Hannon, G.J. , Beach, D. and Lassar, A.B. (1995) Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. *Science*, 267, 1018-1021.
71. Andres, V. and Walsh, K. (1996) Myogenin expression, cell cycle withdrawal and phenotypic differentiation are

## EP 2 292 631 A1

temporally separable events that precedes cell fusion upon myogenesis. *J. Cell Biol.*, 132, 657-668.

72. Tsurimoto, T. PCNA Binding Proteins. *Frontiers In Bioscience*, 4:849-858, 1999.

73. Levkau B, Koyama H, Raines EW, Clurman BE, Herren B, Orth K, Roberts JM, Ross R. Cleavage of p21cip1/wa1 and p27 kip1 mediates apoptosis in endothelial cells through activation of cdk2: role of a caspase cascade. *Mol Cell*. 1998;1:553-563.

74. Adachi S, et al. Cyclin A/cdk2 activation is involved in hypoxia-induced apoptosis in cardiomyocytes *Circ Res*. 88:408, 2001.

75. Ichijo H, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. *Science* 275:90-94 (1997).

76. Toblume, K., Inage, T., Takeda, K., Enomoto, S., Miyazono, K. and Ichijo, H. (1997) Molecular cloning and characterization of the mouse apoptosis signal-regulating kinase 1. *Biochem. Biophys. Res. Commun.*, 239, 905-910.

77. Asada M, Yamada T, Ichijo h, Della D, Miyazono K, Fukumuro K, and Mizutani S Apoptosis Inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation. *EMBO J*, 18:1223-1234, 1999.

78. Saitoh H, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK)1. *EMBO J*. 17: 2596-2606, 1998.

79. Nishiyama A, et al. Identification of Thioredoxin-binding Protein-2/Vitamin D3 Up-regulated Protein 1 as a Negative Regulator of Thioredoxin Function and Expression. *J Biol Chem*, 31, 21645-21650, 1999.

80. Junn E, et al. Vitamin D3 Up-Regulated Protein1 Mediates Oxidative Stress Via Suppressing the Thioredoxin Function. *J Immunol*. 164:6287-6295, 2000.

81. Holmgren, A. (1985) *Annu. Rev. Biochem.* 54, 237-271.

82. Chae, H. Z., Chug, S. J. & Rhee, S. G. (1994) *J. Biol. Chem.* 269, 27670-27678.

83. Netto, L. E. S., Chae, H. Z., Kang, S., Rhee, S. G. & Stadtman, E. R. (1996) *J. Biol. Chem.* 271, 15315-15321.

84. Chae, H. Z., Uhm, T. B. & Rhee, S. G. (1994) *Proc. Natl. Acad. Sci USA* 91, 7022-7026.

85. Kwon, S. J., Park, J., Chol, W., Kim, I. H. & Kim, K. (1994) *Biochem. Biophys. Res. Comm.* 201, 8-15.

86. Kang, S. W., Baines, I. C. & Rhee, S. G. (1998) *J. Biol. Chem.* 273, 6303-6311.

87. Hirotsu, S, et al. Crystal structure of a multifunctional 2-Cys peroxiredoxin heme-binding protein 23 kDa/proliferation-associated gene product. *Proc. Natl Acad Sci, USA*. 96, 12333-12338, 1999.

88. Slow, R. C. M., et al. (1995) *FEBS Lett*. 368, 239-242.

89. Prosper, M., Ferbus, D., Karczinski, I. & Goubin, G. (1993) *J. Biol. Chem.* 268, 11050-11056.

90. Sauri, H., Butterfield, L., Kim, A. & Shau, H. (1995) *Biochem. Biophys. Res. Commun.* 208, 964-969.

91. Ishii T et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. *J Biological Chem* 2000, 275:16023-16029

92. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. *Genes Dev*. 1999 Jan 1;13(1):76-86.

93. Lee, J-M, et al. Phosphatidylinositol 3-Kinase, Not Extracellular Signal-regulated Kinase, Regulates Activation



of the Antioxidant-Responsive Element in IMR-32 Human Neuroblastoma Cells J. Biol. Chem., 276:20011-20016, 2001.

94. Kim YC, Masutani H, Yamaguchi Y, Itoh K, Yamamoto M, Yodoi J. Hem-in-induced activation of the thioredoxin gene by Nrf2. A differential regulation of the antioxidant responsive element by a switch of its binding factors. J Biol Chem. 2001 276:18399-406.

95. Cho HY, Jedlicka AE, Reddy SP, Kensler TW, Yamamoto M, Zhang LY, Kleeberger SR. Role of NRF2 In Protection Against Hyperoxic Lung Injury in Mice. Am J Respir Cell Mol Biol 2002, 26:175-182.

96. Kumuda C. Das, Paula M. B. Pahl, Xiao-Ling Guo, and Carl W. White. Induction of Peroxiredoxin Gene Expression by Oxygen in Lungs of Newborn Primates. Am. J. Respir. Cell Mol. Biol. 2001, 25:226-232.

97. Wen S-T, and Van Etten, RA The PAG gene product, a stress-induced protein with antioxidant properties, is an Abi SH3-binding protein and a physiological inhibitor of c-Abi tyrosine kinase activity. Genes and Development, 19: 2456-2467, 1997.

98. Kharbanda, S., Yuan, Z. M., Weichselbaum, R. & Kufe, D. Determination of cell fate by c-Abi activation in the response to DNA damage. Oncogene 17, 3309-3318 (1998).

99. Yuan ZM et al, Nature 1996 18; 382(6588):272-4.

100. Jost, C. A., Marin, M. C. & Kaelin, W. J. p73 is a human p53-related protein that can induce apoptosis. Nature 389, 191-194 (1997).

101. Agami, R, Blandino G, Oren M, Shaul Y. Interaction of c-Abi and p73 [alpha] and their collaboration to induce apoptosis Nature 399, 809 - 813 (1999).

102. Sun X, et al. Activation of the cytoplasmic c-Abi tyrosine kinase by reactive oxygen species. J Biol. Chem. 2000, 275:17237-17240.

103. Kumar S, et. al. Targeting of the c-Abi Tyrosine Kinase to Mitochondria in the Necrotic Cell Death Response to Oxidative Stress J. Biol. Chem., 276, 17281-17285, 2001.

104. Chen, K.S. and DeLuca, H.F. Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3 JOURNAL Biochim. Biophys. Acta 1219 (1), 26-32 (1994).

105. Zhang et al. Clinical Pharmacology & Therapeutics (1995) 58(1), 44-53.

106. Tetsuro Ishii, Ken Itoh, Junetsu Akasaka, Toru Yanagawa, Satoru Takahashi, Hiroshi Yoshida, Shiro Bannai and Masayuki Yamamoto, Carcinogenesis Vol. 21 (5):1013-1016, (2000).

107. Das KC, Pahl PM, Guo XL, White CW, Am. J. Respir. Cells Mol. Biol., (2001), 25(2):226-32.

108. Immenschuh S, Iwahara S, Satoh H, Nell C, Katz N, Muller-Eberhard U., Biochemistry (1995) 17;34(41): 13407-11.

109. Ken Itoh, Nobunao Wakabayashi, Yasutake Katoh, Tetsuro Ishii, Kazuhiko Igarashi, James Douglas Engel, 1 and Masayuki Yamamoto, Genes and Development, 13(1) : 76-86, (1999).

## Experimental Results II

### Intravenous Administration Of Human Bone Marrow-Derived Endothelial Progenitor Cells Induces Neovascularization And Prevents Cardiomyocyte Apoptosis Within Five Days Post-Infarction.

[0164] We sought to determine how soon after intravenous injection of bone marrow-derived endothelial progenitor cells does neovascularization develop in hearts of rats having undergone permanent LAD ligation 48 hours earlier. When animals were sacrificed at two days after intravenous injection of Dil-labelled human CD34+ cells obtained by G-CSF

mobilization (>98% CD34 purity, containing 6-12% CD117bright angioblasts), numerous DII positive interstitial cells were seen in the peri-infarct region, but no defined vascular structures expressing DII could be identified, data not shown. In contrast, animals sacrificed at five days post-infarction of human CD34+ cells demonstrated numerous DII-positive vascular structures at the peri-infarct region and 3.5-fold higher numbers of capillaries in comparison to rats receiving saline, figure 21(a) ( $p<0.01$ ). The increase in microvasculature at 5 days was accompanied by 3.3-fold lower numbers of apoptotic cardiomyocytes at the peri-infarct region, defined by dual positivity for troponin I and TUNEL, in comparison to controls receiving saline, figure 21(b) ( $p<0.01$ ). Together, these data indicate that the vasculogenic process of differentiation and organization of bone marrow-derived angioblasts to a mature, functional network of capillaries in the ischemic myocardium takes from two to five days.

#### Intravenous Administration Of Human Bone Marrow-Derived Endothelial Progenitor Cells Induces Cell Cycling Of Cardiomyocyte Progenitors And Cardiomyocyte Differentiation.

[0165] We examined cardiac tissue from experimental and control animals sacrificed at five days by immunohistochemistry and confocal microscopy for evidence of cycling cardiomyocytes, as has been suggested to occur rarely in the adult heart after acute ischemia. While no mature troponin-positive cycling cardiomyocytes were detected in any control or experimental animals at day 5 post-infarction, animals receiving human bone marrow-derived CD34+ cells demonstrated numerous clusters of small, cycling cells at the peri-infarct region that were of rat origin, as defined by a monoclonal antibody specific for rat Ki67, figure 22(a). These cells were negative for cardiomyocyte-specific troponin I, a marker of cardiomyocyte differentiation, but stained positively for alpha-sarcomeric actin, indicating they were immature cells of cardiomyocyte lineage. Similar clusters of cycling cardiomyocyte progenitors were not seen in control animals injected with saline.

[0166] Tissues obtained from animals sacrificed at two weeks after human CD34+ administration no longer demonstrated clusters of small, cycling cardiomyocyte progenitors, but instead a high frequency of large, mature rat cardiomyocytes at the peri-infarct region with detectable DNA activity, as determined by dual staining with mAbs reactive against cardiomyocyte-specific troponin I and rat Ki67, figures 22(b) and (c). The number of cycling, mature cardiomyocytes at the peri-infarct region was 4-fold higher in animals receiving human endothelial progenitor cells than in LAD-ligated controls receiving saline ( $p<0.01$ ) in whom there was a high frequency of cells with fibroblast morphology and reactivity with rat Ki67, but not troponin I. We speculate that the cycling, mature cardiomyocytes seen at day 14 post-infarction in animals who received human endothelial progenitor cells are the differentiated progeny of the small, cycling immature cardiomyocyte progenitors seen in the same anatomical location at day 5 and accompanying the onset of neovascularization. Whether the cycling cardiomyocyte progenitors represent in situ cardiac stem cells normally residing in the heart in a quiescent state, or whether these cells have migrated to the heart from elsewhere in the body, such as the bone marrow, remains to be determined.

#### Myocardial Expression Of HBP23, A Rat Peroxiredoxin Protecting Cells Against Damage By Oxygen Radicals, Is Decreased By Ischemia And Increased By Neovascularization.

[0167] We next sought to identify a molecular mechanism to explain the relationship between neovascularization at the peri-infarct region and proliferation/regeneration of adjacent cardiomyocyte progenitors. We first performed cDNA subtractive hybridization in order to identify patterns of changes in gene expression between normal rat hearts and rat hearts 48 hours after LAD ligation. Since deficits in antioxidants and increased oxidative stress accompanying myocardial infarction have been directly implicated in the pathogenesis of post-infarct heart failure (13-15), we chose to examine changes in expression of particular antioxidant genes. A family of antioxidant enzymes known as peroxiredoxins, which demonstrate peroxidase activity (16) and are induced by oxygen (17), play a critical role in regulating cell survival during periods of oxidative stress, such as ischemia. They serve to maintain the thiol-disulfide status of the cytosol by undergoing reversible oxidation-reduction reactions involving electron transfer via disulfide bridges formed with thioredoxin (TRX), which constitutes one of the principal cellular reducing systems in mammals (18). In addition, peroxiredoxins can inhibit c-Abl tyrosine kinase activity induced by oxidative stress (19,20) and can rescue cells from both a pro-apoptotic state and cell cycle arrest induced by the activated c-Abl gene product (21). By cDNA subtractive hybridization, we found that expression of the rat peroxiredoxin HBP23 mRNA was reduced in rat hearts 48 hours after LAD ligation compared with normal rat hearts. By RT-PCR, HBP23 mRNA levels in rat hearts decreased at two weeks post-LAD ligation by a mean of 34% compared with normal rat hearts, figure 23 ( $p<0.01$ ). In contrast, HBP23 mRNA levels in LAD-ligated rat hearts two weeks after receiving human angioblasts returned to levels only 14% lower than in non-ischemic controls. Since mRNA expression of peroxiredoxins is induced by oxygen, these data suggested that HBP23 mRNA expression was inhibited by the acute ischemic event and induced following angioblast-dependent neovascularization.

[0168] Generation Of A DNA Enzyme To Cleave HBP23 mRNA. To investigate whether induced expression of HBP23 is involved in the mechanism by which neovascularization affects myocardial cellular apoptosis, regeneration/prolifera-

tion, and function, we generated a catalytic RNA enzyme targeting specific sequences within the rat HBP23 gene (22,23). We chose to specifically target pyrimidine-purine junctions at or near the translational start site AUG of messenger RNA for rat HBP23, a region that is conserved between species and has low relative free energy (24). In this region, the rat HBP23 sequence differs by only one base from the human homologue, proliferation-associated gene (PAG). To produce the control DNA enzyme, the nucleotide sequence in the two flanking arms of the HBP23 DNA enzyme was scrambled without altering the catalytic domain. The 3' terminus of each molecule was capped with an inverted 3'-3'-linked thymidine for resistance to 3'-to-5' exonuclease digestion.

[0169] The DNA enzyme against HBP23 cleaved the 23-base oligonucleotide synthesized from the sequence of rat HBP23 mRNA, in a dose- and time-dependent manner, figure 24 (a). In contrast, the DNA enzyme did not cleave a 23-base oligonucleotide from the human homologue PAG which differs from the rat HBP23 oligonucleotide by only one base, demonstrating its exquisite target specificity. A DNA enzyme with specificity for the same translational start site in the human PAG gene efficiently cleaved the PAG oligonucleotide, but not the one derived from HBP23 (data not shown). The scrambled control DNA enzyme did not cleave either oligonucleotide. To determine the effect of the DNA enzyme on endogenous HBP23 production, cardiomyocyte monolayers obtained from fetal rat hearts were grown to confluence and transfected with species-specific DNA enzymes or scrambled control. Densitometric analysis of RT-PCR products following reverse transcription of cellular mRNA showed that the HBP23 DNA enzyme inhibited steady-state mRNA levels in cultured rat cells by over 80%, figure 24 (b), relative to the scrambled DNA.

#### In Vivo Administration Of A DNA Enzyme To Prevent Induction Of HBP23 mRNA In Rat Myocardium. Neovascularization Is Not Affected, But Its Effects On Cardiomyocyte Apoptosis, Regeneration, And Function Are Abrogated.

[0170] To investigate the in vivo relevance of induced expression of HBP23 in experimental myocardial infarction, 48 hours after LAD ligation rats were injected with human bone marrow-derived endothelial progenitor cells intravenously together with intramyocardial injections of either HBP23 DNA enzyme or scrambled control. As shown in figure 25 (a), HBP23 DNA enzyme had no effect on induction of neovascularization by human bone marrow angioblasts. When sacrificed at day 5 post-infarction, rats who received human endothelial progenitors, irrespective of whether HBP23 DNA enzyme or scrambled control was co-injected, demonstrated increased myocardial capillary density in comparison to saline controls. In contrast, injection of the HBP23 DNA enzyme, but not the scrambled control, abrogated the anti-apoptotic effects of neovascularization, figure 25 (b), and the improvement in cardiac function, figure 25 (c). Among animals receiving human endothelial progenitor cells and demonstrating myocardial neovascularization, treatment with HBP23 DNA enzyme resulted in 1.7-fold higher levels of cardiomyocyte apoptosis ( $p < 0.01$ ) and 38% mean deterioration in cardiac function as assessed by echocardiography ( $p < 0.01$ ). In addition, the HBP23 DNA enzyme exerted striking effects on cardiomyocyte progenitor proliferation/regeneration. Whereas peri-infarct clusters of small rat cells expressing Ki67 and alpha-sarcomeric actin were easily detected in animals receiving angioblasts together with the scrambled control DNA, none were identified in animals receiving the HBP23 DNA enzyme. These results clearly demonstrate that angioblast-dependent neovascularization protects cardiomyocytes against apoptosis and induces proliferation/regeneration of resident cardiomyocyte lineage progenitors via pathways regulated by peroxiredoxin gene products.

#### DISCUSSION

[0171] In this study we showed that neovascularization of ischemic myocardium by human bone marrow derived angioblasts results in both protection of mature cardiomyocytes at the peri-infarct region against apoptosis and stimulation of cardiomyocyte progenitors at the same site to enter cell cycle, proliferate and regenerate. Moreover, we showed that the mechanism by which angioblast-dependent neovascularization regulates cardiomyocyte survival and self-renewal appears to involve at least one family of genes involved in anti-apoptotic and pro-proliferative pathways accompanying oxidative stress, the peroxiredoxin. While oxygen tension positively regulates peroxiredoxin gene expression (17), whether this alone explains the positive effect of angioblast-mediated neovascularization on HBP mRNA expression is not clear. Since peroxiredoxin mRNA expression is induced by protein kinase C delta (25) it is possible that bone marrow angioblasts may be a source of extracellular signals regulating protein kinase C delta activation and consequently cell survival, such as FGF-1 (26).

[0172] Deficits in antioxidants and increased oxidative stress accompanying myocardial infarction have been directly implicated in the pathogenesis of post-infarct heart failure (13-15). Our study suggests that reduced levels of peroxiredoxins post-infarction may be of direct causality in the subsequent remodelling and failure of the left ventricle. The antioxidant effects of peroxiredoxins are coupled with the physiological electron donor activity of the TRX system (27-29). In addition to directly interacting with TRX, the peroxiredoxin gene products specifically bind the SH3 domain of c-Abl, a non-receptor tyrosine kinase, inhibiting its activation (21). Activation of c-Abl through the SH3 domain by stimuli such as agents that damage DNA induces either arrest of the cell cycle in phase G1 or cellular apoptosis (30). Cell cycle arrest is dependent on the kinase activity of c-Abl which downregulates the activity of the cyclin-dependent kinase Cdk2

and induces the expression of p21 (31). By associating with c-Abl *in vivo*, peroxiredoxins can inhibit tyrosine phosphorylation induced by c-Abl overexpression and rescue cells from both the cytostatic and pro-apoptotic effects of the activated c-Abl gene product (32). Our *in vivo* demonstration that co-administration of a DNA enzyme directed against the rat peroxiredoxin HBP23 abrogated the anti-apoptotic and pro-proliferative effects of human angioblast-dependent neovascularization in the infarcted rat heart argues strongly that this family of genes is directly implicated in the mechanism of action by which neovascularization results in improvement in cardiac function and prevention of heart failure.

[0173] Throughout life, a mixture of young and old cells is present in the normal myocardium. Although most myocytes seem to be terminally differentiated, there is a fraction of younger myocytes that retains the capacity to replicate (33). In the present study, human angioblast-dependent neovascularization resulted, within five days, in proliferation of small, endogenous rat cardiomyocyte precursors at the peri-infarct region. The dividing myocyte precursors could be identified by immunohistochemical criteria on the basis of concomitant cell surface expression of alpha-sarcomeric actin, but not troponin I, and proliferating nuclear structures, defined by an antibody specific for rat Ki67. Since this process was followed within fourteen days by increasing numbers in the same location of mature, cycling cardiomyocytes, defined on the basis of morphology, cell surface expression of troponin I, and nuclear expression of Ki67, we conclude that cycling cardiomyocyte precursors differentiated *in situ* to become new, mature, functional cardiomyocytes. Whether these, precursors are derived from a resident pool of cardiomyocyte stem cells or from a renewable source of circulating bone marrow-derived stem cells that home to the damaged myocardium remains to be determined. Moreover, while the signals required for *in situ* expansion of cardiomyocyte precursors appear to involve, at least in part, pathways regulated by members of the peroxiredoxin gene family, the signals required for cardiomyocyte differentiation are, at present, unknown. Gaining an understanding of these issues may open the possibility of manipulating the biology of endogenous cardiomyocytes in order to augment the healing process after myocardial ischemia.

#### METHODS AND MATERIALS

[0174] *Purification and characterization of cytokine-mobilized human CD34+ cells.* Single-donor leukopheresis products were obtained from humans treated with recombinant G-CSF 10 mg/kg (Amgen, CA) sc daily for four days. Donors were healthy individuals undergoing standard institutional procedures of bone marrow mobilization, harvesting and isolation for allogeneic stem cell transplants. Mononuclear cells were separated by Ficol-Hypaque, and highly-purified CD34+ cells (>98% positive) were obtained using magnetic beads coated with anti-CD34 monoclonal antibody (mAb) (Miltenyi Biotec, CA). Purified CD34 cells were stained with fluorescein-conjugated mAbs against CD34 and CD117 (Becton Dickinson, CA), AC133 (Miltenyi Biotec, CA), CD54 (Immunotech, CA), CD62E (BioSource, MA), VEGFR-2, Tie-2, vWF, eNOS, CXCR1, CXCR2, and CXCR4 (all Santa Cruz Biotech, CA), and analysed by four-parameter fluorescence using FACScan (Becton Dickinson, CA). Cells positively selected for CD34 expression were also stained with phycoerythrin (PE)-conjugated anti-CD117 mAb (Becton Dickinson, CA), and sorted for bright and dim fluorescence using a Facstar Plus (Becton Dickinson) and a PE filter. Intracellular staining for GATA-2 was performed by permeabilizing one million cells from each of the brightly and dimly fluorescing cell populations using a Pharmingen Cytofix/Cytoperm kit, incubating for 30 minutes on ice with 10ul of fluorochrome-conjugated mAbs against both CD117 and CD34 surface antigens (Becton Dickinson, CA). After resuspension in 250ul of Cytofix/Cytoperm solution for 20 minutes at 4 degrees C, cells were incubated with a fluorochrome-labeled mAb against GATA-2 (Santa Cruz Biotech, CA) or IgG control for 30 minutes at 4 degrees C, and analyzed by three-parameter flow cytometry.

[0175] *Animals, surgical procedures, and injection of human cells.* Rowett (mu/mu) athymic nude rats (Harlan Sprague Dawley, Indianapolis, Indiana) were used in studies approved by the "Columbia University Institute for Animal Care and Use Committee". After anesthesia, a left thoracotomy was performed, the pericardium was opened, and the left anterior descending (LAD) coronary artery was ligated. Sham-operated rats had a similar surgical procedure without having a suture placed around the coronary artery.

[0176] *Histology and measurement of infarct size.* Following excision at 2 and 15 weeks, left ventricles from each experimental animal were sliced at 10-15 transverse sections from apex to base. Representative sections were fixed in formalin and stained for routine histology (H&E) to determine cellularity of the myocardium, expressed as cell number per high power field (HPF) (600X). A Masson trichrome stain was performed, which labels collagen blue and myocardium red, to evaluate collagen content on a semiquantitative scale (0-3+), with 1+ light blue, 2+ light blue and patches of dark blue, and 3+ dark blue staining. This enabled measurement of the size of the Myocardial scar using a digital image analyzer. The lengths of the infarcted surfaces, involving both epicardial and endocardial regions, were measured with a planimeter digital image analyzer and expressed as a percentage of the total ventricular circumference. Final infarct size was calculated as the average of all slices from each heart. All studies were performed by a blinded pathologist (MJS). Infarct size was expressed as percent of total left ventricular area. Final infarct size was calculated as the average of all slices from each heart.

[0177] *Quantitation of capillary density.* In order to quantitate capillary density and species origin of the capillaries, additional sections were stained freshly with mAbs directed against rat or human cD31 (Serotec, UK, and Research

Diagnostics, NJ, respectively), factor VIII (Dako, CA), and rat or human MHC class I (Accurate Chemicals, CT). Arterioles were differentiated from large capillaries by the presence of a smooth muscle layer, identified by staining sections with a monoclonal antibody against muscle-specific desmin (Dako, Ca). Staining was performed by immunoperoxidase technique using an Avidin/Biotin Blocking Kit, a rat-absorbed biotinylated anti-mouse IgG, and a peroxidase-conjugate (all Vector Laboratories Burlingame, CA). Capillary density was determined at 5 days and 2 weeks post infarction from sections labeled with anti-CD31 mAb, and confirmed with anti-factor VIII mAb, and compared to the capillary density of the unimpaired myocardium. Values are expressed as the number of CD31-positive capillaries per HPF (400x).

**[0178] Quantitation of cardiomyocyte proliferation.** Cardiomyocyte DNA synthesis and cell cycling was determined by dual staining of rat myocardial tissue sections obtained from LAD-ligated rats at two weeks after injection of either saline or CD34+ human cells, and from healthy rats as negative controls, for cardiomyocyte-specific troponin I and human- or rat-specific Ki67. Briefly, paraffin embedded sections were microwaved in a 0.1M EDTA buffer, and stained with either a primary monoclonal antibody against rat Ki67 at 1:3000 dilution (gift of Giorgio Catorretti, Columbia University) or human Ki67 at 1:300 dilution (Dako, CA) and incubated overnight at 4 degrees C. Following washes, sections were incubated with a species-specific secondary antibody conjugated with alkaline phosphatase at 1:200 dilution (Vector Laboratories Burlingame, CA) for 30 minutes and positively-staining nuclei were visualized as blue with a BCIP/NBT substrate kit (Dako, CA). Sections were then incubated overnight at 4 degrees C with a monoclonal antibody against cardiomyocyte-specific troponin I (Accurate Chemicals, CT) and positively-staining cells were visualized as brown through the Avidin/Biotin system described above. Cardiomyocytes progressing through cell cycle in the infarct zone, peri-infarct region, and area distal to the infarct were calculated as the proportion of troponin I-positive cells per high power field co-expressing Ki67. For confocal microscopy, fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse IgG was used as secondary antibody to detect Ki67 in nuclei. A Cy5-conjugated mouse mAb against alpha-sarcomeric actin (clone 5C5; Sigma) was used to detect cardiomyocytes, and propidium iodide was used to identify all nuclei.

**[0179] Measurement of myocyte apoptosis by DNA end-labeling of paraffin tissue sections.** For in situ detection of apoptosis at the single cell level we used the TUNEL method of DNA end-labeling mediated by dextrynucleotidyltransferase (TdT) (Boehringer Mannheim, Mannheim, Germany). Rat myocardial tissue sections were obtained from LAD-ligated rats at two weeks after injection of either saline or CD34+ human cells, and from healthy rats as negative controls. Briefly, tissues were deparaffinized with xylene and rehydrated with graded dilutions of ethanol and two washes in phosphate-buffered saline (PBS). The tissue sections were then digested with Proteinase K (10ug/ml in Tris/HCL) for 30 minutes at 37.0 C. The slides were then washed 3 times in PBS and incubated with 50ul of the TUNEL reaction mixture (TdT and fluorescein-labeled dUTP) and incubated in a humid atmosphere for 60 minutes at 37.0 C. For negative controls TdT was eliminated from the reaction mixture. Following 3 washes in PBS, the sections were then incubated for 30 minutes with an antibody specific for fluorescein-conjugated alkaline phosphatase (AP) (Boehringer Mannheim, Mannheim, Germany). The TUNEL stain was visualized with a substrate system in which nuclei with DNA fragmentation stained blue, (BCIP/NBT substrate system, DAKO, Carpinteria, CA). The reaction was terminated following three minutes of exposure with PBS. To determine the proportion of blue-staining apoptotic nuclei within myocytes, tissue was counter-stained with a monoclonal antibody specific for desmin. Endogenous peroxidase was blocked by using a 3% hydrogen peroxidase solution in PBS for 15 minutes, followed by washing with 20% goat serum solution. An anti-troponin I antibody (Accurate Chemicals, CT) was incubated overnight (1:200) at 40 degrees C. Following 3 washes sections were then treated with an anti-rabbit IgG, followed by a biotin conjugated secondary antibody for 30 minutes (Sigma, Saint Louis, Missouri). An avidin-biotin complex (Vector Laboratories, Burlingame, CA) was then added for an additional 30 minutes and the myocytes were visualized brown following 5 minutes exposure in DAB solution mixture (Sigma, Saint Louis, Missouri). Tissue sections were examined microscopically at 20X magnification. Within each 20X field 4 regions were examined, containing at least 250 cells per region and cumulatively approximating 1 mm<sup>2</sup> of tissue, at both the peri-infarct site and distally to this site. Stained cells at the edges of the tissue were not counted. Results were expressed as the mean number of apoptotic myocytes per mm<sup>2</sup> at each site examined.

**[0180] Analyses of myocardial function:** Echocardiographic studies were performed using a high frequency liner array transducer (SONOS 5500, Hewlett Packard, Andover, MA). 2D images were obtained at mid-capillary and apical levels. End-diastolic (EDV) and end-systolic (ESV) left ventricular volumes were obtained by bi-plane area-length method, and % left ventricular ejection fraction was calculated as  $[(EDV-ESV)/EDV] \times 100$ .

**[0181] cDNA Subtractive Hybridization:** This technique enabled comparison of the pattern of gene expression between hearts from normal rats and rats who underwent left anterior descending (LAD) coronary artery ligation 48 hours earlier. Briefly, messenger RNA was isolated from each heart, and 1 µg was used for first-strand cDNA synthesis with random primers. The subtractive hybridization was performed with the PCR-select cDNA subtraction kit (CLONTECH), following the manufacturer's recommendations. After second-strand synthesis, the two cDNA libraries were digested with RsaI. Digestion products of the "tester" library were ligated to a specific adapter (T7 promoter), then hybridized with a 30-fold excess of the "driver" library for subtraction. After hybridization, the remaining products were further amplified by PCR. In the forward subtraction, which determines the genes that are overexpressed in the ischemic sample, the ischemic tissue is the "tester" and the normal tissue is the "driver." In the reverse subtraction, the "tester" and the "driver" are

switched to determine the genes that are down-regulated in the ischemic sample.

**[0182] Reverse transcription-polymerase chain reaction (RT-PCR) analysis of HBP23 mRNA expression:** Total RNA was extracted using RNeasy Kits from Qiagen (Valencia, CA) from normal rat hearts or from hearts of rats who underwent LAD ligation two weeks earlier and received either saline or human angiotensin. RNA was reverse transcribed with SMART cDNA Synthesis Kit (Clontech, Palo Alto, CA). Amplification reactions were conducted in a 25ul volume with an initial step of 94C for 5 min, followed by 26-32 cycles of 94C for 30 sec and 68C for 1 min, using TITANIUM Taq PCR Kits (Clontech, Palo Alto, CA). Primers for HBP23 were 5'-GCTGATGAAGGTATCTCTTCAGGGGCCTC (SEQ ID NO: 10) and 5'-GATGGTCTGCCCTTACCAATAGTGGGAG (SEQ ID NO:11). Rat GAPDH was used as internal control (forward primer 5'TGAAGGTCGGAGTCAACGGATTG3' (SEQ ID NO:12), reverse primer 5'CATGTGGGCCA TGAGG TCCA CCAC3' ((SEQ ID NO:13)). Ethidium bromide stained bands of amplified fragments were quantified by densitometric.

**[0183] DNA enzymes and RNA substrates:** DNA enzymes with 3'-3' inverted thymidine were synthesized by Integrated DNA technologies (Coralville, IA) and purified by RNase-free IE-HPLC or RP-HPLC. The short RNA substrates corresponding to target DNA enzyme sequences were chemically synthesized followed by RNase-free PAGE purification and also made by in vitro transcription from a DNA template. Rat HBP23 cDNA and human PAG cDNA were amplified by RT-PCR from total RNA of cultured rat fetal cardiomyocytes and HUVEC, respectively, using the following primer pair: 5'TTTACCTCTTGACTTTTACTTTTGTGTGCCAC3' (forward primer) and 5'CCAGCTGGGCACACTT-CACCATG3' (reverse primer). HBP23 and PAG cDNA were cloned into pGEM-T vectors (Promega) to obtain plasmid constructs pGEM-ratHBP23 and pGEM-humanPAG. cDNA sequences were verified using an automatic sequencing machine. 32P-labeled-nucleotide rat HBP23 and human PAG RNA transcripts were prepared by in vitro transcription (SP6 polymerase, Promega) in a volume of 20ml for 1 hour at 32°C. Unincorporated label and short nucleotides (<350base) were separated from radiolabeled species by centrifugation on Chromaspin-200 columns (Clontech, Palo Alto, CA). Synthetic RNA substrates were end-labeled with 32P using T4 polynucleotide kinase and incubated with 0.05%5uM HBP23 or scrambled DNA enzyme. Reactions were allowed to proceed at 37°C and were "quenched" by transfer of aliquots to tubes containing 90% formamide, 20mM EDTA and loading dye. Samples were separated by electrophoresis on 15% TBE-urea denaturing polyacrylamide gels and detected by autoradiography at -80°C. Primary rat fetal cardiomyocytes were obtained from Clontec (USA) and grown in medium containing 2% FCS, 100ug/ml streptomycin and 100 IU/ml penicillin at 37°C in a humidified atmosphere of 5% CO<sub>2</sub>. Cells were used in experiments between passage 6 and 8. Subconfluent (70-80%) rat fetal cardiomyocytes were transfected using 0.5ml of serum-free medium containing 0.05%5uM HBP23 or scrambled DNA enzyme and 20 ug/ml cationic lipids (DQTAP). After incubation for eight hours cells were lysed using Trizol reagent (LifeSciences, CA) to isolate RNA for RT-PCR of HBP23 expression, as above.

## REFERENCES

### [0184]

- MacLellan WR and Schneider MD. Genetic dissection of cardiac growth control pathways Annu. Rev. Physiol. 2000. 62:289-320.
- Soonpaa MH, Field LJ. Assessment of cardiomyocyte DNA synthesis in normal and injured adult mouse hearts. Am J Physiol 272, H220-6 (1997).
- Kellerman S, Moore JA, Zierhut W, Zimmer HG, Campbell J, Gerdes AM. Nuclear DNA content and nucleation patterns in rat cardiac myocytes from different models of cardiac hypertrophy. J Mol Cell Cardiol 24, 497-505 (2992).
- Colucci, W. S. Molecular and cellular mechanisms of myocardial failure. Am. J. Cardiol. 80(11A), 15L-25L (1997).
- Ravichandran, L. V. and Puvanekrishnan, R. In vivo labeling studies on the biosynthesis and degradation of collagen in experimental myocardial myocardial infarction. Biochem. Intl. 24, 405-414 (1991).
- Agocha, A., Lee, H. W., Eghali-Webb, M. Hypoxia regulates basal and induced DNA synthesis and collagen type I production in human cardiac fibroblasts: effects of TGF-beta, thyroid hormone, angiotensin II and basic fibroblast growth factor. J. Mol. Cell. Cardiol. 29, 2233-2244 (1997).
- Pfeffer, J. M., Pfeffer, M. A., Fletcher, P. J., Braunwald, E. Progressive ventricular remodeling in rat with myocardial infarction. Am. J. Physiol. 260, H1406-414 (1991).

8. Kajstura J, Leri A, Finato N, di Loreto N, Beltrami CA, Anversa P. Myocyte proliferation in end-stage cardiac failure in humans. *Proc Natl Acad Sci USA* 95, 8801-8805 (1998).
9. Beltrami AP, et al. Evidence that human cardiac myocytes divide after myocardial infarction. *N Engl J Med* 344, 1750-7 (2001).
10. Kocher, AA, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. *Nat. Med.* 7, 430-6 (2001).
11. Vander Heiden MG, Plas DR, Rathmell JC, Fox CJ, Harris MH, Thompson CB. Growth factors can influence cell survival through effects on glucose metabolism. *Mol Cell Biol* 21, 5899-5912 (2001).
12. Rössig L, Jadidi AS, Urbich C, Badier C, Zeiher AM, and Dimmeler S. Akt-dependent phosphorylation of p21Cip1 regulates PCNA binding and proliferation of endothelial cells. *Mol Cell Biol* 21, 5644-5657 (2001).
13. Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. *Am J Pathol.* 148, 291-300 (1996).
14. Hill MF, Singal PK. Right and left myocardial antioxidant responses during heart failure subsequent to myocardial infarction. *Circulation* 96, 2414-20 (1997).
15. Cessell D, et al. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. *Circ Res* 89, 279-86 (2001).
16. Chae, H. Z., Chung, S. J. & Rhee, S. G. Thioredoxin-dependent peroxide reductase from yeast. *J. Biol. Chem.* 269, 27670-27678 (1994).
17. Das KC, Pahl PM, Guo X-L, and White CW. Induction of peroxiredoxin gene expression by oxygen in lungs of newborn primates. *Am. J. Respir. Cell Mol. Biol.*, 25, 226-232, 2001.
18. Holmgren, A. Thioredoxin. *Annu. Rev. Biochem.* 54, 237-271 (1985).
19. Sun X, et al. Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. *J Biol. Chem.* 275, 17237-17240 (2000).
20. Kumar S, et al. Targeting of the c-Abl tyrosine kinase to mitochondria in the necrotic cell death response to oxidative stress. *J. Biol. Chem.* 276, 17281-17285 (2001).
21. Wen S-T, and Van Etten, RA. The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. *Genes and Development* 9, 2458-2467 (1997).
22. Breaker, R.R. Making catalytic DNAs. *Science* 290, 2095-2096 (2000).
23. Khachigian, L.M. Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. *J Clin Invest* 106, 1189-1195 (2000).
24. Zuker, M. On finding all suboptimal foldings of an RNA molecule. *Science* 244, 48-52 (1989).
25. Li B, Ishii T, Choon Ping Tan CP, Soh JW, and Goff SP. Pathways of induction of Peroxiredoxin I expression in osteoblasts. Roles of p38 mitogen-activated protein kinase and protein kinase c. *J. Biol. Chem.*, 277, 12418-12422 (2002).
26. Wet MM and Palfrey HC. Divergence in the anti-apoptotic signalling pathways used awareness by nerve growth factor and basic fibroblast growth factor (bFGF) in PC12 cells: rescue by bFGF involves protein kinase Cδ. *Biochem. J.* 352:175-182 (2000).
27. Chae, H. Z., Chung, S. J. & Rhee, S. G. *J. Biol. Chem.* 269, 27670-27678 (1994).

**EP 2 292 631 A1**

28. Kwon, S. J., Park, J., Choi, W., Kim, T. H. & Kim, K. *Biochem. Biophys. Res. Comm.* 201, 8-15 (1994).
29. Kang, S. W., Baines, I. C. & Rhee, S. G. *J. Biol. Chem.* 273, 6303-6311 (1998).
- 5 30. Wen S-T, and Van Etten, RA. The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. *Genes and Development* 19, 2456-2467 (1997).
- 10 31. Kharbanda, S., Yuan, Z. M., Welchselbaum, R. and Kufe, D. Determination of cell fate by c-Abl activation in the response to DNA damage. *Oncogene* 17, 3309-3318 (1998).
32. Yuan 2M, Huang Y, Whang Y, Sawyers C, Welchselbaum R, Kharbanda S, and Kufe D. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. *Nature* 382, 272-4 (1998).
- 15 33. Anversa P and Nadal-Ginard B. Myocyte renewal and ventricular remodelling *Nature* 415, 240 - 243 (2002).
- 20
- 25
- 30
- 35
- 40
- 45
- 50
- 55



# EP 2 292 631 A1

## SEQUENCE LISTING

5 <110> THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK ET AL.  
 <120> REGENERATION OF ENDOGENOUS MYOCARDIAL TISSUE BY INDUCTION OF NEOVASCULARIZATION  
 <130> 0575/66602-A-PCT  
 10 <140> NOT YET KNOWN  
 <141> HERewith  
 <150> 13  
 15 <170> PatentIn version 3.2  
 <210> 1  
 <211> 2780  
 <212> DNA  
 <213> HOMO SAPIENS  
 20 <220>  
 <221> CDS  
 <222> (314) ..(1489)  
 <223>  
 25 <400> 1  
 aaactaacc ctctttttct ccaaaaggagt gcttgctggag atcggatctt tctccagca 60  
 attgggggaa agaaggtttt ttctctgact tcgcttagtg taaccagcgg cytatatttt 120  
 ttaggcgctt ttctgaaaaa ctagtagtta atattcattt gtttaaatct tattttattt 180  
 30 ttaagctcaa actgcttaag aataccttaa ttctctaaag tgaaataatt ttitgcaaag 240  
 ggggttctct gatttggagc tttttttttt ttccaccgtc atttctaaat cttaaaaacca 300  
 actcagttcc atc atg gtg atg ttc aag aag atc aag tct ttt gag gtg 349  
 35 Met Val Met Phe Lys Lys Ile Lys Ser Phe Glu Val  
 1 5 10  
 gtc ttt aac gac cct gaa aag gtg tac ggc agt ggc gag aag gtg gct 397  
 Val Phe Asn Asp Pro Glu Lys Val Tyr Gly Ser Gly Glu Lys Val Ala  
 15 20 25  
 40 ggc cgg gtg ata gtg gag gtg tgt gaa gtc act cgt gtc aaa gcc gtt 445  
 Gly Arg Val Ile Val Glu Val Cys Glu Val Thr Arg Val Lys Ala Val  
 30 35 40  
 45 agg atc ctg gct tgc gga gtg gct aaa gtg ctt tgg atg cag gga tcc 493  
 Arg Ile Leu Ala Cys Gly Val Ala Lys Val Leu Trp Met Gln Gly Ser  
 45 50 60  
 cag cag tgc aaa cag act tgc gag tac ctg cgc tat gaa gac acg ctt 541  
 Gln Gln Cys Lys Thr Ser Glu Tyr Leu Arg Tyr Glu Asp Thr Leu  
 50 65 70 75  
 ctt ctg gaa gac cag cca aca ggt gag aat gag atg gtg atc atg aga 589  
 Leu Leu Glu Asp Gln Pro Thr Gly Glu Asn Glu Met Val Ile Met Arg  
 80 85 90

EP 2 292 631 A1

5	cct gga aac aaa tat gag tac aag ttc ggc ttt gag ctt cct caa ggg Pro Gly Asn Lys Tyr Glu Tyr Lys Phe Gly Phe Glu Leu Pro Gln Gly 95 100 105	637
	cct ctg gga aca tcc ttc aaa gga aaa tat ggg tgt gta gac tac tgg Pro Leu Gly Thr Ser Phe Lys Gly Lys Tyr Gly Cys Val Asp Tyr Trp 110 115 120	685
10	gtg aag gct ttt ctt gac cgc ccg agc cag cca act caa gag aca aag Val Lys Ala Phe Leu Asp Arg Pro Ser Gln Pro Thr Gln Glu Thr Lys 125 130 135 140	733
	aaa aac ttt gaa gta gtg gat ctg gtg gat gtc aat acc cct gat tta Lys Asn Phe Glu Val Val Asp Leu Val Asp Val Asn Thr Pro Asp Leu 145 150 155	781
15	atg gca cct gtg tct gct aaa aaa gaa aag aaa gtt tcc tgc atg ttc Met Ala Pro Val Ser Ala Lys Lys Glu Lys Lys Val Ser Cys Met Phe 160 165 170	829
	att cct gat ggg cgg gtg tct gtc tct gct cga att gac aga aaa gga Ile Pro Asp Gly Arg Val Ser Val Ser Ala Arg Ile Asp Arg Lys Gly 175 180 185	877
25	ttc tgt gaa ggt gat gag att tcc atc cat gct gac ttt gag aat aca Phe Cys Glu Gly Asp Glu Ile Ser Ile His Ala Asp Phe Glu Asn Thr 190 195 200	925
	tgt tcc cga att gtg gtc ccc aaa gct gcc att gtg gcc cgc cac act Cys Ser Arg Ile Val Val Pro Lys Ala Ala Ile Val Ala Arg His Thr 205 210 215 220	973
30	tac ctt gcc aat ggc cag acc aag gtg ctg act cag aag ttg tca tca Tyr Leu Ala Asn Gly Gln Thr Lys Val Leu Thr Gln Lys Leu Ser Ser 225 230 235	1021
	gtc aga ggc aat cat att atc tca ggg aca tgc gca tca tgg cgt ggc Val Arg Gly Asn His Ile Ile Ser Gly Thr Cys Ala Ser Trp Arg Gly 240 245 250	1069
35	aag agc ctt cgg gtt cag aag atc agg cct tct atc ctg ggc tgc aac Lys Ser Leu Arg Val Gln Lys Ile Arg Pro Ser Ile Leu Gly Cys Asn 255 260 265	1117
	atc ctt cga gtt gaa tat tcc tta ctg acc tat gtt agc gtt cct gga Ile Leu Arg Val Glu Tyr Ser Leu Leu Ile Tyr Val Ser Val Pro Gly 270 275 280	1165
45	tcc aag aag gtc atc ctt gac ctg ccc ctg gta att ggc agc aga tca Ser Lys Lys Val Ile Leu Asp Leu Pro Leu Val Ile Gly Ser Arg Ser 285 290 295 300	1213
	ggc cta agc agc aga aca tcc agc atg gcc agc cga acc agc tct gag Gly Leu Ser Ser Arg Thr Ser Ser Met Ala Ser Arg Thr Ser Ser Glu 305 310 315	1261
50	atg agt tgg gta gat ctg aac atc cct gat acc cca gaa gct cct ccc Met Ser Trp Val Asp Leu Asn Ile Pro Asp Thr Pro Glu Ala Pro Pro 320 325 330	1309

EP 2 292 631 A1

5	<p> tgc tat atg gat gtc att cct gaa gat cac cga ttg gag agc cca acc 1357  Cys Tyr Met Asp Val Ile Pro Glu Asp His Arg Leu Glu Ser Pro Thr  335 340 345 </p>	
	<p> act cct ctg cta gat gac atg gat ggc tct caa gac agc cct atc ttt 1405  Thr Pro Leu Leu Asp Asp Met Asp Gly Ser Gln Asp Ser Pro Ile Phe  350 355 360 </p>	
10	<p> atg tat gcc cct gag ttc aag ttc atg cca cca cag act tat act gag 1453  Met Tyr Ala Pro Glu Phe Lys Phe Met Pro Pro Pro Thr Tyr Thr Glu  365 370 375 380 </p>	
	<p> gtg gat ccc tgc atc ctc aac aac aat gtg cag tga gcatgtggaa 1499  Val Asp Pro Cys Ile Leu Asn Asn Asn Val Gln  385 390 </p>	
15	<p> gaaaagaagc agctttacct acctgtttct ttttgtctct ctctctggac actcactttt 1559 </p>	
	<p> tcagaguctc aacagtctct gcaatggagt gtgggtccac cttagcctct gacttccata 1619 </p>	
20	<p> tctaggagggt ggtcagcagg caatctcctg ggccttaaaag gatgcggact catcctcagc 1679 </p>	
	<p> cagcgcccat gttgtgatac aggggtgttt gttggatggg tttaaaaata actagaaaaa 1739 </p>	
25	<p> ctcaggccca tccattttct cagatctcct tgaaaaattga ggccttttcg atagtctcgg 1799 </p>	
	<p> gtcaggtaaa aatggctctc tggcgttaagc ttttcaagggt tttttggagg ctttttgtta 1859 </p>	
30	<p> attgtgatag gaacttttga ccttgaactt acgtatcatg tggagaagag ccaattttaa 1919 </p>	
	<p> aaactaggaa gatgaaaagg gaaattgttg ccaaaacttt gggaaaagga ggttcttaaa 1979 </p>	
35	<p> atcagtgctt cccctttgtg cacttgtaga aaaaaagaa aaaccttcta gagctgattt 2039 </p>	
	<p> gatggacaat ggagagagct ttccctgtga ttataaaaaa ggaagctlagc tgcctcacgg 2099 </p>	
40	<p> tcacttttgc ttaagagtat accttaacct ggctttttaa gcagtagtaa ctgcccacc 2159 </p>	
	<p> aaaggcttta aaagccattt ttggagccta ttgcaactgtg ttctcctact gcaaatattt 2219 </p>	
45	<p> tcataatggg ggaatggttt ctcttcattg aagtccttgg aattgattct aagggtatgt 2279 </p>	
	<p> tcttagcact ttaattcctg tcaaattttt tgttctctcc ttctgcctac ttaaatgtta 2339 </p>	
50	<p> gctgaaactg gtcactgtg tctctagggt taagcctaaa gacaaaaaa attttactac 2399 </p>	
	<p> ttttgagatt gcccaattgt acagaattat ataattctaa cgtttaaatc atgtgaaagg 2459 </p>	
55	<p> gttctgtctg tcagccttgc ccactgtgac ttcaaaccca aggaggaact ctgatacaag 2519 </p>	
	<p> atgcccaacc ctgtgatcag aacctccaaa tactgccatg agaaactaga gggcaggtct 2579 </p>	
60	<p> tcataaaagc cttttgaacc ccttccctgc cctgtgttag gagatagggg tattggcccc 2639 </p>	
	<p> tcactgcagc tgcagcact tggtcagta ctctcagcca tagcactttg ttactgtctc 2699 </p>	
65	<p> tgtgtcagag caetgagctc cacccttttc tgagagttat tacagccaga aagtgtgggc 2759 </p>	
	<p> tgaagatggt tggtttcatg t 2780 </p>	

EP 2 292 631 A1

5 <210> 2  
 <211> 391  
 <212> PRT  
 <213> HOMO SAPIENS  
  
 <400> 2  
 10 Met Val Met Phe Lys Lys Ile Lys Ser Phe Glu Val Val Phe Asn Asp  
 1 5 10 15  
  
 Pro Glu Lys Val Tyr Gly Ser Gly Glu Lys Val Ala Gly Arg Val Ile  
 20 25 30  
 15 Val Glu Val Cys Glu Val Thr Arg Val Lys Ala Val Arg Ile Leu Ala  
 35 40 45  
  
 Cys Gly Val Ala Lys Val Leu Trp Met Gln Gly Ser Gln Gln Cys Lys  
 50 55 60  
 20 Gln Thr Ser Glu Tyr Leu Arg Tyr Glu Asp Thr Leu Leu Glu Asp  
 65 70 75 80  
 25 Gln Pro Thr Gly Glu Asn Glu Met Val Ile Met Arg Pro Gly Asn Lys  
 85 90 95  
  
 Tyr Glu Tyr Lys Phe Gly Phe Glu Leu Pro Gln Gly Pro Leu Gly Thr  
 100 105 110  
 30 Ser Phe Lys Gly Lys Tyr Gly Cys Val Asp Tyr Trp Val Lys Ala Phe  
 115 120 125  
 35 Leu Asp Arg Pro Ser Gln Pro Thr Gln Glu Thr Lys Lys Asn Phe Glu  
 130 135 140  
  
 Val Val Asp Leu Val Asp Val Asn Thr Pro Asp Leu Met Ala Pro Val  
 145 150 155 160  
 40 Ser Ala Lys Lys Glu Lys Lys Val Ser Cys Met Phe Ile Pro Asp Gly  
 165 170 175  
 45 Arg Val Ser Val Ser Ala Arg Ile Asp Arg Lys Gly Phe Cys Glu Gly  
 180 185 190  
  
 Asp Glu Ile Ser Ile His Ala Asp Phe Glu Asn Thr Cys Ser Arg Ile  
 195 200 205  
 50  
 55

EP 2 292 631 A1

5 Val Val Pro Lys Ala Ala Ile Val Ala Arg His Thr Tyr Leu Ala Asn  
210 215 220

10 Gly Gln Thr Lys Val Leu Thr Gln Lys Leu Ser Ser Val Arg Gly Asn  
225 230 235 240

15 His Ile Ile Ser Gly Thr Cys Ala Ser Trp Arg Gly Lys Ser Leu Arg  
245 250 255

20 Val Gln Lys Ile Arg Pro Ser Ile Leu Gly Cys Asn Ile Leu Arg Val  
260 265 270

25 Glu Tyr Ser Leu Leu Ile Tyr Val Ser Val Pro Gly Ser Lys Lys Val  
275 280 285

30 Ile Leu Asp Leu Pro Leu Val Ile Gly Ser Arg Ser Gly Leu Ser Ser  
290 295 300

35 Arg Thr Ser Ser Met Ala Ser Arg Thr Ser Ser Glu Met Ser Trp Val  
305 310 315 320

40 Asp Leu Asn Ile Pro Asp Thr Pro Glu Ala Pro Pro Cys Tyr Met Asp  
325 330 335

45 Val Ile Pro Glu Asp His Arg Leu Glu Ser Pro Thr Thr Pro Leu Leu  
340 345 350

50 Asp Asp Met Asp Gly Ser Gln Asp Ser Pro Ile Phe Met Tyr Ala Pro  
355 360 365

55 Glu Phe Lys Phe Met Pro Pro Pro Thr Tyr Thr Glu Val Asp Pro Cys  
370 375 380

Ile Leu Asn Asn Asn Val Gln  
385 390

<210> 3  
<211> 1176  
<212> DNA  
<213> HOMO SAPIENS

<400> 3  
atggtgatgt tcaagaagat caagctcttt gaggtggtct ttaacgacct tgaagggtg 60  
tacggcaytg gcgagaaggt ggctggcgg gctatagtgg aggtgtgtga agttactcgt 120  
gtcaaaagcgg ttaggatcct ggcttgcgga gtggctaaag tgctcttgat gcagggatcc 180

EP 2 292 631 A1

	cagcagtgca aacagacttc ggagtagctg cgctatgaag acacgcttct tctggaagac	240
5	cagccaacag gtgagaatga gatggcgatc atgagacctg gaacacaaata tgagtacaag	300
	ttcgggtttg agcttccctca gggggcctctg ggaacatcct tcaaaaggaaa atatgggtgt	360
	gtagactact ggggtgaaggc ttttcttgac cgcccagacc agccaactca agagacaaag	420
10	aaaaactttg aagtagtggg tctggtaggat gtcaataccc ctgatttaac ggcacctgtg	480
	tctgtctaaaa aagaaaaagaa agtttccctg atgttcattc ctgattggcg ggtgtctgtc	540
	tctgtctgaa ttgacagaaa aggattctgt gaaggtagtg agatttccat ccattgtgac	600
15	tttgagaata catgttcccg aattgtggtc cccaagctg ccattgtggc ccgccacact	660
	taccttgcca atggccagac caaggtagct actcagaagt tgtcatcagt cagaggcaat	720
	catattatct cagggaatg cgcattcatgg cgtggcaaga gccttcgggt tcagaagatc	780
20	aggcctctta tctctggctg caacatcctt cgaagtgaat attccttact gatctatgtt	840
	agcgttccct gatccaagaa ggtcatcctt gacctgcccc tggcaattgg cagcagatca	900
	ggctctaagca gcagaacttc cagcatggcc agccgaacca gctctgagat gagttgggta	960
25	gatctgaaca tccctgatac ccacagaagct cctccctgct atattggatgt cattcctgaa	1020
	gatcaccgat tggagagccc aaccactcct ctgctagatg acatggatgg ctctcaagac	1080
	agccctatct ttatgtatgc cctgagttc aagttcatgc caccaccgac ttatactgag	1140
30	gtggatccct gcatcctcaa caacaatgtg cagtga	1176
	<210> 4	
	<211> 20	
35	<212> DNA	
	<213> ARTIFICIAL SEQUENCE	
	<220>	
	<221> PRIMER DIRECTED TO RAT Cinc	
40	<400> 4	
	gaagatagat tgcaccgatg	20
	<210> 5	
	<211> 16	
45	<212> DNA	
	<213> ARTIFICIAL SEQUENCE	
	<220>	
	<221> PRIMER DIRECTED TO RAT Cinc	
50	<400> 5	
	catagcctct cacatttc	18

55

**EP 2 292 631 A1**

	<210> 6	
	<211> 25	
	<212> DNA	
	<213> ARTIFICIAL SEQUENCE	
5	<220>	
	<223> PRIMER DIRECTED TO RAT Cinc	
	<400> 6	
	g g c c c g t c c g c c a a t g a g c t g c g c	25
10		
	<210> 7	
	<211> 28	
	<212> DNA	
	<213> ARTIFICIAL SEQUENCE	
15	<220>	
	<223> PRIMER DIRECTED TO RAT Cinc	
	<400> 7	
	c t t g g g g a c a c c c t t c a g c a t c t t t t c g g	28
20		
	<210> 8	
	<211> 21	
	<212> DNA	
	<213> ARTIFICIAL SEQUENCE	
25	<220>	
	<223> PRIMER DIRECTED TO RAT Cinc	
	<400> 8	
	c t c t a c c c a c g g c a a g t t c a a	21
30		
	<210> 9	
	<211> 20	
	<212> DNA	
	<213> ARTIFICIAL SEQUENCE	
35	<220>	
	<223> PRIMER DIRECTED TO RAT Cinc	
	<400> 9	
	g g g a t g a c c t t g c c c a c a g c	20
40		
	<210> 10	
	<211> 30	
	<212> DNA	
	<213> ARTIFICIAL SEQUENCE	
45	<220>	
	<223> PRIMER DIRECTED TO HBp23	
	<400> 10	
	g c t g a t g a a g g t a t c t c t t t c a g g g g c c t c	30
50		

```

5      <210> 11
      <211> 29
      <212> DNA
      <213> ARTIFICIAL SEQUENCE

      <220>
      <223> PRIMER DIRECTED TO HBP23

      <400> 11
10     gatggctctgc cccttaccac tagtggaag

      <210> 12
      <211> 24
      <212> DNA
15     <213> ARTIFICIAL SEQUENCE

      <220>
      <223> PRIMER DIRECTED TO GADPH

      <400> 12
20     tgaaggctcgg agtcaacgga ttctg

      <210> 13
      <211> 24
      <212> DNA
25     <213> ARTIFICIAL SEQUENCE

      <220>
      <223> REVERSE PRIMER DIRECTED TO GADPH

      <400> 13
30     catgtgggcc atgaggtcca ccac

```

### Claims

1. An agent for use in the treatment of a disorder of a subject's heart involving loss of cardiomyocytes, the agent comprising an amount of a CXC chemokine or a gene encoding a CXC chemokine effective to cause cardiomyocyte proliferation within the subject's heart so as to thereby treat the disorder.
2. The agent of claim 1, wherein the agent is a CXC chemokine.
3. The agent of claim 2, wherein the chemokine is Stromal-Derived Factor-1, I1-8 or Gro-Alpha.
4. The agent of claim 2, wherein the chemokine is Stromal-Derived Factor-1.
5. The agent of claim 4, wherein the chemokine is Stromal-Derived Factor-1 alpha or Stromal-Derived Factor-1 beta.
6. The agent of any one of claims 1 to 5, which is administered intramyocardially or intracoronary.
7. The agent of any one of claims 1 to 6, which is administered via a stent, a scaffold, or as a slow-release formulation.
8. The agent of any one of claims 1 to 7 further comprising a second agent.
9. The agent of claim 8, wherein the second agent is GM-CSF, G-CSF, IL-8, a Gro family chemokine, an inhibitor of CXCR4 or an inhibitor of SDF-1.



**EP 2 292 631 A1**

10. The agent of any one of claims 1 to 9, which is for treating a cardiovascular disease, congestive heart failure, myocardial infarct, myocardial ischemia, or cardiomyopathy.
- 5 11. The agent of any one of claims 1 to 9, which is for treating myocardial infarct.
12. The agent of any one of claims 1 to 11, wherein the agent comprises between 0.2 $\mu$ g/ml to 5 $\mu$ g/ml of the CXC chemokine at a maximum volume of 10ml for a 70kg human subject.
- 10 13. The agent of any one of claims 1 to 12, wherein administration of the agent results in improved cardiac function.
14. The agent of claim 13, wherein improved cardiac function is determined by improved ejection fraction.
- 15 15. Use of an amount of a CXC chemokine or a gene encoding a CXC chemokine effective to cause cardiomyocyte proliferation within the subject's heart in the manufacture of a medicament for treating a disorder of a subject's heart involving loss of cardiomyocytes.
16. The use of claim 15, wherein the CXC chemokine is Stromal Derived Factor-1, IL-8 or Gro-Alpha.
17. The use of claim 16, wherein the CXC chemokine is Stromal Derived Factor-1.
- 20 18. The use of claim 17, wherein the CXC chemokine is Stromal Derived Factor-1 alpha or Stromal Derived Factor-1 beta.
19. The use of any one of claims 15 to 18, wherein the medicament is for intramyocardial administration or intracoronary administration.
- 25 20. The use of any one of claims 15 to 19, wherein the medicament is for administration via a stent, a scaffold, or as a slow-release formulation.
21. The use of any one of claims 15 to 20, wherein the medicament further comprises a second agent.
- 30 22. The use of claim 21, wherein the second agent is GM-CSF, G-CSF, IL-8, a Gro family chemokine, an inhibitor of CXCR4 or an inhibitor of SDF-1.
- 35 23. The use of any one of claims 15 to 22, which is for treating a cardiovascular disease, congestive heart failure, myocardial infarct, myocardial ischemia or cardiomyopathy.
24. The use of any one of claims 15 to 23, wherein the medicament is for treating myocardial infarct.
- 40 25. The use of any one of claims 15 to 24, wherein the medicament comprises between 0.2 $\mu$ g/ml to 5 $\mu$ g/ml of the CXC chemokine at a maximum volume of 10ml for a 70kg human subject.
26. The use of any one of claims 15 to 25, wherein the medicament induces improved cardiac function.
- 45 27. The use of claim 26, wherein improved cardiac function is determined by improved ejection fraction.
28. The agent of claim 1, wherein the agent is a gene encoding a CXC chemokine.
- 50
- 55




FIGURE 1B




FIGURE 1C




FIGURE 1D





FIGURE 2A



**FIGURE 2B**







FIGURE 2C














FIGURE 3D








FIGURE 4A





FIGURE 4B



angioblast concentration (cells/mm<sup>2</sup>) and condition

FIGURE 4C





**FIGURE 4D**

2 x 10<sup>5</sup> angioblasts



saline



2 x 10<sup>5</sup> angioblasts



rat MHC class I

dual staining for rat Ki-67 (blue) and troponin I (brown)

□ LAD ligation + saline  
▨ LAD ligation + 2 x 10<sup>5</sup> angioblasts




FIGURE 4E





FIGURE 4F



angioblast concentration (cells/mm<sup>3</sup>) and condition






FIGURE 4H




$10^3$  angioblasts



$2 \times 10^5$  angioblasts

FIGURE 5



## FIGURE 6

```

1 aaactaaccc ctctttttct ccaaaggagt gcttggtggag atcgatctt ttctccagca
61 attgggggaa agaaggcttt ttctctgact tgcgttagtg taaccagcgg cgtatatattt
121 ttagggcgcct ttctgaaaac ctagtagtta atattcoatct gtttaaatct tattttattt
181 ttaagctcaa actgccttaag aataccctaa ttccctaaag tgaataaatt ttctgcaaaag
241 ggggtttctc gatttgaggc tttttttttc ttccaccgtc atttctaaact cttaaaacca
301 actcagttcc atcatgggtga tgttcaagaa gatcaagtcct tttagaggtgg tctttaacga
361 ccctgaaaag gtgtacggca gtggcgagaa ggtggctggc cgggtgatag tggaggtgtg
421 tgaagttact cgtgtcaaa cgttaggat cctggcttgc ggaagtggcta aagtgtcttg
481 gatgcaggga tccccagcag gcaaacagac ttccgsagta cctgcctatg aagcacgct
541 tcttctggaa gaccagccaa cagggtgagaa tgagatgggt atcatgagac ctggaaaacaa
601 atatgagtac aaagtctggct ttgagcttcc tcaggggcct ctgggaacat ccttcaaaag
661 aaaaatcggg tgtgtagact actgggtgaa ggccttttctt gaccgcccga gccagccaac
721 tcaagagaca aagaaaaact ctgaagtagt ggaatcgggt gatgtcaata cccctgattt
781 aatggcacct gtgtctgcta aaaaagaaaa gaaagtcttc tgcattgtca ttcttgatgg
841 gcgggtgctc gtctctgctc gaattgacag aaaaaggattc tgtgaagggt atgagatttc
901 catccatgct gatcttgaga atacatgttc ccgaattgtg tgcctccaaag ctgccattgt
961 ggcctccacc acttaccttg ccaatggcca gaccaagggt ctgactcaga agttgtcatc
1021 agtcagaggc aatcatatta tctcaggggc atgcgcatac tggcgtggca agagccttcg
1081 ggttcagaag atcaggcctt ctatcctggg ctgcaacatc cttcgagttg aatattcctt
1141 actgatctat gttagcgttc ctggatccaa gaaggtcatc cctcgactgc cgggtgtaat
1201 tggcagcaga tcaggtctaa gcagcagaa atccagcatg gccagccgaa ccagctctga
1261 gatgagttgg gtatattcga acatccctga taccccagaa gctcctcctt gctatatgga
1321 tgtcattctc gaagatcacc gattggagag cccaaccact cctctcgtag atgacatgga
1381 tggctctcaa gacagcccta tctttatgta tgcctctgag ttcaagttca tgcaccacc
1441 gacttatact gaggctggatc cctgcctcct caacaacaat gtgcagtga catgtggaag
1501 aaaagaagca gctttaacct cttgttctct ttgtctctc ttccctggaca ctcaactttt
1561 cagagactca acagtctctg caatggagtg tgggtccacc ttagacctg ctgcctaat
1621 gtaggagggt gtccagaggc aatctcctgg gccttaagg atcgggactc atcctcagcc
1681 agcgcccatg ttgtgatata ggggtgtttg ttggatgggt ttagacctg acttcctaat
1741 tcaggcccat ccattttctc agatctcctt gaaaattgag gccttttctga tagtttctgg
1801 tcagggtaaaa atggcctcct ggcgtaagct ttcaagggt ttttggaggc tttttgaaaa
1861 ttgtgatagg aaactttggac cttgaactta cgtatcatgt ggagaagagc caatttaaca
1921 aactaggaag atgaaaagg aaattgtggc caaaactttg ggaaaaggag gttcttaaaa
1981 tcagtgtttc ccttttgtgc acttgtagaa aaaaagaaa aacctcttag agctgatttg
2041 atggacaatg gagagagctt tccctgtgat tataaaaaag gaagctagct gctctacggt
2101 catctttgct taagagtata ctttaacctg gctttttaa gctagttaac tgcctactg
2161 aaggctctaa aagccatttt tggagcctat tgcactgtgt tctcctactg caaatatttt
2221 catatgggag gatggttttc tctcatgta agtccctgga attgatcta atgtgatgtt
2281 cttagcactt taattctctg caaatttttt gtctctccct tctgccatct baaattgtaag
2341 ctgaaactgg tctactgtgt crctagggtt aagccaaaag gctttttaa gctttttaa
2401 tttagagatt ccccaatgta cagaattata taattctaac gcttaaatca tgtgaaagg
2461 ttgctgctgt cccgccttgc cactgtgact tcaaacccaa ggagggaactc ttgtacaa
2521 tgcaccaacc tgtgatcaga accctccaat actgccatga gaaactagag ggcagggtctt
2581 catcaaaagc ctttgaaccc ccttctgccc ctgtgttagt agatagggat attggccctt
2641 cactgcagct gccagcactt ggtcagtcac tctcagccat agcactttgt tcaactgctt
2701 gtgtcagagc actgagctcc acccttttct gagagttatt acagccagaa agtgcgggct
2761 gaagatgggt ggtttcatgt

```

FIGURE 7

```

314      ATggtgA  Tgttcaagaa  gATcaagtct  tttagggttg  tctttaacga
361      ccttgaaaa  gtracggca  gtggcgagaa  ggtggctggc  cgggtgATag  tggagggtg
421      tgaagttact  cgtgtcaaa  ccgttaggAT  cctggcttgc  ggaagtggta  aagtctttg
481      gATgcaggga  Tcccagcagt  gcaaacagac  ttccgagtac  ctgcgtATg  aagacacgt
541      ttctctggaa  gaccagccaa  caggtgagaa  TgagATggtg  ATcATgagac  ctggaacaa
601      ATATgagtag  aagttcggt  ttgagcttcc  tca9gggcct  ctgggaacAT  ccttcaaag
661      aaahATggtg  tbtgtagact  actgggtgaa  ggcctttctt  gaccgccca  gccagccaa
721      tcaagagaca  aagaaaaact  ttgaagtagt  ggATctggtg  gATgtcaATa  cccctgATT
781      aATggcact  gtgtctgcta  aaaaagaaa  gaaagtctcc  tgcATgttca  TtcctgATg
841      gcgggtgtct  gtctctgtc  gaATTgacag  aaaaggATtc  tgtgaagtg  ATgagATtc
901      cATccATgct  gactttgaga  ATacATgttc  ccgaATgtg  gtcccaaa  ctgccATTgt
961      ggcggccac  acttaccttg  ccaATggcca  gaccaaggtg  ctgactcaga  agttgtcATc
1021  agtcagagc  aATcATAtTA  Tctcagggac  ATcgcATcA  Tggcgtggca  agagccttg
1081  ggttcagaag  ATcaggcctt  ctATcctggg  ctgcaacATc  ctteaggtt  aATATcctt
1141  actgATctAT  gttagcgttc  ctggATccaa  gaaggTcATc  cttagacctg  cccctggtaAT
1201  tggcagcaga  Tcaggtctaa  gcagcagaac  ATccagcATg  gccagccgaa  ccagctctga
1261  gATgagttgg  gtAgATctga  acATccctgA  Taccacagaa  gctccctcc  gctATATgga
1321  TgtcATTcct  gaagATcacc  gATtgagag  cccaaacct  cctctgctag  ATgacATgga
1381  Tggctctcaa  gacagccctA  TctttATgtA  Tgccctgag  ttcaagttca  Tgccaccac
1441  gacttATact  ggggtgATc  cctgcATcct  caacaacaAT  gtgcagtga

```

FIGURE 8

```

314      atggtga      tgttcaagaa      gatcaagtct      tttgaggttg      tctttaacga
361      ccctgaaaag      gtgtacggca      gtgGcgagaa      ggtgGctgGc      cgggtgatag      tggaggtgtg
421      tgaagttact      cgtgtcaaaG      Ccgttaggat      cctgGcttGc      ggagtGccta      aagtGctttg
481      gatGcaggga      tccaGcAgc      GcaaacAgac      ttcggagtaC      ctGGctatg      aagacacGct
541      tcttctggaa      gaccaGcCaa      caggTgagaa      tgagatggtg      atcatgagac      ctggaacaa
601      atatgagtaC      aagttcgGct      ttgaGcttcc      tcaggggCct      ctgggaacat      ccttcaaaag
661      aaaatatggg      tgtgtagact      actggggTgaa      gGcttttctt      gaccGcccca      GccaGccaac
721      tcaagagaca      aagaaaaact      ttgaagtagt      ggatctggTg      gatgtcaata      cccctgattt
781      aatgCacct      gtgtctGcTa      aaaaagaaaa      gaaagtctcc      tGcatgttca      ttcttgatgg
841      GCgggtgtct      gtctctGctc      gaattgacag      aaaaggattc      tgtgaaggtg      atgagatttc
901      catcatGct      gactttgaga      atacatgttc      ccgaattgtg      gtcccaaaG      CtGcattgt
961      gGccGccac      acttaccttg      CcaatgGcCa      gaccaaagtg      Ctgactcaga      agttgtcatc
1021      agtcagagGc      aatcatatta      ttctcaggag      atGCGcatca      tggCgtgGCa      agaGccttcg
1081      gggttcagaag      atcagGcctt      ctatcctggg      CtGCaacatc      cttcgagttg      aatatccctt
1141      actgatctat      gtraGcgttc      ctggatccaa      gaaggtcatc      cttgacctGc      cccctggtaat
1201      tgGcagCaga      tcagggtctaa      GcagCagaac      atccaGcatg      GCCaGcGgaa      ccaGctctga
1261      gataggttg      gtgatatgga      acatccctga      taccacagaa      Gctctccct      Gctatatgga
1321      tgtcattct      gaagatcacc      gattggagaG      Cccaacact      cctctGctag      atgacatgga
1381      tggGctctaa      gacaGcccta      tctttatgta      tGccctgag      ttcaagttca      tGccaccacc
1441      gacttatact      gaggttgatc      cctGcAtcct      caacaacaat      gtGcagtgga

```



FIGURE 9

```

314      atgGtga  tGtTcaagaa  gatcaaGTct  ttTgagGTgG  Tctttaacga
361  cccTgaaaaG  GTGTacggca  GTggcgagaa  gGTggctggc  cgGTgigataG  TggagGTGTG
421  TgaAGTtact  cGTGTcaaaG  cGTttaggat  cctggtttgc  ggaGTggcta  aaGTgctttg
481  gatgcaggga  tccagcaGT  gcaaacagac  ttcggaGTac  ctgcgctatg  aagacacgct
541  tctcttgga  gaccagccaa  cagGTgagaa  tgagatgGTg  atcatgagac  ctggaacaa
601  atatgaGTac  aacttcggct  ttgagcttcc  tcaggggcct  ctgggaacat  cctTcaaaGg
661  aaaatatggG  TGTGTagact  actggGTgaa  ggcttttctt  gaccgcccga  gccagccaac
721  tcaagagaca  aagaaaaact  ttgaaGTaGT  ggaTctgGTg  gatGTcaata  cccctgattt
781  aatggcacct  GTGTctgcta  aaaaagaaaa  gaaaGTttcc  tgcatGTtca  ttccctgatgg
841  gcggGTGTct  GTctctgctc  gaattgacag  aaaagatttc  tGTgaagGTg  atgagatttc
901  catccatgct  gactttgaga  atacatGTtc  ccgaattGTg  GTccccaaag  ctgccattGT
961  ggcccgccac  acttaccttg  ccaatggcca  gaccaagGTg  ctgactcaga  aGTGTcact
1021  aGTcagaggc  aatcataTta  tctcagggac  atgcgcatca  tggcGTggca  agagccttcg
1081  gGTcagaag  atcaggccct  ctatccTggg  ctgcaacatc  cttcgaGTg  aatatccctt
1141  actgatctat  GTtagcGTtc  ctggatocaa  gaagGTcatc  cttgacctgc  cccTgGTaat
1201  tggcagcaga  tcagGTctaa  gcagcagaac  atccagcatg  gccagccgaa  ccagctctga
1261  gatgaGTtgg  GTagatctga  acatccctga  taccocagaa  gctcctccct  gctatatgga
1321  TGtattct  gaagatcacc  gattggagag  cccaaccact  cctctgctag  atgacatgga
1381  tggctctcaa  gacagcccta  tctttatGTa  tggccctgag  TtcaaGTtca  tggcaccacc
1441  gacttatact  gagGTggatc  cctgcatcct  caacaaacat  GTgcaGTga

```

FIGURE 10

```

314      Ccctgaaaag      atggtga      tgttcaagaa      gatcaagtct      ttgaggtgg      ttttaACga
361      gtgtACggca      gtggcgagaa      ggtgctggc      cgggtgatag      tggaggtgtg
421      tgaagttACT      cgtgtcaaa      ccgttaaggat      cctggcttgc      ggaatggcta      aagtgtcttg
481      gatgcaggga      tcccagcagt      gcaaACagAC      ttcgaggtAC      ctgcgtatg      aaACACgct
541      tcttctggaa      gACcagccaa      Caggtgagaa      tgagatggg      atcatgagAC      ctggaaACaa
601      atatgagtAC      aagttcggt      ttgagcttcc      tcaggggcct      ctgggaACat      ccttcaaaag
661      aaaatatggg      tgtgtagACT      ACTgggtgaa      ggcttttctt      gACcgcccg      gccagccaaC
721      tcaagagACa      aagaaaaACT      ttgaagtagt      ggtctgggtg      gatgcaata      Ccctgattt
781      aatggcACT      gtgtctgcta      aaaaagaaaa      gaaagtctcc      tgcattgttca      ttctgatgg
841      gcgggtgtct      gtctctgctc      gaattgACag      aaaaggattc      tgtgaagggtg      atgagatttc
901      catccatgct      gACTtttgaga      atACatgttc      ccgaattgtg      gtcccaaaag      ctggccattgt
961      ggcccgccAC      ACTtACcttg      ccaatggcca      gACcaagggtg      ctgACTcaga      agttgtcctc
1021      agtcagaggc      aatcatatta      tctcagggAC      atggcatca      tggcgtggga      agagccttcg
1081      ggttcagaag      atcaggcctt;      ctatcctggg      ctgcaACatc      cttcgagttg      aatattcctt
1141      ACTgatctat      gtagcgttc      ctggatccaa      gaaggtcatc      ctgACctgc      ccttggtaat
1201      tggcagcaga      tcaggtctaa      gcagcagaAC      atccagcatg      gccagccgaa      Ccagctctga
1261      gatgagttgg      gtagatctga      ACatccctga      tACccagaa      gctctccct      gctatatgga
1321      tgtcatctct      gaagatcACc      gattggagag      ccaACcACT      cctctgctag      atgACatgga
1381      tggctctcaa      gACagcccta      tctttatgta      tgccctggag      tcaaagttca      tggcACcACC
1441      gACTtatACT      gaggtggatc      cctgcatcct      caACaACaat      gtgcagtga

```

FIGURE 11

314 atgggtga tgtTcaagaa gatcaagTct Tttgaggtgg Tcrttaacga  
 361 ccctgaaaag gtgtacggca gtggcgagaa ggtggtctggc cgggtgatag tggaggtgtg  
 421 tgaagTtact cgtgTcaaaG cgtTaggat cctggcttgc ggaTggcra aagtgtttg  
 481 gatgcaggga Tccagcagt gcaaacagac TtcggagTac ctgcttatg aagacacgct  
 541 TcTtctggaa gaccagccaa caggtgagaa tgagatggtg atcatgagac ctggaacaa  
 601 aTatgagTac aagTtcggct TtgagctTcc Tcaggggctt ctgggaacat cctTcaaaGg  
 661 aaaaTatggg tgtgTagact actgggtgaa ggcTttTctt gaccgccga gccagccaac  
 721 Tcaagagaca aagaaaaact TtgaagTagt ggaTctggtg gatgTcaatA cccctgattT  
 781 aatggcacct gtgtctgcta aaaaagaaaa gaaGTtTcc tgcattTca Ttcctgatgg  
 841 gcgggtgtct gTctctgtcT gaattgacag aaaaggattc tgtgaaggtg atgagattc  
 901 caTccatgct gactTtgaga atacatgTtc cgaattgtg gTcccaaaG ctgcaattgt  
 961 ggcctgccac actTaccctg ccaatggcca gaccaaggtg ctgactcaga agTgtcaTc  
 1021 agTcagaggc aatcaatAta Tctcagggac atgcgcatca tggcgtggca agagcctTcg  
 1081 ggtTcagaag atcaggccctT ctatTcctggg ctgcaacatc cTtcgagTtg aatattccTt  
 1141 actgaTctat gTtagcgTtc ctggaTccaa gaagTcaTc cTtgacctgc ccctggTaat  
 1201 tggcagcaga TcaggTctaa gcagcagaac atccagcatg gccagccgaa ccagcttga  
 1261 gatgagTtgg gTgaTctga acatccctga Taccacagaa gctctccctt gctatattga  
 1321 tgtcaTtccT gaagatcacc gatTggagag cccaaccact ccTctgctag atgacatgga  
 1381 tggctTcaaa gacagcccta TcrtTtatgta tgcctctgag TtcaagTtca tgccaccacc  
 1441 gactTatTact gaggtggatc cctgcaTccT caacaacaat gtgcagtgga

**FIGURE 12**

DNAzyme conc. :		0.05 $\mu$ M			0.5 $\mu$ M			5 $\mu$ M						
time (mins)	0	5	60	120	0	5	20	60	120	0	5	20	60	120



FIGURE 13B




FIGURE 13A




FIGURE 14B




FIGURE 14A




FIGURE 15B




FIGURE 15A




FIGURE 16B




FIGURE 16A






FIGURE 17A





FIGURE 17B



**FIGURE 18**




FIGURE 19A




FIGURE 19B




FIGURE 20B




FIGURE 20A




FIGURE 21B






FIGURE 21A




# FIGURE 22A

Early Proliferation/Regeneration Of Immature Cardiomyocyte.  
Lineage Progenitors Accompanying Neovascularization

(confocal microscopy: red nucleus, yellow Ki67, blue cytoplasm alpha-sarcomeric actin)




**FIGURE 22B**  
**Later Differentiation And Regeneration Of Mature Cardiomyocytes**  
**Accompanying Neovascularization**  
(immunohistochemistry: blue nucleus rat Ki67, brown cytoplasm troponin I)



**FIGURE 22C**

(c)



Confocal microscopy showing nuclear cycling (blue nucleus, green rat Ki67)  
of troponin I-positive mature cardiomyocyte (red cytoplasm)



**FIGURE 23**  
number of apoptotic myocytes/high  
powered field at peri-infarct region





FIGURE 24A (a)



(b)

FIGURE 24B







FIGURE 25A



**FIGURE 25B**





## EUROPEAN SEARCH REPORT

 Application Number  
EP 10 16 4397

## DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	WO 01/94420 A (UNIV COLUMBIA [US]; ITESCU SILVIU [US]) 13 December 2001 (2001-12-13)  * page 5, lines 8-17 * * page 12, line 21 - page 13, line 18 * * page 14, lines 5-13 * * claims 28-33 * -----	1-8, 10, 11, 15-18, 21, 23, 24	INV. C07H21/00 A61K48/00 C12Q1/68
A	WO 99/65507 A1 (GEN HOSPITAL CORP [US]) 23 December 1999 (1999-12-23) * page 7, line 21 - page 8, line 8 * * claims 1,5,7 * -----	1-28	
A	DAMÁS J K ET AL: "CXC-chemokines, a new group of cytokines in congestive heart failure--possible role of platelets and monocytes.", CARDIOVASCULAR RESEARCH 14 JAN 2000 LNKD-PUBMED:10728363, vol. 45, no. 2, 14 January 2000 (2000-01-14), pages 428-436, XP002618592, ISSN: 0008-6363 * the whole document * -----	1-28	
A	BOYLE ET AL: "Inhibition Of Interleukin-8 Blocks Myocardial Ischemia-Reperfusion Injury", JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, MOSBY-YEAR BOOK, INC., ST. LOUIS, MO, US, vol. 116, no. 1, 1 July 1998 (1998-07-01), pages 114-121, XP005694324, ISSN: 0022-5223, DOI: DOI:10.1016/S0022-5223(98)70249-1 * the whole document * ----- -/--	1-28	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (IPC)  A61K

 1  
BPO FORM 1503 (3.0.02) (P.02/01)

Place of search	Date of completion of the search	Examiner
Munich	26 January 2011	Engl, Brigitte

## CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone  
 Y: particularly relevant if combined with another document of the same category  
 A: technological background  
 O: non-written disclosure  
 P: intermediate document

T: theory or principle underlying the invention  
 E: earlier patent document, but published on, or after the filing date  
 D: document cited in the application  
 L: document cited for other reasons

& : member of the same patent family, corresponding document



## EUROPEAN SEARCH REPORT

Application Number  
EP 10 16 4397

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X,P	<p>SCHUSTER MICHAEL DAVID ET AL: "Stromal derived growth factor (SDF)-1 augments myocardial neovascularization and cardiomyocyte regeneration induced by human bone marrow angioblasts.", CIRCULATION, vol. 106, no. 19 Supplement, 5 November 2002 (2002-11-05), pages II-65, XP009143447.</p> <p>ABSTRACTS FROM SCIENTIFIC SESSIONS; CHICAGO, IL, USA; NOVEMBER 17-20, 2002 ISSN: 0009-7322</p> <p>* the whole document *</p> <p>-----</p>	1	
			TECHNICAL FIELDS SEARCHED (IPC)
The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	
Munich		26 January 2011	
		Examiner	
		Engl, Brigitte	
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone</p> <p>Y : particularly relevant if combined with another document of the same category</p> <p>A : technological background</p> <p>O : non-written disclosure</p> <p>P : intermediate document</p>		<p>T : theory or principle underlying the invention</p> <p>E : earlier patent document, but published on, or after the filing date</p> <p>D : document cited in the application</p> <p>L : document cited for other reasons</p> <p>A : member of the same patent family, corresponding document</p>	

EPO FORM 1505 (REV. 01-07-01)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 10 16 4397

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

26-01-2011

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0194420	A	13-12-2001	AU 7533901 A	17-12-2001
			CA 2412436 A1	13-12-2001
			EP 1290033 A1	12-03-2003
			JP 2004509847 T	02-04-2004
			MX PA02012067 A	19-08-2004
			US 2008057069 A1	06-03-2008
WO 9965507	A1	23-12-1999	AU 4696899 A	05-01-2000

EPO FORM PAGES

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82



## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Patent documents cited in the description

- US 10128738 B [0001]
- US 3687808 A [0069]
- US 4469863 A [0069]
- US 4476301 A [0069]
- US 5023243 A [0069]
- US 5177196 A [0069]
- US 5188997 A [0069]
- US 5264423 A [0069]
- US 5276019 A [0069]
- US 5278302 A [0069]
- US 5286717 A [0069]
- US 5321131 A [0069]
- US 5399676 A [0069]
- US 5405939 A [0069]
- US 5453496 A [0069]
- US 5455233 A [0069]
- US 5466677 A [0069]
- US 5476925 A [0069]
- US 5519126 A [0069]
- US 5536821 A [0069]
- US 5541306 A [0069]
- US 5550111 A [0069]
- US 5563253 A [0069]
- US 5571799 A [0069]
- US 5587361 A [0069]
- US 5194599 A [0069]
- US 5565555 A [0069]
- US 5527899 A [0069]
- US 5721218 A [0069]
- US 5672697 A [0069]
- US 5625050 A [0069]
- US 6248878 B [0083]
- US 6251666 B [0083]
- EP 0360257 A, Hampel [0163]
- US 4987071 A, Cech [0163]

## Non-patent literature cited in the description

- Soonpaa MH ; Field LJ. Assessment of cardiomyocyte DNA synthesis in normal and injured adult mouse hearts. *Am J Physiol*, 1997, vol. 272, H220-6 [0163] [0184]
- Kellerman S ; Moore JA ; Zierhut W ; Zimmer HG ; Campbell J ; Gerdes AM. Nuclear DNA content and nucleation patterns in rat cardiac myocytes from different models of cardiac hypertrophy. *J Mol Cell Cardiol*, 1992, vol. 24, 497-505 [0163]
- Colucci, W. S. Molecular and cellular mechanisms of myocardial failure. *Am. J. Cardiol.*, 1997, vol. 80 (11A), 15L-25L [0163]
- Ravichandran, L. V. ; Puvanakrishnan, R. in vivo labelling studies on the biosynthesis and degradation of collagen in experimental myocardial infarction. *Biochem. Intl.*, 1991, vol. 24, 405-414 [0163]
- Agocha, A. ; Lee, H. W. ; Eghali-Webb, M. Hypoxia regulates basal and induced DNA synthesis and collagen type I production in human cardiac fibroblasts: effects of TGF-beta, thyroid hormone, angiotensin II and basic fibroblast growth factor. *J. Mol. Cell. Cardiol.*, 1997, vol. 29, 2233-2244 [0163]
- Pfeffer, J. M. ; Pfeffer, M. A. ; Fletcher, P. J. ; Braunwald, E. Progressive ventricular remodeling in rat with myocardial infarction. *Am. J. Physiol.*, 1991, vol. 260, H1406-414 [0163] [0184]
- Kocher, AA et al. Neovascularization of ischemic myocardium by human bone-marrow-derived endothelial progenitor cells prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. *Nat Med*, 2001, vol. 7, 430-6 [0163]
- Kennedy, M. et al. A common precursor for primitive erythropoiesis and definitive haematopoiesis. *Nature*, 1997, vol. 388, 488-493 [0163]
- Chou, K. ; Kennedy, M. ; Kazarov, A. ; Papadimitriou, K. A common precursor for hematopoietic and endothelial cells. *Development*, 1998, vol. 125, 725-732 [0163]
- Elefanty, A. G. ; Robb, L. ; Birner, R. ; Begley, C. G. Hematopoietic-specific genes are not induced during in vitro differentiation of scl-null embryonic stem cells. *Blood*, 1997, vol. 90, 1435-1447 [0163]
- Labastie, M. C. ; Cortes, F. ; Romeo, P. H. ; Dulac, C. ; Peault, B. Molecular identity of hematopoietic precursor cells emerging in the human embryo. *Blood*, 1998, vol. 92, 3624-3635 [0163]
- Rafii S et al. Isolation and characterization of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion. *Blood*, 1994, vol. 84, 10-19 [0163]
- Shi, Q. et al. Evidence for circulating bone marrow-derived endothelial cells. *Blood*, 1998, vol. 92, 382-387 [0163]

- Lin, Y.; Weisendorf, D. J.; Solovey, A.; Hebbel, R. P. Origins of circulating endothelial cells and endothelial outgrowth from blood. *J. Clin. Invest.*, 2000, vol. 105, 71-77 [0163]
- Asahara, T. et al. Isolation of putative progenitor cells for endothelial angiogenesis. *Science*, 1997, vol. 275, 964-967 [0163]
- Takahashi, T. et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. *Nat. Med.*, 1999, vol. 5, 434-438 [0163]
- Kalka, C. et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. *Proc. Natl. Acad. Sci. USA*, 2000, vol. 97, 3422-3427 [0163]
- Kajstura J.; Lerli A.; Finato N.; di Loreto N.; Beltramo CA.; Anversa P. Myocyte proliferation in end-stage cardiac failure in humans. *Proc Natl Acad Sci, USA*, 1998, vol. 95, 8801-8805 [0163]
- Beltrami AP et al. Evidence that human cardiac myocytes divide after myocardial infarction. *N Engl J Med*, 2001, vol. 344, 1750-7 [0163] [0164]
- Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat. Med.*, 1995, vol. 1, 27 [0163]
- Strieter, RM et al. Interleukin-8: a chemokine factor that induces neovascularization. *Am. J. Pathol.*, 1992, vol. 141, 1279-1284 [0163]
- Murdoch C.; Monk PN.; Finn A. Cxcl chemokine receptor expression on human endothelial cells. *Cytokine*, 1999, vol. 11, 704-12 [0163]
- Koch, AE et al. Interleukin-8 (IL-8) as a macrophage-derived mediator of angiogenesis. *Science*, 1992, vol. 258, 1798-1801 [0163]
- Strieter, RM et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. *J. Biol. Chem.*, 1995, vol. 270, 27348-27357 [0163]
- Angiolillo, AL et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. *J Exp Med*, 1995, vol. 182, 155-62 [0163]
- Feli C.; Augustin HG. Endothelial cells differentially express functional CXC-chemokine receptor-4 (CXCR-4/fusin) under the control of autocrine activity and exogenous cytokines. *Biochem Biophys Res Commun*, 1998, vol. 247, 38-45 [0163]
- Tachibana, K et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. *Nature*, 1998, vol. 393, 591-594 [0163]
- Mohle R.; Bautz F.; Rafil S.; Moore MA.; Brugger W.; Kanz L. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. *Blood*, 1998, vol. 91, 4523-30 [0163]
- Imai, K et al. Selective secretion of chemoattractants for haemopoietic progenitor cells by bone marrow endothelial cells: a possible role in homing of haemopoietic progenitor cells to bone marrow. *Br J Haematol*, 1999, vol. 106, 905-11 [0163]
- Peled, A et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. *Science*, 1999, vol. 283, 845-88 [0163]
- Voermans C.; Gerritsen WR.; von dem Borne AE.; van der Schoot CE. Increased migration of cord blood-derived CD34+ cells, as compared to bone marrow and mobilized peripheral blood CD34+ cells across uncoated or fibronectin-coated filters. *Exp. Hematol.*, 2000, vol. 27, 1806-14 [0163]
- Janowska-Wieczorek, A. et al. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34+ cells and their transmigration through reconstituted basement membrane. *Blood*, 1999, vol. 93, 3379-3390 [0163]
- Heymans, S. et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. *Nat. Med.*, 1999, vol. 5, 1135-1142 [0163]
- Luca M.; Huang S.; Gershenwald JE.; Singh RK.; Reich R.; Bar-Eli M. Expression of Interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. *Am J Pathol*, 1997, vol. 151, 1105-1113 [0163]
- Masure, S.; Proost, P.; Van Damme, J.; Opdenakker, MD. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. *Eur. J. Biochem.*, 1991, vol. 198, 391-398 [0163]
- Hart, P. H. et al. Activation of human monocytes by granulocyte-macrophage colony-stimulating factor: increased urokinase-type plasminogen activator activity. *Blood*, 1991, vol. 77, 841-848 [0163]
- Stacey, K. J.; Fowles, L. F.; Colman, M. S.; Ostrowski, M. C.; Hume, D. A. Regulation of urokinase-type plasminogen activator gene transcription by macrophage colony-stimulating factor. *Mol. Cell. Biol.*, 1995, vol. 15, 3430-3441 [0163]
- Pei, X. H. et al. G-CSF increases secretion of urokinase-type plasminogen activator by human lung cancer cells. *Clin. Exp. Metastasis*, 1998, vol. 18, 551-558 [0163]
- Semerád, CL et al. A role for G-CSF receptor signalling in the regulation of hematopoietic cell function but not lineage commitment or differentiation. *Immunity*, 1999, vol. 11, 153-161 [0163]
- Nagasawa, T et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. *Nature*, 1996, vol. 382, 635-638 [0163]

- Rempel SA ; Dudas S ; Ge S ; Gutierrez JA. Identification and localization of the cytokine SDF1 and its receptor, CXCR chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. *Clin Cancer Res*, 2000, vol. 6, 102-11 [0163]
- Globerson, A. Hematopoietic stem cells and aging. *Exp. Gerontol.*, 1999, vol. 34, 137-146 [0163]
- de la Rubia, J. ; Diaz, M.A. ; Verdeguer, A. et al. Donor age-related differences in PBPC mobilization with rHuG-CSF. *Transfusion*, 2001, vol. 41, 201-206 [0163]
- Leferovich JM et al. Heart regeneration in adult MRL mice. *Proc Natl Acad Sci USA*, 2001, vol. 98, 9830-9835 [0163]
- Vander Heiden MG ; Plas DR ; Rathmell JC ; Fox CJ ; Harris MH ; Thompson CB. Growth factors can influence cell survival through effects on glucose metabolism. *Mol Cell Biol*, 2001, vol. 21, 5899-5912 [0163] [0184]
- Rössig L ; Jadidi AS ; Urbich C ; Badorff C ; Zehner AM ; Dimmeler S. Akt-dependent phosphorylation of p21Cip1 regulates PCNA binding and proliferation of endothelial cells. *Mol Cell Biol*, vol. 21, 5644-5657 [0163]
- Tomita S et al. Autologous transplantation of bone marrow cells improves damaged heart function. *Circulation*, 1999, vol. 100, 11-247 [0163]
- Orlic D et al. Bone marrow cells regenerate infarcted myocardium. *Nature*, 2001, vol. 410, 701-705 [0163]
- Kehat I et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. *J Clin Invest.*, 2001, vol. 108, 407-14 [0163]
- Rossi et al. *Aids Research and Human Retroviruses*, 1992, vol. 8, 183 [0163]
- Hampel ; Tritz. *Biochemistry*, 1989, vol. 28, 4929 [0163]
- Hamper et al. *Nucleic Acids Res.*, 1990, vol. 18, 299 [0163]
- Perrotta ; Been. *Biochemistry*, 1992, vol. 31, 16 [0163]
- Guerrier-Takada et al. *Cell*, 1983, vol. 35, 849 [0163]
- Forster ; Altman. *Science*, 1990, vol. 249, 783 [0163]
- Saville ; Collins. *Cell*, 1990, vol. 61, 685-696 [0163]
- Saville ; Collins. *Proc. Natl. Acad. Sci. USA*, 1991, vol. 88, 8828-8830 [0163]
- Guo ; Collins. *EMBO J.*, 1995, vol. 14, 368 [0163]
- Matzura O ; Wennborg A. RNAdraw: an integrated program for RNA secondary structure calculation and analysis under 32-bit Microsoft Windows. *Comput Appl Biosci*, 1998, vol. 12, 247-9 [0163]
- Santoro SW ; Joyce GF. A general purpose RNA-cleaving DNA enzyme. *Proc Natl Acad Sci USA*, 1997, vol. 94, 4262-6 [0163]
- Santoro SW ; Joyce GF. Mechanism and utility of an RNA-cleaving DNA enzyme. *Biochemistry*, 1998, vol. 37, 13330-42 [0163]
- MacLellan WR ; Schneider MD. Genetic dissection of cardiac growth control pathways. *Annu. Rev. Physiol.*, 2000, vol. 62, 289-320.7 [0163]
- Sherr CJ ; Roberts JM. CDK inhibitors: positive and negative regulators of G(1)-phase progression. *Genes Dev.*, 1999, vol. 13, 1501-1512 [0163]
- Hill MF ; Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. *Am J Pathol.*, 1996, vol. 148, 291-300 [0163] [0184]
- Hill MF ; Singal PK. Right and left myocardial antioxidant responses during heart failure subsequent to myocardial infarction. *Circulation*, 1997, vol. 96, 2414-20 [0163] [0184]
- Li, Y. ; Jenkins, C.W. ; Nichols, M.A. ; Xiong, Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. *Oncogene*, 1994, vol. 9, 2261-2268 [0163]
- Steinman, R.A. ; Hoffman, B. ; Iro, A. ; Guillof, C. ; Liebermann, D.A. ; El-Housseini, M.E. Induction of p21 (WAF1/CIP1) during differentiation. *Oncogene*, 1994, vol. 9, 3389-3396 [0163]
- Halevy, O. ; Novitsch, B.G. ; Spicer, D.B. ; Skapek, S.X. ; Rhee, J. ; Hannon, G.J. ; Beach, D. ; Lassar, A.B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. *Science*, 1995, vol. 267, 1018-1021 [0163]
- Andres, V. ; Walsh, K. Myogenin expression, cell cycle withdrawal and phenotypic differentiation are temporally separable events that precedes cell fusion upon myogenesis. *J. Cell Biol.*, 1996, vol. 132, 657-666 [0163]
- Tsurimoto, T. PCNA Binding Proteins. *Frontiers in Bioscience*, 1999, vol. 4, 849-858 [0163]
- Levkau B ; Koyama H ; Raines EW ; Clurman BE ; Herren B ; Orth K ; Roberts JM ; Ross R. Cleavage of p21cip1/waf1 and p27 kip1 mediates apoptosis in endothelial cells through activation of cdk2: role of a caspase cascade. *Mol Cell.*, 1998, vol. 1, 553-563 [0163]
- Adachi S et al. Cyclin A/cdk2 activation is involved in hypoxia-induced apoptosis in cardiomyocytes. *Circ Res.*, 2001, vol. 88, 408 [0163]
- Ichijo H et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. *Science*, 1997, vol. 275, 90-94 [0163]
- Tobiume, K. ; Inage, T. ; Takeda, K. ; Enomoto, S. ; Miyazono, K. ; Ichijo, H. Molecular cloning and characterization of the mouse apoptosis signal-regulating kinase 1. *Biochem. Biophys. Res. Commun.*, 1997, vol. 239, 905-910 [0163]

- Asada M; Yamada T; Ichijo H; Della D; Miyazono K; Fukumuro K; Mizutani S. Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation. *EMBO J.*, 1999, vol. 18, 1223-1234 [0163]
- Saitoh H et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK1). *EMBO J.*, 1998, vol. 17, 2596-2606 [0163]
- Nishiyama A et al. Identification of Thioredoxin-binding Protein-2/Vitamin D3 Up-regulated Protein 1 as a Negative Regulator of Thioredoxin Function and Expression. *J Biol Chem.*, 1999, vol. 31, 21645-21650 [0163]
- Junn E et al. Vitamin D3 Up-Regulated Protein1 Mediates Oxidative Stress Via Suppressing the Thioredoxin Function. *J Immunol.*, 2000, vol. 164, 6287-6295 [0163]
- Holmgren, A. *Annu. Rev. Biochem.*, 1985, vol. 54, 237-271 [0163]
- Chae, H. Z. ; Chug, S. J. ; Rhee, S. G. *J. Biol. Chem.*, 1994, vol. 269, 27670-27678 [0163]
- Netto, L. E. S. ; Chae, H. Z. ; Kang, S. ; Rhee, S. G. ; Stadtman, E. R. *J. Biol. Chem.*, 1996, vol. 271, 15315-15321 [0163]
- Chae, H. Z. ; Uhm, T. B. ; Rhee, S. G. *Proc. Natl. Acad. Sci. USA*, 1994, vol. 91, 7022-7026 [0163]
- Kwon, S. J. ; Park, J. ; Choi, W. ; Kim, I. H. ; Kim, K. *Biochem. Biophys. Res. Comm.*, 1994, vol. 201, 8-15 [0163]
- Kang, S. W. ; Baines, I. C. ; Rhee, S. G. *J. Biol. Chem.*, 1998, vol. 273, 6303-6311 [0163] [0184]
- Hirotsu, S et al. Crystal structure of a multifunctional 2-Cys peroxiredoxin heme-binding protein 23 kDa/proliferation-associated gene product. *Proc. Natl Acad Sci, USA*, 1999, vol. 96, 12333-12338 [0163]
- Slow, R. C. M. et al. *FEBS Lett.*, 1995, vol. 368, 239-242 [0163]
- Prosper, M. ; Ferbus, D. ; Karczinski, I. ; Goubin, G. *J. Biol. Chem.*, 1993, vol. 268, 11050-11056 [0163]
- Seuri, H. ; Butterfield, L. ; Kim, A. ; Shau, H. *Biochem. Biophys. Res. Commun.*, 1995, vol. 208, 964-969 [0163]
- Ishii T et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. *J Biological Chem*, 2000, vol. 275, 16023-16029 [0163]
- Itoh K; Wakabayashi N; Katoh Y; Ishii T; Igarashi K; Engel JD; Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. *Genes Dev.*, 01 January 1999, vol. 13 (1), 78-86 [0163]
- Lee, J-M et al. Phosphatidylinositol 3-Kinase, Not Extracellular Signal-regulated Kinase, Regulates Activation of the Antioxidant-Responsive Element in IMR-32 Human Neuroblastoma. *Cells J. Biol. Chem.*, 2001, vol. 276, 20011-20016 [0163]
- Kim YC; Masutani H; Yamaguchi Y; Itoh K; Yamamoto M; Yodoi J. Hemin-Induced activation of the thioredoxin gene by Nrf2. A differential regulation of the antioxidant responsive element by a switch of its binding factors. *J Biol Chem.*, 2001, vol. 276, 18399-406 [0163]
- Cho HY; Jedlicka AE; Reddy SP; Kensler TW; Yamamoto M; Zhang LY; Kleeberger SR. Role of NRF2 in Protection Against Hyperoxic Lung Injury in Mice. *Am J Respir Cell Mol Biol*, 2002, vol. 26, 175-182 [0163]
- Kumada C. Das; Paula M. B. Pahl; Xiao-Ling Guo; Carl W. White. Induction of Peroxiredoxin Gene Expression by Oxygen in Lungs of Newborn Primates. *Am. J. Respir. Cell Mol Biol*, 2001, vol. 25, 226-232 [0163]
- Wen S-T; Van Etten. RA The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. *Genes and Development*, 1997, vol. 19, 2456-2467 [0163]
- Kharbada, S. ; Yuan, Z. M. ; Welchselbaum, R. ; Kufe, D. Determination of cell fate by c-Abl activation in the response to DNA damage. *Oncogene*, 1998, vol. 17, 3309-3318 [0163] [0184]
- Yuan ZM et al. *Nature*, 1996, vol. 382 (6588), 272-4 [0163]
- Jost, C. A. ; Marin, M. C. ; Kaelin, W. J. p73 is a human p53-related protein that can induce apoptosis. *Nature*, 1997, vol. 389, 191-194 [0163]
- Agami, R ; Blandino G ; Oren M ; Shaul Y. Interaction of c-Abl and p73 [alpha] and their collaboration to induce apoptosis. *Nature*, 1999, vol. 399, 809-813 [0163]
- Sun X et al. Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. *J Biol. Chem.*, 2000, vol. 275, 17237-17240 [0163] [0184]
- Kumar S. Targeting of the c-Abl Tyrosine Kinase to Mitochondria in the Necrotic Cell Death Response to Oxidative Stress. *J. Biol. Chem.*, 2001, vol. 276, 17281-17285 [0163]
- Chen, K.S. ; DeLuca, H.F. Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. *JOURNAL Biochim. Biophys. Acta*, 1994, vol. 1219 (1), 26-32 [0163]
- Zhang et al. *Clinical Pharmacology & Therapeutics*, 1995, vol. 58, 44-53 [0163]
- Tetsuro Ishii ; Ken Itoh ; Junetsu Akasaka ; Toru Yanagawa ; Satoru Takahashi ; Hiroshi Yoshida ; Shiro Bannai ; Masayuki Yamamoto. *Carcinogenesis*, 2000, vol. 21 (5), 1013-1016 [0163]

- **Das KC ; Pahl PM ; Guo XL ; White CW.** *Am. J. Respir. Cells Mol. Biol.*, 2001, vol. 25 (2), 226-32 [0163]
- **Immschuh S ; Iwahara S ; Satoh H ; Neil C ; Katz N ; Muller-Eberhard U.** *Biochemistry*, 1995, vol. 34 (41), 13407-11 [0163]
- **Ken Itoh ; Nobunao Wakabayashi ; Yasutake Katoh ; Tetsuro Ishii ; Kazuhiko Igarashi ; James Douglas Engel ; 1 and Masayuki Yamamoto.** *Genes and Development*, 1999, vol. 13 (1), 76-86 [0163]
- **MacLellan WR ; Schneider MD.** Genetic dissection of cardiac growth control pathways. *Annu. Rev. Physiol.*, 2000, vol. 62, 289-320 [0184]
- **Kellerman S ; Moore JA ; Zierhut W ; Zimmer HG ; Campbell J ; Gerdes AM.** Nuclear DNA content and nucleation patterns in rat cardiac myocytes from different models of cardiac hypertrophy. *J Mol Cell Cardiol.*, vol. 24 (2992), 497-505 [0184]
- **Colucci, W. S.** Molecular and cellular mechanisms of myocardial failure. *Am. J. Cardiol.*, 1997, vol. 80 (11A), 15L-25L [0184]
- **Ravichandran, L. V. ; Puvanekrishnan, R.** In vivo labeling studies on the biosynthesis and degradation of collagen in experimental myocardial infarction. *Biochem. Int.*, 1991, vol. 24, 405-414 [0184]
- **Agocha, A. ; Lee, H. W. ; Eghall-Webb, M.** Hypoxia regulates basal and induced DNA synthesis and collagen type I production in human cardiac fibroblasts: effects of TGF-beta, thyroid hormone, angiotensin II and basic fibroblast growth factor. *J. Mol. Cell. Cardiol.*, 1997, vol. 29, 2233-2244 [0184]
- **Kajstura J ; Leri A ; Finato N ; di Loreto N ; Beltramo CA ; Anversa P.** Myocyte proliferation in end-stage cardiac failure in humans. *Proc Natl Acad Sci USA*, 1998, vol. 95, 8801-8805 [0184]
- **Kocher, AA et al.** Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. *Nat. Med.*, 2001, vol. 7, 430-6 [0184]
- **Rössig L ; Jaidi AS ; Urbich C ; Badier C ; Zeller AM ; Dimmeler S.** Akt-dependent phosphorylation of p21cip1 regulates PCNA binding and proliferation of endothelial cells. *Mol Cell Biol*, 2001, vol. 21, 5644-5657 [0184]
- **Ceaselli D et al.** Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. *Circ Res*, 2001, vol. 89, 279-86 [0184]
- **Chae, H. Z. ; Chung, S. J. ; Rhee, S. G.** Thioredoxin-dependent peroxide reductase from yeast. *J. Biol. Chem.*, 1994, vol. 269, 27670-27678 [0184]
- **Das KC ; Pahl PM ; Guo X-L ; White CW.** Induction of peroxiredoxin gene expression by oxygen in lungs of newborn primates. *Am. J. Respir. Cell Mol. Biol.*, 2001, vol. 25, 226-232 [0184]
- **Holmgren, A.** Thioredoxin. *Annu. Rev. Biochem.*, 1985, vol. 54, 237-271 [0184]
- **Kumar S et al.** Targeting of the c-Abl tyrosine kinase to mitochondria in the necrotic cell death response to oxidative stress. *J. Biol. Chem.*, 2001, vol. 276, 17281-17285 [0184]
- **Wen S-T ; Van Etten, RA.** The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. *Genes and Development*, 1997, vol. 29, 2456-2467 [0184]
- **Breaker, R.R.** Making catalytic DNAs. *Science*, 2000, vol. 290, 2095-2096 [0184]
- **Khachigian, L.M.** Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. *J Clin Invest*, 2000, vol. 106, 1189-1195 [0184]
- **Zuker, M.** On finding all suboptimal foldings of an RNA molecule. *Science*, 1989, vol. 244, 48-52 [0184]
- **LI B ; Ishii T ; Choon Ping Tan CP ; Soh JW ; Goff SP.** Pathways of induction of Peroxiredoxin I expression in osteoblasts. Roles of p38 mitogen-activated protein kinase and protein kinase c. *J. Biol. Chem.*, 2002, vol. 277, 12418-12422 [0184]
- **Wet MM ; Palfrey HC.** Divergence in the anti-apoptotic signalling pathways used awareness by nerve growth factor and basic fibroblast growth factor (bFGF) in PC12 cells: rescue by bFGF involves protein kinase C $\delta$ . *Biochem. J.*, 2000, vol. 352, 175-182 [0184]
- **Chae, H. Z. ; Chung, S. J. ; Rhee, S. G.** *J. Biol. Chem.*, 1994, vol. 269, 27670-27678 [0184]
- **Kwon, S. J. ; Park, J. ; Choi, W. ; Kim, T. H. ; Kim, K.** *Biochem. Biophys. Res. Comm.*, 1994, vol. 201, 8-15 [0184]
- **Wen S-T ; Van Etten, RA.** The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. *Genes and Development*, 1997, vol. 19, 2456-2467 [0184]
- **Yuan 2M ; Huang Y ; Whang Y ; Sawyers C ; Weichselbaum R ; Kharbanda S ; Kufe D.** Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. *Nature*, 1996, vol. 382, 272-4 [0184]
- **Anversa P ; Nadal-Ginard B.** Myocyte renewal and ventricular remodelling. *Nature*, 2002, vol. 415, 240-243 [0184]